	dbSNP_ID	GENE_SYMBOL	DRUG_NAME	NOTES	SENTENCE	ALLELE_PharmGKB	ALLELE_23andme
0	rs1801131	MTHFR (PA245)	"fluorouracil (PA128406956),""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	(no entry)	Genotype G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.	G	T
1	rs1801131	MTHFR (PA245)	oxaliplatin (PA131285527)	Statistics given as trend for increased overall relative response per MTHFR 1298C allele comparing patients receiving 5FU and FOLFOX.	Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.	GG + GT	T
2	rs1801131	MTHFR (PA245)	benazepril (PA448561)	When in a haplotype with rs1801133 allele G, and where only one copy of this GG haplotype was present. Patients with this haplotype had a significantly lower diastolic and systolic blood pressure (DBP and SBP) response to benazepril between baseline and 15 days of treatment, as compared to those with any other haplotype. Please note: alleles have been complemented to the plus chromosomal strand.	Allele G is associated with decreased response to benazepril in people with Hypertension.	G	T
3	rs1801131	MTHFR (PA245)	methotrexate (PA450428)	(no entry)	Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	GT + TT	T
4	rs1801131	"C1orf167 (PA142672417),""CLCN6 (PA26551)"",""MTHFR (PA245)"""	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.	TT	T
5	rs1801131	MTHFR (PA245)	methotrexate (PA450428)	Alleles given as C and A. Efficacy of treatment was measured as change of DAS28 from start of treatment to 6months after initiation of treatment. Effect seen in patients receiving monotherapy for methotrexate. In combination with MTHFR A1298C, patients with 677CC-1298CC or 677TT-1298AA had better response to methotrexate by DAS28 change. (p=0.013).	Genotype GT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	GT	T
6	rs1801131	MTHFR (PA245)	methotrexate (PA450428)	(no entry)	Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.	GG	T
7	rs1801131	MTHFR (PA245)	Vitamin B-complex, Incl. Combinations (PA164713398)	Please note that allele has been complemented to the positive strand. Patients who carried either the A allele of rs1801133 or the G allele of rs1801131 were recruited into the study (genotypes are not given) and given a capsule containing reduced B vitamins and macronutrients or a placebo. Patients taking the B vitamin capsule showed a significant decrease in MADRS score over 8 weeks of treatment compared to those taking placebo.	Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.	G	T
8	rs1801133	MTHFR (PA245)	"fluorouracil (PA128406956),""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	(no entry)	Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.	A	G
9	rs1801133	MTHFR (PA245)	disulfiram (PA449376)	The drop in percentage of cocaine-positive urines for patients with the CT and TT genotypes over the 10 weeks of disulfiram treatment was significantly greater compared to those with the CC genotype. Please note alleles have been complemented to the positive chromosomal strand.	Genotypes AA + AG are associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG.	AA + AG	G
10	rs1801133	MTHFR (PA245)	benazepril (PA448561)	Patients with the AA genotype had a greater change in diastolic blood pressure between baseline and after 15 days of treatment, compared to those with the AG and GG genotypes. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to benazepril in people with Hypertension as compared to genotypes AG + GG.	AA	G
11	rs1801133	MTHFR (PA245)	benazepril (PA448561)	When in a haplotype with rs1801131 allele G, and where only one copy of this GG haplotype was present. Patients with this haplotype had a significantly lower diastolic and systolic blood pressure (DBP and SBP) response to benazepril between baseline and 15 days of treatment, as compared to those with any other haplotype. Please note alleles have been complemented to the plus chromosomal strand.	Allele G is associated with decreased response to benazepril in people with Hypertension.	G	G
12	rs1801133	MTHFR (PA245)	"capecitabine (PA448771),""fluorouracil (PA128406956)"",""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	FOLFOX (54.4%) and CAPOX (45.6%) regimens. Measured as cumulative survival over 100 months since diagnosis.	Genotype AA is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele G.	AA	G
13	rs1801133	MTHFR (PA245)	methotrexate (PA450428)	Alleles were given as C and T. Response measured as relapse-free survival and overall survival.	Genotype AG is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	AG	G
14	rs1801133	"CLCN6 (PA26551),""MTHFR (PA245)"""	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	G
15	rs1801133	MTHFR (PA245)	methotrexate (PA450428)	Alleles given as C and T. Efficacy of treatment was measured as change of DAS28 from start of treatment to 6months after initiation of treatment. Effect seen in patients receiving monotherapy for methotrexate. In combination with MTHFR A1298C, patients with 677CC-1298CC or 677TT-1298AA had better response to methotrexate by DAS28 change. (p=0.013).	Genotype AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + GG.	AG	G
16	rs1801133	MTHFR (PA245)	"bevacizumab (PA130232992),""capecitabine (PA448771)"",""cisplatin (PA449014)"",""docetaxel (PA449383)"",""epirubicin (PA449476)"",""oxaliplatin (PA131285527)"",""trastuzumab (PA451743)"""	"Patients with the AA genotype had decreased progression-free survival and overall survival in multivariable analysis. However, note that these were only a ""nominally"" significant associations: formally significant was defined as p<0.0026, and nominally significant as p<0.05. No association with response was found. Please note that alleles have been complemented to the plus chromosomal strand."	Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.	AA	G
17	rs1801133	MTHFR (PA245)	fluorouracil (PA128406956)	Patients receiving fluorouracil-based chemotherapy. Response included complete response (CR) and partial response (PR). Non-response included progressive disease (PD) and stable disease (SD). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	AA + AG	G
18	rs1801133	MTHFR (PA245)	methotrexate (PA450428)	Authors say this variant is associated with non-response in recessive model (minor allele/minor allele vs minor/major + major major and describe variant as C677T). Alleles complemented to plus chromosomal strand.	Genotype AA is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.	AA	G
19	rs1801133	MTHFR (PA245)	Vitamin B-complex, Incl. Combinations (PA164713398)	Please note that allele has been complemented to the positive strand. Patients who carried either the A allele of rs1801133 or the G allele of rs1801131 were recruited into the study (genotypes are not given) and given a capsule containing reduced B vitamins and macronutrients or a placebo. Patients taking the B vitamin capsule showed a significant decrease in MADRS score over 8 weeks of treatment compared to those taking placebo.	Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.	A	G
20	rs5065	NPPA-AS1 (PA165752124)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	Individuals with the GG genotype had reduced urinary excretion of potassium, as compared to AA homozygotes, during the 24 hours after drug administration.	Genotype GG is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.	GG	A
21	rs5065	NPPA-AS1 (PA165752124)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	Homozygotes for the G allele had increased urinary excretion of sodium chloride as compared to AA homozygotes, during the 24 hours after drug administration.	Genotype GG is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.	GG	A
22	rs5063	NPPA-AS1 (PA165752124)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	Homozygotes for the T allele had reduced urinary excretion of sodium chloride as compared to CC homozygotes, during the 24 hours after drug administration.	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.	TT	C
23	rs1061622	TNFRSF1B (PA36610)	infliximab (PA452639)	Only the abstract of this article is available.	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele T.	G	T
24	rs1061622	TNFRSF1B (PA36610)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.	GG	T
25	rs1061622	TNFRSF1B (PA36610)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"",""ustekinumab (PA166048654)"""	Patients treated for the first time with one of these 4 biological therapies and completed at least 6 months of treatment. All the patients had moderate-severe psoriasis despite previous conventional treatment, or had contraindication with phototherapy, acitretin, methotrexate, and cyclosporine.	Genotypes GG + GT are associated with decreased response to adalimumab, etanercept, infliximab or ustekinumab in people with Psoriasis as compared to genotype TT.	GG + GT	T
26	rs1061622	TNFRSF1B (PA36610)	etanercept (PA449515)	Response to etanercept was determined using the Assessment in Ankylosing Spondylitis 20 (ASAS20) and Assessment in Ankylosing Spondylitis 40 (ASAS40). Patients with the GT genotype had a significantly decreased response to etanercept at 12 months after the initiation of etanercept treatment compared to patients with the GG or TT genotypes. However, there was no significant difference in response between the different genotypes at 3 months after initiation of treatment.	Genotype GT is associated with decreased response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes GG + TT.	GT	T
27	rs1061631	TNFRSF1B (PA36610)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	G
28	rs2072671	CDA (PA98)	gemcitabine (PA449748)	Patients with the AA genotype had a better response to gemcitabine therapy than patients with either the AC or the CC genotype. However, progression free survival did not significantly differ between genotype groups. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001). There were also two SNPs in this study that, when taken together, affected tumor response to therapy: rs2072671 and rs760370. Using patients with 0 variants as reference, patients with 1-2 variants had an increased OR of 3.40 (P = 0.004).	Genotype AA is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.	AA	A
29	rs2072671	CDA (PA98)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	This SNP was presented as CDA Lys27Gln. Patients homozygous for the wildtype allele (Lys/Lys) showed significantly longer time to progression (P=.006) and overall survival (P=.002) as compared to patients carrying the Gln allele.	Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	AA	A
30	rs10916852	SH2D5 (PA142670927)	gemcitabine (PA449748)	Associated with longer time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotypes GT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	GT + TT	G
31	rs7512595	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	A	A
32	rs529520	OPRD1 (PA31942)	buprenorphine (PA448685)	"Opioid dependence. Four cohorts were analyzed. The first three were women taking buprenorphine or methadone, women taking only buprenorphine and women taking only methadone, where opiod-positive urine drug screens or missing urine drug screens were both considered a ""positive"" drug screen. The fourth was women taking only buprenorphine were missing urine drug screens were coded as ""missing"" and not as ""positive"". No significant results were seen when considering women only taking methadone, but significant results were seen for all other cohorts: women with the AA genotype were more likely to have opioid- ""positive"" urine drug screens, as compared to those with the CC genotype. Patients were treated with buprenorphine or methadone for 24 weeks."	Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.	AA	A
33	rs581111	OPRD1 (PA31942)	buprenorphine (PA448685)	"Opioid dependence. Four cohorts were analyzed. The first three were women taking buprenorphine or methadone, women taking only buprenorphine and women taking only methadone, where opiod-positive urine drug screens or missing urine drug screens were both considered a ""positive"" drug screen. The fourth was women taking only buprenorphine were missing urine drug screens were coded as ""missing"" and not as ""positive"". No significant results were seen when considering women only taking methadone, but significant results were seen for all other cohorts: women with the AA and AG genotypes were more likely to have opioid- ""positive"" urine drug screens, as compared to those with the GG genotype. Patients were treated with buprenorphine or methadone for 24 weeks."	Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.	AA + AG	A
34	rs1741981	HDAC1 (PA29226)	Corticosteroids For Systemic Use (PA164712636)	Adults with the CC genotype showed significantly lower percent forced expiratory volume in 1 second (%FEV1) increases in response to systemic corticosteroids, as compared to those with the CT or TT genotype. Patients were treated for 7 days. Note that this allele was significantly related to asthma severity (same direction of association; corrected p=0.036).	Genotype CC is associated with decreased response to Corticosteroids For Systemic Use in people with Asthma as compared to genotypes CT + TT.	CC	T
35	rs1741981	HDAC1 (PA29226)	corticosteroids (PA10832)	Children with the CC genotype showed significantly lower percent forced expiratory volume in 1 second (%FEV1) increases in response to inhaled corticosteroids, as compared to those with the CT or TT genotype. Patients were treated for 8 weeks. Note that this allele was significantly related to asthma severity (same direction of association; corrected p=0.036).	Genotype CC is associated with decreased response to corticosteroids in children with Asthma as compared to genotypes CT + TT.	CC	T
36	rs7543016	CMPK1 (PA162382539)	gemcitabine (PA449748)	Associated with longer time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CG + GG.	CC	G
37	rs4492666	CMPK1 (PA162382539)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the CC genotype became significantly associated with shorter survival but only in patients treated with gemcitabine. In addition, when the CC genotype was combined with the TT genotype at rs2284449, the AA genotype at rs2044139, the AA genotype at rs232043, or the TT genotype at rs720106, overall survival was significantly shorter for patients treated with gemcitabine.	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	CC	A
38	rs11211524	CMPK1 (PA162382539)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the CC genotype became significantly associated with shorter survival but only in patients treated with gemcitabine.	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	CC	A
39	rs35687416	CMPK1 (PA162382539)	gemcitabine (PA449748)	Associated with longer overall survival and time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	GG	G
40	rs1044457	CMPK1 (PA162382539)	gemcitabine (PA449748)	Associated with longer overall survival and time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	CC	C
41	rs11591147	PCSK9 (PA38617)	hmg coa reductase inhibitors (PA133950441)	There was a 55.6% greater reduction in low-density lipoprotein cholesterol (LDL-C) in carriers of the T alleles as compared to those with the GG genotype. Note that carriers of the T allele were also associated with significantly decreased LDL-C levels at baseline (p=0.00022), though the result for response to statins was adjusted for this association. A p-value <0.0045 was considered statistically significant. The authors do not specify the composition of T allele carriers (i.e. heterozygotes, homozygotes, or both).	Allele T is associated with increased response to hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype GG.	T	G
42	rs17111584	USP24 (PA37248)	rosuvastatin (PA134308647)	The minor allele of this SNP is associated with decreased LDL-C reduction on rosuvastatin.	Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.	CC + CT	T
43	rs1137101	LEPR (PA229)	simvastatin (PA451363)	Subjects with the GG genotype (Arg/Arg) had smaller reductions in serum total cholesterol levels when treated with simvastatin as compared to subjects with genotype AA+AG (Arg/Gln+Gln/Gln).	Genotype GG is associated with decreased response to simvastatin in men with Hyperlipidemias as compared to genotypes AA + AG.	GG	A
44	rs11580409	ERICH3 (PA142672422)	"citalopram (PA449015),""escitalopram (PA10074)"""	This is one of SNP in a cluster (rs11580409 and rs11210490 and rs696692) that showed some association with plasma serotonin concentrations and was suspected to be associated with SSRI clinical response. When tested in the PGRN-AMPS GWAS and in two independent SSRI response GWAS (STAR*D and ISPC) rs11580409 in ERICH3 was associated with response at 4 weeks in the ISPC population and response at 6 weeks in the STAR*D population but not associated with response in the PGRN-AMPS cohort. Baseline plasma serotonin concentrations before SSRI therapy, as well as changes in serotonin were used as a biomarker for response to SSRIs and GWAS was done w/respect to changes in plasma serotonin concentration.	Allele A is associated with increased response to citalopram and escitalopram in people with Depressive Disorder as compared to allele C.	A	A
45	rs3753380	PTGFR (PA290)	latanoprost (PA164774763)	Measured mean short-term diurnal intraocular pressure reduction in treated vs. untreated eye.	Genotype CC is associated with increased response to latanoprost as compared to genotypes TT + CT.	CC	T
46	rs3766355	PTGFR (PA290)	latanoprost (PA164774763)	Difference was seen after 30 days of treatment and efficacy was measured by decrease in intraocular pressure.	Genotype CC is associated with increased response to latanoprost in people with Glaucoma or Ocular Hypertension as compared to genotypes AA + AC.	CC	C
47	rs928655	GBP6 (PA134964409)	etanercept (PA449515)	(no entry)	Genotypes AG + GG is associated with increased response to etanercept in people with Psoriasis as compared to genotype AA.	AG + GG	G
48	rs12082710	TGFBR3 (PA36487)	antidepressants (PA452229)	Homozygote carriers of the T allele were more frequent among responders to antidepressant treatment as compared to non-responders. Response to treatment was defined as a score reduction of greater than 50% on the 21-item Hamilton Depression Rating Scale (HAM-D) between score at admission and score 5 weeks after treatment initiation.	Genotype TT is associated with increased response to antidepressants in people with Depression as compared to genotypes CC + CT.	TT	T
49	rs3917643	F3 (PA158)	simvastatin (PA451363)	With simvastatin treatment (40 mg/day), the rate of reduction in maximum rates of formation of thrombin-antithrombin complexes and of prothrombin 1.2 fragments was greater following vascular injury in CT patients as compared to TT patients. There were no CC patients in this study. Baseline levels and at-site levels after injury were higher in CT patients than in TT patients.	Genotype CT is associated with increased response to simvastatin in people with Myocardial Ischemia as compared to genotype TT.	CT	T
50	rs3918290	DPYD (PA145)	fluorouracil (PA128406956)	Patients with the CC genotype had a higher complete remission (CR) rate as compared to those with the CT genotype. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	CC	C
51	rs1801159	DPYD (PA145)	capecitabine (PA448771)	The frequency of the C allele (*5) was higher in patients with partial response to capecitabine treatment. However, no significant association was seen for progression-free survival (p=0.07) or overall survival (p=0.10). Additionally, none of these associations were significant in a group of patients with colorectal cancer (n=55). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with increased response to capecitabine in people with gastroesophageal cancer as compared to genotype TT.	CC + CT	T
52	rs1801159	DPYD (PA145)	"capecitabine (PA448771),""fluorouracil (PA128406956)"",""s 1 (combination) (PA166115442)"""	Patients with the CC or CT genotype were less likely to respond to fluorouracil-based chemotherapy as compared to those with the TT genotype. Significant after correction for age, sex, tumor histology and chemotherapeutic regimen. Response was assessed clinically and histopathologically: clinically, patients with complete remission or partial remission were considered responsive, while those with stable disease or progressive disease were considered non-responsive; histopathologically, patients with less than 10% residual tumor cells were classified as responders, all other patients were classified as non-responders. This SNP is also known as DPYD*5. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with decreased response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	CC + CT	T
53	rs1801265	DPYD (PA145)	fluorouracil (PA128406956)	Patients with the AA genotype had a higher complete remission (CR) rate as compared to those with the GG genotype. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	AA	G
54	rs629301	SORT1 (PA36023)	hmg coa reductase inhibitors (PA133950441)	as measured by lesser reductions in LDL-C. These individuals were also more likely to start out with higher LDL-C before treatment.	Allele T is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases and Hypercholesterolemia as compared to allele G.	T	G
55	rs646776	CELSR2 (PA26394)	hmg coa reductase inhibitors (PA133950441)	Carriers of this SNP respond to statins with an additional 1.5% increase per allele in LDL-C lowering effect compared with non-carriers.	Allele C is associated with increased response to hmg coa reductase inhibitors as compared to allele T.	C	C
56	rs17602729	AMPD1 (PA24776)	"folic acid (PA449692),""methotrexate (PA450428)"""	(no entry)	Allele A is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	A	G
57	rs17602729	AMPD1 (PA24776)	methotrexate (PA450428)	(no entry)	Genotypes AA + AG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	AA + AG	G
58	rs12044852	CD58 (PA26227)	"interferon beta-1a (PA450037),""interferon beta-1b (PA450039)"""	Patients with relapsing remitting multiple sclerosis. Patients with the CC genotype had a higher increase in mean multiple sclerosis severity score over two years of follow-up, as compared to those with the AA or AC genotype. This SNP was also significantly associated with the occurrence of multiple sclerosis.	Genotype CC is associated with decreased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to genotypes AA + AC.	CC	C
59	rs10494227	ZNF697 (PA142670495)	"interferon beta-1a (PA450037),""interferon beta-1b (PA450039)"""	In the discovery GWAS stage, the Bonferroni adjusted statistical significance threshold was <=1.74E-10, however no SNPs reached this level, likely due to sample size limitations, and so the significance level was set at <=1.0E-3. In the validation stage, the significance level was set at <0.05, and SNPs that did not have the same direction of response as the discovery stage were considered spurious associations and omitted from further analysis. In further validation in a cohort treated with glutiramer acetate (GA), this SNP was not associated with response. Response was defined as no relapses and no change on Kurtzke Expanded Disability Status Scale (EDSS) scores in the 2 years after starting interferon beta therapy. Non-reponse defined as having >= 2 relapses or an increase in EDSS by at least 1 point in the 2 years follow-up after a minimum duration of 6 months post initiation of therapy.	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.	A	A
60	rs7541245	FMO5 (PA28189)	metformin (PA450395)	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records.	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele C.	A	C
61	rs12083537	IL6R (PA29835)	tocilizumab (PA165292659)	Response was defined as changes in swollen joint count (SJC). The genotype was NOT associated with EULAR-response, and median tender joint count, levels of circulating C-reactive protein, and disease activity (DAS28-CRP) as other response parameter.	Genotype AA is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype AG.	AA	A
62	rs12083537	IL6R (PA29835)	tocilizumab (PA165292659)	Patients with the AA genotype had better low disease activity (LDA) response at 12 months of treatment as compared to those with the AG and GG genotype. However, no significant association with European League Against Rheumatism (EULAR) response or remission response was seen. There was an allelic association with DAS28 improvement, where patients with the A allele had higher improvement in DAS28 as compared to patients with the G allele (p=0.027).	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	A
63	rs4329505	IL6R (PA29835)	tocilizumab (PA165292659)	Response was defined as changes in swollen joint count (SJC). The genotype was NOT associated with EULAR-response, and median tender joint count, levels of circulating C-reactive protein, and disease activity (DAS28-CRP) as other response parameter.	Genotypes CC + CT is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype TT.	CC + CT	T
64	rs11264359	FDPS (PA28075)	Bisphosphonates (PA164712563)	Increased hip bone mineral density change. BMD measured at baseline and after treatment with antiresortive drugs (alendronate, risedronate or raloxifene) for at least 12 months. Most of them (>90%) were also given vitamin D and calcium supplements.	Allele A is associated with increased response to Bisphosphonates in people with Osteoporosis as compared to allele G.	A	A
65	rs12566888	PEAR1 (PA162399233)	ticagrelor (PA165374673)	Healthy control plasma incubated with 15uM ticagrelor. Significant difference observed in maximal platelet aggregation at baseline and after ticagrelor treatment.	Genotype TT is associated with increased response to ticagrelor in healthy individuals as compared to genotype GT.	TT	G
66	rs12041331	PEAR1 (PA162399233)	ticagrelor (PA165374673)	Healthy control plasma incubated with 15uM ticagrelor.	Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotypes AG + GG.	AA	G
67	rs12041331	PEAR1 (PA162399233)	ticagrelor (PA165374673)	Healthy controls plasma incubated with 50uM ticagrelor.	Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotype GG.	AA	G
68	rs2106089	SPTA1 (PA36101)	benazepril (PA448561)	Only when rs4762 genotype (AGT gene) is also taken into account (gene-gene interaction model). Please see study for analysis details - the allele conferring increased likelihood of response/ sensitivity was not clear. Please note, this study reported alleles C>T - here we have represented the complementary alleles on the plus strand (G>A).	Allele G is associated with response to benazepril in men with Hypertension as compared to allele A.	G	A
69	rs2298805	FCER1A (PA28056)	"desloratadine (PA164776964),""mizolastine (PA166129535)"""	(no entry)	Genotype AA is associated with increased response to desloratadine and mizolastine in people with Urticaria as compared to genotypes AG + GG.	AA	G
70	rs1417938	CRP (PA120)	fenofibrate (PA449594)	Patients with the TT genotype had a greater reduction in C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, as compared to carriers of the A allele. In strong linkage disequilibrium with rs3091244 and rs1205 (r2 = 0.4 - 0.9, p < 0.001) and in weak linkage disequilibrium with rs3093059 (r2 = 0.17, p < 0.05).	Genotype TT is associated with increased response to fenofibrate in people with metabolic syndrome as compared to genotypes AA + AT.	TT	T
71	rs6688363	ATP1A2 (PA30796)	olanzapine (PA450688)	The number of T alleles present in a patient was positively associated with CGI-S score.	Allele T is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele C.	T	C
72	rs6427528	CD84 (PA26242)	etanercept (PA449515)	Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index. Only 1 patient had genotype AA.	Genotype AG is associated with increased response to etanercept in people with Psoriasis as compared to genotype GG.	AG	A
73	rs1801274	FCGR2A (PA28063)	"cyclophosphamide (PA449165),""doxorubicin (PA449412)"",""paclitaxel (PA450761)"",""trastuzumab (PA451743)"""	(no entry)	Genotype AA is associated with increased response to cyclophosphamide, doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.	AA	A
74	rs1801274	FCGR2A (PA28063)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	Patients with the GG genotype had a higher psoriasis body surface area (BSA) after 6-8 weeks of treatment, as compared to those with the AA or AG genotype. No significant difference in psoriasis BSA were seen after 12 weeks of treatment. Additionally, no significant differences between these genotype groups were seen when considering the mean percentage psoriasis body surface area (BSA) improvement over 12 weeks.	Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	GG	A
75	rs1801274	FCGR2A (PA28063)	infliximab (PA452639)	Association only existing for the time point at 3 month but not for later time points 6 and 12 month. Response was determined using European League Against Rheumatism (EULAR) criteria.	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A.	G	A
76	rs1801274	FCGR2A (PA28063)	adalimumab (PA10004)	as measured by DAS28 after 14 weeks treatment.	Allele A is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	A	A
77	rs1801274	FCGR2A (PA28063)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	This was only significant in patients with follow-up times greater than or equal to 6 months. Association is stated in text and abstract as for RR + RH genotype shown here as GG+AG (although table 4 and figure 2 have HH and HR as associated).	Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic, Crohn Disease, Psoriasis and Spondylitis, Ankylosing as compared to genotype AA.	AG + GG	A
78	rs1801274	FCGR2A (PA28063)	cetuximab (PA10040)	ONLY significant when combined in an analysis with rs396991. The median progression-free survival time for patients with the rs1801274 GG genotype and/or the rs396991 TT genotype was significantly longer as compared with carriers of rs1801274 A allele and/or rs396991 G allele (5.5 vs 4.1 months). This association remained significant in Cox multivariate analysis. However, on its own, this SNP was NOT significantly associated with progression-free survival time. Patients received polychemotherapy with cisplatin or carboplatin, fluorouracil and cetuximab and had metastatic squamous cell head and neck cancer.	Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG.	GG	A
79	rs1801274	FCGR2A (PA28063)	cetuximab (PA10040)	Overall survival and progression-free survival were used as indicators of response to cetuximab.	Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	AA	A
80	rs1801274	FCGR2A (PA28063)	tocilizumab (PA165292659)	(no entry)	Allele A is not associated with response to tocilizumab in people with Arthritis, Rheumatoid as compared to allele G.	A	A
81	rs1801274	FCGR2A (PA28063)	rituximab (PA451261)	The AA genotype was associated with improved EULAR response and improved remission at 6 months, improved EULAR response and improvement in DAS28 at 12 months and improvements EULAR response and DAS28 at 18 months. Please note that alleles have been complemented to the positive strand.	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	A
82	rs2661319	RGS4 (PA34375)	risperidone (PA451257)	(no entry)	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	C	T
83	rs1056515	RGS5 (PA34376)	"bevacizumab (PA130232992),""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"""	For specifically tumors occurring in the right colon. Patients were receiving treatment with bevacizumab + FOLFIRI (fluorouracil, leucovorin, irinotecan). Patients with the TT genotype responded better than patients with the GG or GT genotype.	Genotype TT is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes GG + GT.	TT	G
84	rs3917412	SELE (PA35640)	"capecitabine (PA448771),""fluorouracil (PA128406956)"",""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	FOLFOX (54.4%) and CAPOX (45.6%) regimens. Measured as cumulative survival over 100 months since diagnosis.	Genotype CC is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele T.	CC	T
85	rs7515157	FMO2 (PA164741534)	glibenclamide (PA449782)	No allele was given for the association, so the minor allele from dbSNP at this location was used. Response to treatment was measured as reduction of HbA1c below 6.5% at 1-year of treatment.	Allele T is associated with increased response to glibenclamide in people with as compared to allele C.	T	C
86	rs77977790	PAPPA2 (PA33373)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. This association was significant in the initial GWAS (in GALA II), but it was not significant in an attempted replication by imputation in silico in GALA I. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.	CT	T
87	rs800292	CFH (PA29261)	bevacizumab (PA130232992)	as determined by lower changes in visual acuity score. Genotype AG seemed to have intermediate levels. This variant was not associated with significant difference in central retinal thickness or max lesion thickness. Please note; the alleles reported for this SNP were C and T, however according to dbSNP this is a G (Val)>A(Ile) change and so here we use G to represent C and A to represent T (the gene is on the plus chromosome strand).	Genotype GG is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype AA.	GG	G
88	rs1061170	CFH (PA29261)	photodynamic therapy (PA165984462)	Visual acuity post-PDT was significantly worse in patients with the TT genotype than for patients with either the TC or CC genotype. This is interesting because having the C allele puts patients at higher risk of developing age-related macular degeneration. While this association with PDT was found to be true for the cohort overall (P=0.05), when subjects were separated based on lesion type, significance was only found in patients with predominantly classic lesions, not in those with occult lesions.	Genotype TT is associated with decreased response to photodynamic therapy in people with Macular Degeneration as compared to genotypes CC + CT.	TT	C
89	rs1061170	CFH (PA29261)	ranibizumab (PA164746012)	Patients with the TT genotype had a greater improvement in mean visual acuity, as measured by either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.	Genotype TT is associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	TT	C
90	rs1061170	CFH (PA29261)	"bevacizumab (PA130232992),""ranibizumab (PA164746012)"""	Neovascular age-related macular degeneration. Meta-analysis with 13 studies. Anti-VEGF treatment was much less effective in patients with the CC genotype as compared to those with the CT or TT genotype. Significant results were also seen when considering exclusively Caucasians, though no significant results were seen when considering exclusively East Asians. 10 of the 13 studies defined a positive outcome from anti-VEGF therapy as improvement in visual function (visual acuity), while the remaining three define it as an improvement in retinal morphology (resolution of macular edema). A sub-analysis was done on studies only considering response as improvement in visual acuity, with significant results.	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	CC	C
91	rs1061170	CFH (PA29261)	bevacizumab (PA130232992)	Visual acuity improved later (7-28 days after treatment) in individuals with CC genotype compared to early (0-7 days after treatment) in individuals with CT and TT genotypes.	Genotype CC is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes CT + TT.	CC	C
92	rs10919563	PTPRC (PA34011)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	(no entry)	Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele A.	G	G
93	rs1563828	MDM4 (PA30719)	"docetaxel (PA449383),""epirubicin (PA449476)"""	Patients with the AA genotype had a higher rate of pathological complete response as compared to those with the AG or GG genotype.	Genotype AA is associated with increased response to docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes AG + GG.	AA	A
94	rs1800896	IL10 (PA29778)	etanercept (PA449515)	When this genotype is combined with the rs1800629 GG genotype. Those with the CC-GG combination genotype were more likely to be responders to treatment, as compared to those with any other combination of genotypes. However, no significant difference in genotype frequencies was seen between responders and non-responders when considering the rs1800629 or 1800896 SNPs alone. Responders defined using the American College of Rheumatology (ACR) response criteria and response criteria based on the modified disease activity score (DAS)28 index. Non-responders failed to fulfill both these criteria.	Genotype CC is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	CC	T
95	rs7079	AGT (PA42)	benazepril (PA448561)	Only when rs2640543 genotype (AGTR1 gene) is also taken into account (gene-gene interaction model). Please see study for analysis details - the genotype conferring increased likelihood of response/ sensitivity was not clear. Please note, this study reported alleles C>A - here we have represented the complementary alleles on the plus strand (G>T).	Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype TT.	GG	G
96	rs7079	AGT (PA42)	benazepril (PA448561)	Patients with the TT genotype had a greater decrease in diastolic blood pressure between baseline and 3 years of treatment, compared to those with the GT or GG genotypes. Genotypes were analyzed in an exploratory group (n=733), a confirmatory group (n=714) and for the total population (n=1447). A significant result for systolic blood pressure was seen in the total population. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased response to benazepril in people with Hypertension as compared to genotypes GG + GT.	TT	G
97	rs7079	AGT (PA42)	benazepril (PA448561)	When in a haplotype with rs4762 allele G and rs699 allele A. Patients with this haplotype had a greater decrease in diastolic blood pressure between baseline and 3 years of treatment, compared to those with any other combination of alleles at these positions. Haplotypes were analyzed in an exploratory group (n=733), a confirmatory group (n=714) and for the total population (n=1447). Significant results were only seen for the confirmatory and total populations. Please note alleles have been complemented to the plus chromosomal strand.	Allele T is associated with increased response to benazepril in people with Hypertension.	T	G
98	rs699	AGT (PA42)	irbesartan (PA450084)	Patients with the GG genotype had a greater change in left ventricular mass between baseline and after 12 weeks of treatment, compared to other genotypes. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.	GG	A
99	rs699	AGT (PA42)	quinapril (PA451205)	This SNP was presented as AGT M253T. T homozygotes (genotype GG) had greater minimal lumen diameter, lower late lumen loss, and lower restenosis rates after percutaneous coronary intervention as compared to patients carrying the A allele, which codes for the M amino acid.	Genotype GG is associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotypes AA + AG.	GG	A
100	rs699	AGT (PA42)	benazepril (PA448561)	When in a haplotype with rs4762 allele G and rs7079 allele T. Patients with this haplotype had a greater decrease in diastolic blood pressure between baseline and 3 years of treatment, compared to those with any other combination of alleles at these positions. Haplotypes were analyzed in an exploratory group (n=733), a confirmatory group (n=714) and for the total population (n=1447). Significant results were only seen for the confirmatory and total populations. Please note alleles have been complemented to the plus chromosomal strand.	Allele A is associated with increased response to benazepril in people with Hypertension.	A	A
101	rs699	AGT (PA42)	atenolol (PA448499)	Carriers of the G allele had a greater decrease in systolic blood pressure between baseline and after 12 weeks of treatment, as compared to AA homozygotes. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG are associated with increased response to atenolol in people with Hypertension as compared to genotype AA.	AG + GG	A
102	rs4762	AGT (PA42)	benazepril (PA448561)	Only when rs2106809 genotype (ACE2 gene) is also taken into account (gene-gene interaction model). Please see study for analysis details - the genotype conferring increased likelihood of response/ sensitivity was not clear. Please note, this study reported alleles C>T - here we have represented the complementary alleles on the plus strand (G>A).	Genotype GG is associated with response to benazepril in men with Hypertension as compared to genotype AA.	GG	G
103	rs4762	AGT (PA42)	benazepril (PA448561)	When in a haplotype with rs699 allele A and rs7079 allele T. Patients with this haplotype had a greater decrease in diastolic blood pressure between baseline and 3 years of treatment, compared to those with any other combination of alleles at these positions. Haplotypes were analyzed in an exploratory group (n=733), a confirmatory group (n=714) and for the total population (n=1447). Significant results were only seen for the confirmatory and total populations. Please note alleles have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to benazepril in people with Hypertension.	G	G
104	rs5051	AGT (PA42)	atenolol (PA448499)	No differences in the change in diastolic blood pressure was seen between genotypes, between baseline and 12 weeks of treatment. ANOVA was used, so p-value refers to associations when comparing all three genotypes against each other. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are not associated with response to atenolol in people with Hypertension as compared to genotype CC.	CT + TT	C
105	rs5051	AGT (PA42)	atenolol (PA448499)	Carriers of the A allele had a greater decrease in systolic blood pressure between baseline and after 12 weeks of treatment, as compared to CC homozygotes. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are associated with increased response to atenolol in people with Hypertension as compared to genotype CC.	CT + TT	C
106	rs5051	AGT (PA42)	"benazepril (PA448561),""imidapril (PA452640)"""	Those with the CC genotype had significantly greater reductions in systolic blood pressure (p=0.04), diastolic blood pressure (p=0.014), pulse pressure (p=0.019) and mean arterial pressure (p<0.001) after six weeks of treatment, as compared to those with the CT or TT genotypes. rs5051 genotype was found to be a significant predictor of all the phenotypes listed above (the p-values quoted above refer to this analysis). Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to benazepril or imidapril in people with Hypertension as compared to genotypes CT + TT.	CC	C
107	rs1805087	MTR (PA31272)	"folic acid (PA449692),""hydroxychloroquine (PA164777036)"",""methotrexate (PA450428)"",""sulfasalazine (PA451547)"""	(no entry)	Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	A	A
108	rs1805087	MTR (PA31272)	benazepril (PA448561)	Carriers of the G allele had a significantly smaller drop in diastolic blood pressure between baseline and after 15 days of treatment with benazepril, compared to AA homozygotes.	Genotypes AG + GG are associated with decreased response to benazepril in people with Essential hypertension as compared to genotype AA.	AG + GG	A
109	rs1805087	MTR (PA31272)	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	A
110	rs1130609	RRM2 (PA299)	"cladribine (PA449027),""cytarabine (PA449177)"""	As measured by a poorer overall survival.	Genotypes GT + TT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype GG.	GT + TT	T
111	rs5030743	RRM2 (PA299)	"cladribine (PA449027),""cytarabine (PA449177)"""	As measured by a poorer overall survival. Note this is a G/C SNP, therefore the risk allele could potentially get mixed up.	Genotypes CG + GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype CC.	CG + GG	C
112	rs10192566	LPIN1 (PA30436)	rosiglitazone (PA451283)	Patients with the G allele in rs10192566 had a larger decrease in fasting plasma glucose, 2-h postprandial glucose, and HbA1c than those without.	Allele G is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	G	C
113	rs1801701	APOB (PA50)	irbesartan (PA450084)	Patients with the CC genotype had a greater change in left ventricular mass between baseline and after 12 weeks of treatment, compared to other genotypes. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes CT + TT.	CC	C
114	rs676210	APOB (PA50)	fenofibrate (PA449594)	AA genotype participants had greater lowering of triglycerides than did AG or GG individuals.	Genotype AA is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes AG + GG.	AA	G
115	rs1367117	APOB (PA50)	irbesartan (PA450084)	reduction in systolic blood pressure. Treatment was with 150 mg/day for 12 weeks. The dose was doubled after six weeks if the diastolic blood pressure was >= 90 mmHg. Avg reduction in G carriers was 14 mm Hg.	Genotype GG is associated with response to irbesartan in people with Hypertension.	GG	G
116	rs12999804	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	[stat_test: chi squared allele test]	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	A	A
117	rs10209881	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	Please note; allele frequencies in the responder group deviate from Hardy-Weinberg equilibrium (p=0.03) [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	T
118	rs6752303	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	Please note; allele frequencies in the responder group deviate from Hardy-Weinberg equilibrium (p=0.03) [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	T
119	rs9679162	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	Comparing genotypes of patients who achieved disease control and those with disease progression. Please note; allele frequencies in the responder group deviate from Hardy-Weinberg equilibrium in the retrospective cohort (p=0.03) [stat_test: two-tailed chi-squared]	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.	TT	G
120	rs5009910	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	Please note; allele frequencies in the responder group deviate from Hardy-Weinberg equilibrium (p=0.03) [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	T
121	rs12613732	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	[stat_test: chi squared allele test]	Allele G is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	G	T
122	rs7608731	GALNT14 (PA134920089)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	Please note; allele frequencies in the responder group deviate from Hardy-Weinberg equilibrium (p=0.03) [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	T
123	rs1056836	CYP1B1 (PA27094)	"cyclophosphamide (PA449165),""epirubicin (PA449476)"",""fluorouracil (PA128406956)"""	Patients with the CC genotype had a significantly lower pathological complete response rate as compared to those with the CG and GG genotypes.	Genotype CC is associated with decreased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.	CC	C
124	rs6720975	PRKCE (PA33765)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	The study contained a discovery sample and a replication sample, and also did a meta-analysis of the two samples together. Response is defined as patients whose mini-mental state examination (MMSE) points increased, remained stable, or the change in MMSE points between baseline and end of follow-up (deltaMMSE) fell by 1 point or less. Non-responders were defined as worsening of >3 points on the MMSE. Patients had been treated with cholinesterase inhibitors for at least 6 months. The study also assessed the influence of the SNP on deltaMMSE. Please note alleles have been complemented to the plus chromosomal strand, and that this SNP did NOT reach genome-wide significance in any of the samples.	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T	T
125	rs2278773	PRKCE (PA33765)	perphenazine (PA450882)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele C is associated with response to perphenazine in people with Schizophrenia.	C	C
126	rs12467557	NRXN1 (PA31786)	antipsychotics (PA452233)	Patients homozygous for the A allele had significant improvement in positive symptoms (p=0.002), general psychopathology (p=0.005), thought disturbance (p=0.005), activation (p=0.005) and negative symptoms (p=0.005), while patients carrying the G allele showed no overall response. No significant results were seen for anergia (p=0.0505), paranoid belligerence (p=0.1212) or depression (p=0.1183). Additionally, no significant results were seen when the associations for positive and negative symptoms and general psychopathology were tested for replication in a different cohort (CATIE study).	Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.	AA	A
127	rs10490162	NRXN1 (PA31786)	antipsychotics (PA452233)	Patients homozygous for the T allele had significant improvement in positive symptoms (p=0.0045), general psychopathology (p=0.0146), thought disturbance (p=0.0029), activation (p=0.008), anergia (p=0.0266) and negative symptoms (p=0.0047), while patients carrying the C allele showed no overall response. No significant results were seen for paranoid belligerence (p=0.1598) or depression (p=0.1869). Additionally, no significant results were seen when the associations for positive and negative symptoms and general psychopathology were tested for replication in a different cohort (CATIE study). Please note that alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CC + CT.	TT	T
128	rs1427407	BCL11A (PA25300)	hydroxyurea (PA449942)	(no entry)	Allele T is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.	T	T
129	rs766432	BCL11A (PA25300)	hydroxyurea (PA449942)	(no entry)	Allele C is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele A.	C	C
130	rs4671393	BCL11A (PA25300)	hydroxyurea (PA449942)	(no entry)	Allele A is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.	A	A
131	rs11126740	CTNNA2 (PA27009)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Moderate-to-severe plaque psoriasis. Patients were considered responders if they achieved a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI) (PASI75). PASI data was collected at 3 months, 6 months and 1 year. This variant was significantly associated with response at 3 months.	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.	AA	A
132	rs3087403	REV1 (PA162401120)	cisplatin (PA449014)	Presence of at least one T allele is associated with reduced event-free survival (p = 0.004) and overall survival (p < 0.001), with followup until recurrence or death, with a mean follow-up of 143 months.	Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	CT + TT	C
133	rs6542746	SLC5A7 (PA37838)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	C	C
134	rs724710	BCL2L11 (PA25305)	imatinib (PA10804)	The T allele was also significantly associated with presence of mutations in the kinase domain of the BCR-ABL fusion protein and resistance to tyrosine kinase inhibitors. Response was defined as a ratio of BCR-ABl/ABl of less than or equal to 0.1% by 18 months of treatment with imatinib.	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.	T	T
135	rs1143634	IL1B (PA29808)	infliximab (PA452639)	Patients with Crohn's Disease and the GG genotype showed significantly higher IL1B serum concentrations and significantly lower responses to infliximab treatment as compared to those with the AA or AG genotype. Patients with ulcerative colitis were also studied, but no association between genotype and IL1B concentrations or response to treatment was seen.	Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG.	GG	G
136	rs1143627	IL1B (PA29808)	"Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366),""ustekinumab (PA166048654)"""	Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA.	AG + GG	G
137	rs16944	IL1B (PA29808)	"lansoprazole (PA450180),""omeprazole (PA450704)"",""rabeprazole (PA451216)"""	Patients with the AG genotype had a decreased likelihood of Helicobacter pylori (H. pylori) eradication failure, as compared to those with the GG genotype. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AG is associated with increased response to lansoprazole, omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotype GG.	AG	A
138	rs16944	IL1B (PA29808)	"lansoprazole (PA450180),""omeprazole (PA450704)"",""rabeprazole (PA451216)"""	Patients with the AA genotype had a decreased likelihood of Helicobacter pylori (H. pylori) eradication failure, as compared to those with the GG genotype. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to lansoprazole, omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotype GG.	AA	A
139	rs4848306	IL1B (PA29808)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.	AA + AG	G
140	rs4251961	IL1RN (PA29816)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the UC cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.	CC + CT	T
141	rs3738948	ERCC3 (PA27849)	Platinum compounds (PA164713176)	Additive model (100% of patients with GG achieved response, 89.3% of patients with AG genotype, 68.3% of patients with AA genotype). Platinum-based doublets consisting of cisplatin or carboplatin plus gemcitabine, vinorelbine, taxane or pemetrexed. Response defined as complete or partial response; non-response defined as stable disease or progression disease.	Genotypes AG + GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	AG + GG	A
142	rs10170310	SPOPL (PA162404650)	olanzapine (PA450688)	The number of G alleles present in a patient was positively associated with PGI score.	Allele C is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele A.	C	G
143	rs874295	LRP1B (PA30451)	risperidone (PA451257)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to risperidone in people with Schizophrenia.	G	G
144	rs3768652	CACNB4 (PA26014)	antipsychotics (PA452233)	Patients with the AA and AC genotype had a greater decrease in Positive and Negative Syndrome Scale (PANSS)-negative scores over a period of 12 months as compared to those with the CC genotype. Significance was set at p<3.45E-6. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC.	AA + AC	C
145	rs9713	PSMD14 (PA134957776)	risperidone (PA451257)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to risperidone in people with Schizophrenia.	A	A
146	rs17183814	SCN2A (PA35004)	"carbamazepine (PA448785),""phenobarbital (PA450911)"",""phenytoin (PA450947)"",""valproic acid (PA451846)"""	p value was above significance level after correction for multiple testing. Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	A	G
147	rs10188577	SCN1A (PA301)	antiepileptics (PA143485705)	When correcting for age of onset, seizure type and aetiology, those who were heterozygotes were more likely to be drug-resistant. Drug resistance defined as the occurrence of at least four seizures over a year with trials of two or more sodium channel blocking antiepileptics and maximal tolerated doses.	Genotype CT is associated with increased resistance to antiepileptics in people with Epilepsy.	CT	T
148	rs1344706	ZNF804A (PA162410599)	antipsychotics (PA452233)	Response was measured by the difference in PANSS positive and negative scores between baseline admission and four weeks into treatment. Only the change in positive symptom scores was significantly different depending on genotype. Antipsychotics used by study participants included olanzapine (n = 66), amisulpride (n = 47), clozapine (n = 18), quetiapine (n = 19), risperidone (n = 13), ziprasidone (n = 10), aripiprazole (n = 7), bifeprunox (n = 3) and iloperidone (n = 1).	Genotype AA is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotypes AC + CC.	AA	A
149	rs7574865	STAT4 (PA36185)	ustekinumab (PA166048654)	as measured by PASI75 at 4 months and adjusted for weight and FDR.	Genotypes GT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG.	GT + TT	T
150	rs7574865	STAT4 (PA36185)	etanercept (PA449515)	The degree of response was determined by EULAR score. A significant association between rs7574865 and response to etanercept was seen at two years after beginning treatment. No significant association was seen at six months after beginning treatment. No significant associations were seen at either time point when response was measured as number of patients in remission or with low disease activity.	Allele T is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.	T	T
151	rs3738883	TMEFF2 (PA36568)	risperidone (PA451257)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to risperidone in people with Schizophrenia.	G	T
152	rs55754655	AOX1 (PA24842)	azathioprine (PA448515)	(no entry)	Allele G is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to allele A.	G	A
153	rs889895	CREB1 (PA26864)	antidepressants (PA452229)	Subjects with the GG genotype are more likely to show remission. Non-remitters were defined as having a Hamilton Depression Rating Scale (HDRS) score of > 7 after at least one adequate antidepressant trial during the current or most recent depressive episode. No significant differences were seen when considering patients' resistance or responsiveness (please see paper for definitions of these).	Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	GG	A
154	rs2372536	ATIC (PA25094)	"folic acid (PA449692),""methotrexate (PA450428)"""	(no entry)	Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + CG.	CC	C
155	rs2372536	ATIC (PA25094)	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotypes CC + CG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	CC + CG	C
156	rs2372536	ATIC (PA25094)	methotrexate (PA450428)	as measured by comparison of frequencies in poor responders (DAS28/CRP greater than 2.4 at 6 months) and good responders (DAS28/CRP less than 2.4 at 6 months).	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	GG	C
157	rs12995526	ATIC (PA25094)	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	CT + TT	T
158	rs10210302	ATG16L1 (PA134902949)	adalimumab (PA10004)	After 4 and 12 weeks of treatment, a greater percentage of those with the CT or TT genotype had biological response to treatment as compared to those with the CC genotype. Biological response assessed using change in C-reactive protein (CRP). This association remained significant after correction for multiple testing (p=0.027). Significant results were also seen after 20 and 30 weeks of treatment (p=0.00405), but this was not significant after correction for multiple testing (p=0.134).	Genotypes CT + TT is associated with increased response to adalimumab in people with Crohn Disease as compared to genotype CC.	CT + TT	C
159	rs2741049	UGT1A9 (PA419)	oxcarbazepine (PA450732)	(no entry)	Genotype CC is associated with increased response to oxcarbazepine in people with Seizures as compared to genotypes CT + TT.	CC	T
160	rs6759892	UGT1A6 (PA37181)	deferiprone (PA166118041)	Patients with the GG genotype have an increased chance of responding to deferiprone treatment, as compared to those with the GT or TT genotype. Responders were classified based on serum ferritin levels (<2500 mg/mL). Please note that non-significant results were seen when comparing the GG genotype against the TT genotype.	Genotype GG is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.	GG	T
161	rs2070959	UGT1A6 (PA37181)	deferiprone (PA166118041)	Please note that the authors refer to the alleles for this SNP as A and T, rather than A and G. Assuming that the T allele is meant to be the G allele, patients with the AA genotype have an increased chance of responding to deferiprone treatment, as compared to those with the AG or GG genotype. Responders were classified based on serum ferritin levels (<2500 mg/mL for responders).	Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes AG + GG.	AA	A
162	rs2070959	UGT1A6 (PA37181)	deferiprone (PA166118041)	Please note that the authors refer to the alleles for this SNP as A and T, rather than A and G. Assuming that the T allele is meant to be the G allele, patients with the AA genotype have an increased chance of responding to deferiprone treatment, as compared to those with the GG genotype. Responders were classified based on serum ferritin levels (<2500 mg/mL for responders).	Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotype GG.	AA	A
163	rs12052787	UGT1A9 (PA419)	simvastatin (PA451363)	The mean Emax (maximum decrease in LDL-C) was 59.77 ± 22.68, 64.24 ± 24.56, and 61.42 ± 4.617mg/dl, for patients with 0, 1 or 2 copies of the minor T allele. There is a nominally significant association between Emax with this variant.	Allele T is associated with increased response to simvastatin as compared to allele C.	T	C
164	rs2003569	UGT1A9 (PA419)	simvastatin (PA451363)	The mean Emax (maximum decrease in LDL-C) was 59.3 ± 23.0, 62.0 ± 22.4, and 69.7 ± 24.8 mg/dl, for patients with 0, 1 or 2 copies of the minor A allele. The difference in response was greater in African-Americans than in European Americans when stratified by race.	Allele A is associated with increased response to simvastatin as compared to allele G.	A	G
165	rs4148323	UGT1A1 (PA420)	"cisplatin (PA449014),""irinotecan (PA450085)"""	Homozygotes for the A allele had a lower tumor response rate compared to carriers of the G allele. Tumor response - defined as complete or partial response.	Genotype AA is associated with decreased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	AA	G
166	rs1869295	AGAP1 (PA26412)	risperidone (PA451257)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele C is associated with response to risperidone in people with Schizophrenia.	C	G
167	rs3792269	CAPN10 (PA26058)	metformin (PA450395)	Treatment success was defined as 1) achieving HbA1c <7 % and 2) absolute reduction in HbAlc after 6-months of metformin therapy. The relationships between genotypes and outcomes were evaluated using multivariate logistic and linear models.	Allele G is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele A.	G	A
168	rs17194378	CNTN4 (PA26688)	ziprasidone (PA451974)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to ziprasidone in people with Schizophrenia.	A	A
169	rs2933304	(no entry)	duloxetine (PA10066)	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	T	G
170	rs1801282	PPARG (PA281)	rosiglitazone (PA451283)	The response rate to rosiglitazone treatment was lower in the Pro12Pro (CC) group vs. Pro12Ala (CG) variant group (43.72% versus 86.67%, P =0.002). The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 -27.8mg/dL versus 24.3 -41.9 mg/dL, P=0.026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% -1.47% versus 0.57% -1.16%, P =0 .015).	Genotype CG is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	CG	C
171	rs1801282	PPARG (PA281)	pioglitazone (PA450970)	Patients with the CG genotype showed significantly greater decreases in fasting plasma glucose levels and triglyceride levels after 3 months of pioglitazone treatment. However, changes in other biochemical measures were not significant.	Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	CG	C
172	rs12487736	SCAP (PA162402461)	simvastatin (PA451363)	Patients with the TT genotype had less reduction in total cholesterol (p=0.007) and a trend for a lesser reduction in LDL-cholesterol (p=0.088), and did not show a reduction in trigylcerides (p=0.016) compared to patients with the CC+CT genotypes, after 6 months treatment with simvastatin. Please note; variant was described as SCAP 2386A>G, no rsID provided. Alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	TT	C
173	rs12487736	SCAP (PA162402461)	rosuvastatin (PA134308647)	(no entry)	Allele C is associated with increased response to rosuvastatin in people with Metabolic Syndrome as compared to allele T.	C	C
174	rs11716445	RHOA (PA134865095)	"pravastatin (PA451089),""simvastatin (PA451363)"""	The associated effect was on LDL Cholesterol and explained less than 1% of the variation.	Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G.	A	G
175	rs352139	TLR9 (PA38010)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and CD cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes CC + CT.	TT	T
176	rs352139	TLR9 (PA38010)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Responders were classified as those who were treated for >=225 days. Non-responders were those who stopped treatment before 225 days. Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	CT + TT	T
177	rs2535629	ITIH3 (PA29966)	clozapine (PA449061)	Patients were treated for up to 26 weeks prior to assessment. Improvement was measured on the negative symptom Brief Psychiatric Rating Scale measure, but no association was seen in overall BPRS scores.	Genotype AA is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AG + GG.	AA	G
178	rs7427395	CACNA2D3 (PA26013)	antipsychotics (PA452233)	Patients with the CC genotype had a greater decrease in Positive and Negative Syndrome Scale (PANSS)-general scores over a period of 12 months as compared to those with the TT genotype. No significant association was seen when comparing the CT vs CC genotype. Significance was set at p<3.45E-6.	Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.	CC	T
179	rs6806020	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C	T
180	rs760316	FHIT (PA28140)	"interferon beta-1a (PA450037),""interferon beta-1b (PA450039)"""	In the discovery GWAS stage, the Bonferroni adjusted statistical significance threshold was <=1.74E-10, however no SNPs reached this level, likely due to sample size limitations, and so the significance level was set at <=1.0E-3. In the validation stage, the significance level was set at <0.05, and SNPs that did not have the same direction of response as the discovery stage were considered spurious associations and omitted from further analysis. In further validation in a cohort treated with glutiramer acetate (GA), this SNP was not associated with response. Response was defined as no relapses and no change on Kurtzke Expanded Disability Status Scale (EDSS) scores in the 2 years after starting interferon beta therapy. Non-reponse defined as having >= 2 relapses or an increase in EDSS by at least 1 point in the 2 years follow-up after a minimum duration of 6 months post initiation of therapy.	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.	C	C
181	rs13064411	CFAP44 (PA134928828)	hmg coa reductase inhibitors (PA133950441)	Carriers of the minor G allele of the rs13064411 polymorphism, associated with statin-induced PCSK9-levels, showed an association with a decreased LDL-lowering and total cholesterol-lowering response to statins compared with AA carriers measured as delta total and LDL cholesterol [total: delta=0.551 mmol/l (AG+GG) vs. delta=0.732 mmol/l (AA), Pinteraction: 5.2×10E-7; LDL: delta=0.566 mmol/l (AG+GG) vs. delta=0.720 mmol/l (AA), Pinteraction: 1.8×10E-5].	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to genotype AA.	G	A
182	rs167770	DRD3 (PA27479)	duloxetine (PA10066)	as measured by change in HAM-A score at 10-12 weeks.	Genotype AG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + GG.	AG	G
183	rs324023	DRD3 (PA27479)	duloxetine (PA10066)	as measured by change in HAM-A score at 10-12 weeks.	Genotype CT is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes CC + TT.	CT	T
184	rs6280	DRD3 (PA27479)	pramipexole (PA164742949)	(no entry)	Allele T is associated with increased response to pramipexole.	T	C
185	rs6280	DRD3 (PA27479)	risperidone (PA451257)	as measured by decrease in ATEC score.	Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT.	CC + CT	C
186	rs6280	DRD3 (PA27479)	clozapine (PA449061)	This association was found in carriers of the DRD1 rs686 G allele (gene-gene interaction analysis).	Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	TT	C
187	rs6280	DRD3 (PA27479)	paroxetine (PA450801)	Response was measured by a decrease in score on the Montgomery and Asberg Depression Rating Scale (MADRS). Patients were evaluated on this scale after 1, 2, 4 and 6 weeks of treatment. Patients with the CC + CT genotypes showed significantly greater reductions in MADRS scores after 1 and 2 weeks of treatment, as well as a significantly greater percent improvement in MADRS score from baseline after 2 weeks of treatment, compared to those with the TT genotype.	Genotypes CC + CT are associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to genotype TT.	CC + CT	C
188	rs6280	DRD3 (PA27479)	methylphenidate (PA450464)	Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002).	Genotype TT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CC + CT.	TT	C
189	rs324026	DRD3 (PA27479)	duloxetine (PA10066)	as measured by change in HAM-A score at 10-12 weeks.	Genotypes CC + CT are associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotype TT.	CC + CT	C
190	rs3814055	NR1I2 (PA378)	pazopanib (PA165291492)	(no entry)	Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.	T	C
191	rs6438552	GSK3B (PA29009)	lithium (PA450243)	This result is for the combination of GG at this SNP with rs2071427 TT. People with this genotype combination had a 75% chance of being in the Li-responsive group. People with rs2071427 CC/rs6438552 AA had a 44% response rate. Those with 2 or 3 favorable alleles had responses on a gradient between these two results.	Genotype GG is associated with increased response to lithium in people with Bipolar Disorder.	GG	A
192	rs334558	GSK3B (PA29009)	"citalopram (PA449015),""fluoxetine (PA449673)"""	(no entry)	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	GG	A
193	rs4839603	SLC9A9 (PA134889062)	"fentanyl (PA449599),""remifentanil (PA451232)"""	Study looked at intraopertive and postoperative opioid use in two cohorts. Please note that alleles have been complemented to the positive strand.	Genotype GG is associated with decreased dose of fentanyl or remifentanil in people with Pain as compared to genotypes AA + AG.	GG	A
194	rs2640543	AGTR1 (PA43)	benazepril (PA448561)	Only when rs7079 genotype (AGT gene) is also taken into account (gene-gene interaction model). Please see study for analysis details - the genotype conferring increased likelihood of response/ sensitivity was not clear.	Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype AA.	GG	A
195	rs5182	AGTR1 (PA43)	perindopril (PA450877)	Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes.	Genotypes CC + CT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.	CC + CT	C
196	rs5186	AGTR1 (PA43)	nitrendipine (PA146096020)	Patients homozygous for the A allele had a greater reduction in pulse wave velocity as compared to patients carrying the C allele. No difference was seen in reduction of blood pressure between genotypes.	Genotype AA is associated with increased response to nitrendipine in people with Hypertension as compared to genotypes AC + CC.	AA	A
197	rs5186	AGTR1 (PA43)	losartan (PA450268)	This study involves IV administered EXP3174, the active metabolite of losartan. Patients with the CC genotype showed significantly blunted systemic and renal hemodynamic effects of AT1R blockade as compared to patients with the AA genotype. No patients with the AC genotype were studied.	Genotype CC is associated with decreased response to losartan in people with Essential hypertension as compared to genotype AA.	CC	A
198	rs5186	AGTR1 (PA43)	losartan (PA450268)	Subjects carrying the C allele had significantly higher glomerular filtration rate (GFR), decreased mean arterial pressure (MAP), and decreased aldosterone levels when treated with losartan as compared to subjects with the AA genotype. No significant differences in renal plasma flow (ERPF), renal blood flow (RBF), filtration fraction (FF), renal vascular resistance (RVR), and urinary sodium excretion (UnaV) were seen between genotype groups.	Genotypes AC + CC are associated with increased response to losartan in healthy individuals as compared to genotype AA.	AC + CC	A
199	rs5186	AGTR1 (PA43)	perindopril (PA450877)	Patients carrying the C allele had larger decreases in blood pressure, and had a greater reduction in pulse wave velocity as compared to patients homozygous for the A allele.	Genotype AA is associated with decreased response to perindopril in people with Hypertension as compared to genotypes AC + CC.	AA	A
200	rs5186	AGTR1 (PA43)	losartan (PA450268)	Cirrhotiç patients with portal hypertension and the AA genotype showed a higher decrease of hepatic venous pressure gradient as compared to patients carrying the C allele.	Genotype AA is associated with increased response to losartan in people with Liver Cirrhosis as compared to genotypes AC + CC.	AA	A
201	rs5186	AGTR1 (PA43)	candesartan (PA448765)	Subjects with the AC genotype had a greater decrease in N-terminal proB-type natriuretic peptide (NT-proBNP) over 6 months of treatment, as compared to AA homozygotes.	Genotype AC is associated with increased response to candesartan in people with Heart Failure as compared to genotype AA.	AC	A
202	rs5186	AGTR1 (PA43)	angiotensin II (PA166109554)	When infused with synthetic angiotensin II, subjects with the AA genotype exhibited a significant decrease in GFR as compared to subjects carrying the C allele, whose GFRs remained constant throughout infusion. No other differences were seen between genotype groups during infusion with angiotensin II.	Genotype AA is associated with increased response to angiotensin II in healthy individuals as compared to genotypes AC + CC.	AA	A
203	rs5186	AGTR1 (PA43)	candesartan (PA448765)	Homozygotes for the A allele had a greater decrease in systolic and diastolic blood pressure following 2 weeks of treatment, as compared to subjects with the AC genotype.	Genotype AA is associated with increased response to candesartan in people with Heart Failure as compared to genotype AC.	AA	A
204	rs5186	AGTR1 (PA43)	captopril (PA448780)	99mTc-MAG3 clearance (MAG3cle) values were higher in patients who were carriers for the C allele, as compared to AA homozygotes, after treatment with captopril. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment.	Genotypes AC + CC are associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	AC + CC	A
205	rs5186	AGTR1 (PA43)	candesartan (PA448765)	No significant difference in the change of high sensitivity C-reactive protein (hsCRP) between genotypes was seen over 6 months of treatment.	Genotype AC is not associated with response to candesartan in people with Heart Failure as compared to genotype AA.	AC	A
206	rs6809699	P2RY12 (PA134971947)	clopidogrel (PA449053)	in Chinese patients with acute coronary syndrome undergoing PCI. This variant is also called P2RY12 G52T.	Genotypes AA + AC is associated with increased resistance to clopidogrel as compared to genotype CC.	AA + AC	A
207	rs6785930	P2RY12 (PA134971947)	clopidogrel (PA449053)	in Chinese patients with acute coronary syndrome undergoing PCI. This variant is also called P2RY12 C34T.	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.	AA + AG	G
208	rs2046934	P2RY12 (PA134971947)	clopidogrel (PA449053)	(no entry)	Genotype AA is associated with increased response to clopidogrel in people with Coronary Disease as compared to genotypes AG + GG.	AA	G
209	rs1803274	BCHE (PA25294)	rivastigmine (PA451262)	"Patients carrying at least one copy of rs1803274 C>T (also known as the K-variant) demonstrated less response to rivastigmine than patients who were homozygous for the C allele. The primary analysis population was ""intent-to-treat with last-observation carried forward"" in a group of alzheimer's disease patients under 75 years of age. The cohort included patients on either rivastigmine or donepezil. Multiple tests was used to asses response to either of those drugs: severe impairment battery (SIB), Alzheimer's disease cooperative study activities of daily living (ADCS-ADL) mini-mental state examination (MMSE), the 10-item neuropsychiatric inventory (NPI) and global deterioration scale (GDS)."	Genotype CC is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CT + TT.	CC	C
210	rs1803274	BCHE (PA25294)	rivastigmine (PA451262)	"The primary outcome, response, was assessed by the Alzheimer's Disease assessment scale-cognitive scale (ADAS-cog). Supplementary outcomes were estimated with a series of other tests. ""Responders"" were patients that had an equal or better score on the outcome measures at 16 weeks as compared to their baseline scores. The study included patients on rivastigmine mono therapy as well as patients with add-on memantine therapy. Some patients carried the APOE4 allele and some did not. Sub-group analysis showed that among carriers of the APOE4 allele and among AD patients with a high mini-mental state exam score (greater or equal to 16) the T allele was associated with worse response to rivastigmine."	Genotypes CT + TT is associated with decreased response to rivastigmine in people with Alzheimer Disease as compared to genotype CC.	CT + TT	C
211	rs1803274	BCHE (PA25294)	"memantine (PA10364),""rivastigmine (PA451262)"""	"The primary outcome, response, was assessed by the Alzheimer's Disease assessment scale-cognitive scale (ADAS-cog). Supplementary outcomes were estimated with a series of other tests. ""Responders"" were patients that had an equal or better score on the outcome measures at 16 weeks as compared to their baseline scores. The study included patients on rivastigmine mono therapy as well as patients with add-on memantine therapy. Some patients carried the APOE4 allele and some did not. Sub-group analysis showed that among patients co-administered memantine the T allele was associated with worse response to rivastigmine."	Genotypes CT + TT is associated with decreased response to memantine and rivastigmine in people with Alzheimer Disease as compared to genotype CC.	CT + TT	C
212	rs1803274	BCHE (PA25294)	rivastigmine (PA451262)	Patients with Lewy Body dementia were assessed by Simple Reaction Time (SRT) and Choice Reaction Time (CRT), measured in milliseconds (with shorter time-scores indicating better cognition and attention). Patients who were heterozygous (CT) demonstrated improved performance on cognition/attenion assessments after treatment with the cholinesterase inhibitor rivastigmine when compared to patients that were homozygous for the K-variant (rs1803274 TT) (but the analysis combined patients homozygous for the K-variant with patients heterozygous for the A-variant (rs1799807 CT).	Genotype CT is associated with increased response to rivastigmine in people with Lewy Body Disease as compared to genotype TT.	CT	C
213	rs1803274	BCHE (PA25294)	donepezil (PA449394)	Cognitive response to treatment was assessed in patients with mild cognitive decline from Alzheimer’s Disease Assessment (ADAS) Score-Cognition by contrasting total ADAS-Cog score obtained at baseline with that obtained at 36 months after MCI diagnosis (diff. ADAS-Cog score). There was a significantly earlier age of onset for female T allele carriers, and APOE4/T co-carriers. Improved response was associated with reduced brain cholinergic activity in carriers.	Allele T is associated with increased response to donepezil in women with Alzheimer Disease as compared to allele C.	T	C
214	rs8192675	SLC2A2 (PA35876)	metformin (PA450395)	The C allele of rs8192675 was associated with a 0.17% (P = 6.6 × 10-14) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry.	Allele C is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele T.	C	T
215	rs2241766	ADIPOQ (PA134933118)	pioglitazone (PA450970)	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%). When comparing the response rates between patients with the GT versus TT genotypes, the GT genotypes were associated with a greater frequency of response (52.94% versus 12.7% p=0.001) as well as a greater decrease in HbA1c% as compared to patients with the TT genotype (1.15 versus 0.52 p=0.001). Logistic regression analysis showed that rs2241766 GT genotype was associated with response to pioglitazone. *Please note: there were no individuals of genotype GG."	Genotype GT is associated with increased response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	GT	T
216	rs4961	ADD1 (PA31)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	Subjects homozygous for the T allele had increased urinary excretion of calcium as compared to GG homozygotes, during the 24 hours after drug administration.	Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.	TT	G
217	rs2960306	GRK4 (PA28941)	metoprolol (PA450480)	in cox regression analysis when examining the rs1024323 genotype (variant interaction analysis - no association was found examining this variant on its own). Response was measured by time to reach a mean arterial pressure of < or = 107 mm Hg.	Genotypes GT + TT are associated with decreased response to metoprolol in men with hypertensive nephrosclerosis.	GT + TT	G
218	rs2960306	GRK4 (PA28941)	atenolol (PA448499)	This decrease in response was only significant* when considered as part of a haplotype with rs1024323. The finding was that increasing copies of rs2960306T-rs1024323T haplotype were associated with significantly reduced atenolol-induced diastolic blood pressure lowering (-9.1±6.8 versus -6.8±7.1 versus -5.3±6.4 mm Hg in participants with 0, 1, and 2 copies respectively). Analysis of the SNP alone showed a trend towards decreased response with the T allele. The association of the haplotype was only observed in rs1801253 CC genotypes in Whites. *= authors state that the data are statistically significant when Bonferroni-corrected for the number of SNPs tested in the analysis but that they do not meet chip-wide Bonferroni-corrected significance.	Allele T is associated with decreased response to atenolol in people with Hypertension as compared to allele G.	T	G
219	rs1024323	GRK4 (PA28941)	metoprolol (PA450480)	This was an additive effect - patients with the CT genotype had a worse response compared to those with TT but better response compared to those with CC. Using Cox analysis, this was shown to only be significant in men who were also heterozygous or homozygous for the rs2960306 allele T (Leu65) and was not seen in men homozygous for rs2960306 allele G (Arg65). Response was measured by time to reach a mean arterial pressure of < or = 107 mm Hg.	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.	CC	C
220	rs1024323	GRK4 (PA28941)	atenolol (PA448499)	This decrease in response was only significant* when considered as part of a haplotype with rs2960306. The finding was that increasing copies of rs2960306T-rs1024323T haplotype were associated with significantly reduced atenolol-induced diastolic blood pressure lowering (-9.1±6.8 versus -6.8±7.1 versus -5.3±6.4 mm Hg in participants with 0, 1, and 2 copies respectively). Analysis of the SNP alone showed a trend towards decreased response with the T allele. The association of the haplotype was only observed in rs1801253 CC genotypes in Whites. *= authors state that the data are statistically significant when Bonferroni-corrected for the number of SNPs tested in the analysis but that they do not meet chip-wide Bonferroni-corrected significance.	Allele T is associated with decreased response to atenolol in people with Hypertension as compared to allele C.	T	C
221	rs1801058	GRK4 (PA28941)	metoprolol (PA450480)	Note; there were no female TT (V486) homozygotes. Response was measured by time to reach a mean arterial pressure of < or = 107 mm Hg.	Genotype CT is associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype CC.	CT	T
222	rs1870377	KDR (PA30086)	"carfilzomib (PA166165203),""dexamethasone (PA449247)"",""lenalidomide (PA162363968)"""	"as measured by ""minimum residual disease negativity"" (MRD-). Gene is on negative strand, alleles complemented to positive strand. Authors reported for response associated allele as protein change as 472Q."	Genotypes AT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype AA.	AT + TT	T
223	rs2305948	KDR (PA30086)	clopidogrel (PA449053)	Genotype and allele frequency of VEGFR-2 rs2305948 was significantly higher in the CR (clopidogrel resistant) group than in the NCR group (TT: 55.9% vs. 36.1%, P<0.05; T allele: 78.5% vs. 66.8%,P<0.01, respectively).	Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C.	T	C
224	rs2305948	KDR (PA30086)	"carfilzomib (PA166165203),""dexamethasone (PA449247)"",""lenalidomide (PA162363968)"""	Authors indicate repose as CR/nCR/sCR but do not define these and non-response as VGPR and PR/SD (which assume to mean progression/stable disease). There was only one TT individual who had sCR.	Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	CT + TT	C
225	rs2071559	KDR (PA30086)	ranibizumab (PA164746012)	as measured by improvement in mean retinal sensitivity but was not significant when measured by best corrected visual acuity or other methods.	Genotypes AA + AG is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotype GG.	AA + AG	A
226	rs1355368	ADGRL3 (PA134968284)	methylphenidate (PA450464)	Assessed as haplotype block as rs6813183, rs1355368, and rs734644. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The CGC/CGC diplotype showed faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. CGC/CGC has faster response compared to CGC/GAT.	Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	AG + GG	A
227	rs80143932	DCK (PA137)	"cytarabine (PA449177),""idarubicin (PA449961)"""	"Patients were divided into ""good responders"" and ""poor responders"" and frequencies of haplotypes were compared between groups. Good responders were those that went into complete remission with the first induction of AraC and idarubicin and remained relapse free for at least 6 months afterwards. Among the patients there were three compound haplotypes at rs80143932 and rs2306744: CC/CC, CG/CT, and GG/TT. Patients with the G/T haplotype were more likely to be good responders. Patients with the C/C haplotype were more likely to be poor responders. rs80143932 and rs2306744 SNPs were also reported to be in very high linkage disequilibrium."	Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	G	C
228	rs2306744	DCK (PA137)	"cytarabine (PA449177),""idarubicin (PA449961)"""	"Patients were divided into ""good responders"" and ""poor responders"" and frequencies of haplotypes at rs80143932 and rs2306744 were compared between groups. Good responders were those that went into complete remission with the first induction of AraC and idarubicin and remained relapse free for at least 6 months afterwards. Among the patients there were three compound haplotypes at rs80143932 and rs2306744: CC/CC, CG/CT, and GG/TT. Patients with the G/T haplotype were more likely to be good responders. Patients with the C/C haplotype were more likely to be poor responders. rs80143932 and rs2306744 SNPs were also reported to be in very high linkage disequilibrium."	Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	T	C
229	rs4073	CXCL8 (PA29841)	"bevacizumab (PA130232992),""cyclophosphamide (PA449165)"""	(no entry)	Genotypes AA + AT are associated with decreased response to bevacizumab and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	AA + AT	A
230	rs4073	CXCL8 (PA29841)	bevacizumab (PA130232992)	The A allele was more frequent in non-responders than in responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder.	Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes AT + TT.	AA	A
231	rs4073	CXCL8 (PA29841)	ranibizumab (PA164746012)	(no entry)	Genotype AA is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotypes AT + TT.	AA	A
232	rs352046	CXCL5 (PA35573)	hmg coa reductase inhibitors (PA133950441)	Since this is a GC SNP, there is the possibility of stranding error. The CXCL5 gene is on the negative chromosomal strand, so I complemented the reported results, which are: GG patients on statins showed a significant, 58% relative risk reduction (p = 0.0009);GC patients on statins showed a non-significant 25% relative risk reduction(p = 0.48), and CC patients on statins showed a non-significant 39% relative risk INCREASE (p = 0.46).	Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Acute coronary syndrome as compared to genotypes CG + GG.	CC	G
233	rs1353295	AREG (PA24933)	"cetuximab (PA10040),""panitumumab (PA162373091)"""	Patients with the GG genotype showed significantly higher disease control rate (100%) as compared to those with the AA or AG (72%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	G
234	rs13104811	AREG (PA24933)	"cetuximab (PA10040),""panitumumab (PA162373091)"""	Patients with the GG genotype showed significantly higher disease control rate (100%) as compared to those with the AA or AG (70%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	G
235	rs9996584	AREG (PA24933)	"cetuximab (PA10040),""panitumumab (PA162373091)"""	Patients with the AA genotype showed significantly higher disease control rate (89%) as compared to those with the AC (80%) or CC (60%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease). Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	AA	A
236	rs11942466	AREG (PA24933)	"cetuximab (PA10040),""panitumumab (PA162373091)"""	Patients with the AA genotype showed significantly lower disease control rate (25%) as compared to those with the AC (72%) or CC (85%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype AA is associated with decreased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.	AA	C
237	rs11942466	AREG (PA24933)	"capecitabine (PA448771),""radiotherapy (PA166122986)"""	p-value and OR below for multivariate analysis. In univariate analysis, 35.7% of those with the CC genotype achieved pathological complete response, compared with 19.4% of those with the AC genotype and 0% of those with the AA genotype.	Genotypes AA + AC is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype CC.	AA + AC	C
238	rs56061981	CXCL10 (PA35568)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	PEG-interferon alfa (2a and b) was co-adminstered with ribavirin. Response was assessed by sustained virological response (SVR) percent by genotype. When assessed alone, the polymorphism was not significantly associated with SVR. However, in patients infected with hepatitis C- genotype I (N=266), who also carried the rs12979860 CT or TT genotypes, the CT+TT genotypes of rs56061981 became associated with increased rats of SVR when compared to patients with the CC genotype (CC+CT genotype 66.7% vs. CC genotype 33.0%, P = 0.004). Please note, alleles have been complemented to the + chromosomal strand.	Genotypes CT + TT are associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype CC.	CT + TT	C
239	rs12505410	ABCG2 (PA390)	imatinib (PA10804)	As part of a haplotype with rs2725252: those with the G-C haplotype (rs12505410-rs2725252) had a significantly higher cumulative incidence major molecular response (CI-MMR) as compared to those with any other haplotype (i.e. G-A, T-C, T-A). This study was done in an exploratory cohort (n=105) and a validation cohort (n=239); within the validation cohort, patients were either taking a 400mg/day dose of imatinib (n=132) or a 600mg/day dose (n=107). Results were NOT significant for those taking a 600mg/day dose. Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.	G	T
240	rs12505410	ABCG2 (PA390)	imatinib (PA10804)	Individuals with the GG or GT genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the TT genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p=0.32), though significant results were seen when considering all patients (n=239; p=0.045). The authors note that they used the Benjamini and Hochberg method for multiple testing issues.	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	GG + GT	T
241	rs12505410	ABCG2 (PA390)	imatinib (PA10804)	As part of a haplotype with rs2725252. Where response was defined as BCR-ABL/ABL standardized ratio (BCR-ABL^IS) of <=10% at 3 months, <=1% at 12 months and <=0.1% at 18 months. Patients were either taking 400mg/day or 600mg/day dose of imatinib. Those with the G-C haplotype (rs12505410-rs2725252) taking a 400mg/day dose had a significantly better response (under all definitions of response), as compared to those with any other haplotype (i.e. G-A, T-C, T-A). Results were NOT significant for those taking a 600mg/day dose (p=0.209, 0.316 and 0.209, respectively for the different response definitions). Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.	G	T
242	rs13120400	ABCG2 (PA390)	methotrexate (PA450428)	(no entry)	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes TT + CT.	CC	T
243	rs13120400	ABCG2 (PA390)	imatinib (PA10804)	Individuals with the CC or CT genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the TT genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p=0.74). The authors note that they used the Benjamini and Hochberg method for multiple testing issues.	Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	CC + CT	T
244	rs1481012	ABCG2 (PA390)	rosuvastatin (PA134308647)	The minor allele of this SNP is associated with increased fractional LDL-C reduction on rosuvastatin.	Genotypes AG + GG are associated with increased response to rosuvastatin as compared to genotype AA.	AG + GG	A
245	rs2231142	ABCG2 (PA390)	sulfasalazine (PA451547)	After adjusting for age, baseline DAS28, smoking status and shared epitope positivity, those who carried one or more T allele were more likely to achieve remission after 12 months of treatment. Remission defined as an SDAI of <3.3. Please note that alleles have been complemented to the positive chromosomal strand.	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.	GT + TT	G
246	rs2231142	ABCG2 (PA390)	antineoplastic agents (PA452621)	Patients with the GG genotype receiving a FOLFOX/XELOX regimen (respectively: fluorouracil, leucovorin, oxaliplatin; capecitabine, oxaliplatin) had a decreased response rate, as compared to those with the GT or TT genotype. No significant difference in response rate was seen in patients receiving a FOLFIRI regimen (fluorouracil, leucovorin, irinotecan). No significant differences in progression-free survival were seen for either regimen. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.	GG	G
247	rs2231142	ABCG2 (PA390)	allopurinol (PA448320)	"The authors designated ""response to allopurinol"" as a reduction of serum uric acid levels to below 6 mg/dL. Mean age was 68 years, 75% were male. The elevated mean baseline SUA before treatment was 8.9 mg/dL. No other SNPs reached genome wide significance."	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.	T	G
248	rs2231142	ABCG2 (PA390)	allopurinol (PA448320)	Good response was defined as serum urate of < 6 mg/dl on a dose of allopurinol on less than 300 mg/day and poor response was defined as serum urate of greater than or equal to 6 mg/dl despite allopurinol of greater than 300 mg/d. The frequency of the GT and TT genotypes was higher in the poor responder group (N=68) than in the good responder group (N=120). This association remained significant even after adjusting for gender, BMI, ethnicity, estimated glomerular filtration rate, diuretic use, and serum urate concentration at baseline.	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.	GT + TT	G
249	rs2231142	ABCG2 (PA390)	hmg coa reductase inhibitors (PA133950441)	as part of a three SNP genetic risk score with rs10455872 in LPA and rs2075650 in APOE. Associated allele not explicitly stated but methods reference Tomlinson et al. so used the associated allele from there [PMID:20130569].	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.	G	G
250	rs2231142	ABCG2 (PA390)	rosuvastatin (PA134308647)	as measured by achievement of their LDL cholesterol target (significance given for variants of either CYP3A5*1, 6986A>G, rs776746 and ABCG2; 421C>A, rs2231142).	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.	T	G
251	rs2231142	ABCG2 (PA390)	imatinib (PA10804)	Direction of relationship not explicitly stated. Assumed minor allele as T and having lower odds ratio of response. Alleles complemented to plus strand as gene is on minus chromosomal strand.	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.	T	G
252	rs2231142	ABCG2 (PA390)	iguratimod (PA166178387)	Alleles complemented to plus strand.	Genotypes GT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype GG.	GT + TT	G
253	rs2231142	ABCG2 (PA390)	"Opioid anesthetics (PA164712948),""Other general anesthetics (PA164713083)"",""volatile anesthetics (PA166131630)"""	The TT genotype was significantly associated with a shorter recovery time from general anesthesia compared to the GG and GT genotypes.	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.	TT	G
254	rs2231142	ABCG2 (PA390)	allopurinol (PA448320)	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment. This SNP is in perfect LD with rs45499402.	Allele T is associated with decreased response to allopurinol as compared to allele G.	T	G
255	rs17731538	ABCG2 (PA390)	methotrexate (PA450428)	(no entry)	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	GG	G
256	rs2725252	ABCG2 (PA390)	imatinib (PA10804)	Individuals with the AC or CC genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the AA genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p < 0.74). The authors note that they used the Benjamini and Hochberg method for multiple testing issues. Please also note that alleles have been complemented to the plus chromosomal strand.	Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.	AC + CC	C
257	rs2725252	ABCG2 (PA390)	imatinib (PA10804)	As part of a haplotype with rs12505410: those with the G-C haplotype (rs12505410-rs2725252) had a significantly higher cumulative incidence major molecular response (CI-MMR) as compared to those with any other haplotype (i.e. G-A, T-C, T-A). This study was done in an exploratory cohort (n=105) and a validation cohort (n=239); within the validation cohort, patients were either taking a 400mg/day dose of imatinib (n=132) or a 600mg/day dose (n=107). Results were NOT significant for those taking a 600mg/day dose. Please note that alleles have been complemented to the plus chromosomal strand.	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.	C	C
258	rs2725252	ABCG2 (PA390)	imatinib (PA10804)	As part of a haplotype with rs12505410. Where response was defined as BCR-ABL/ABL standardized ratio (BCR-ABL^IS) of <=10% at 3 months, <=1% at 12 months and <=0.1% at 18 months. Patients were either taking 400mg/day or 600mg/day dose of imatinib. Those with the G-C haplotype (rs12505410-rs2725252) taking a 400mg/day dose had a significantly better response (under all definitions of response), as compared to those with any other haplotype (i.e. G-A, T-C, T-A). Results were NOT significant for those taking a 600mg/day dose (p=0.209, 0.316 and 0.209, respectively for the different response definitions). Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.	C	C
259	rs6811453	ADH1A (PA24570)	"cytarabine (PA449177),""fludarabine (PA449655)"",""gemtuzumab ozogamicin (PA164749431)"",""idarubicin (PA449961)"""	rs6811453 was in linkage with rs1826909, another SNP in ADH1A.	Allele A is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele G.	A	G
260	rs1826909	ADH1A (PA24570)	"cytarabine (PA449177),""fludarabine (PA449655)"",""gemtuzumab ozogamicin (PA164749431)"",""idarubicin (PA449961)"""	rs1826909 was in linkage with rs6811453, another SNP in ADH1A.	Allele T is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	T	C
261	rs1800591	MTTP (PA164742099)	atorvastatin (PA448500)	as measured by a larger decreased in log triglyceride levels, compared to patients with the GT and GG genotypes which was minimal. Changes in other parameters were not significantly associated with genotype. This variant was described as MTP -493 GT.	Genotype TT is associated with increased response to atorvastatin in men with Hyperlipoproteinemia Type II.	TT	G
262	rs3774959	NFKB1 (PA248)	flupenthixol (PA10268)	as measured by change in PANSS score.	Genotype AG is associated with increased response to flupenthixol in people with Schizophrenia as compared to genotype GG.	AG	G
263	rs6822844	IL2 (PA195)	rituximab (PA451261)	The GG genotype frequency was increased in responders as compared to non-responders. This was significant in multivariate logistic regression analysis after adjusting for gender, age, corticosteroids, DMARDs and other therapies. SNP is described as being in the IL2-IL21 gene region.	Genotype GG is associated with increased response to rituximab in people with Lupus Erythematosus, Systemic as compared to genotype GT.	GG	G
264	rs6822844	IL2 (PA195)	rituximab (PA451261)	The GG genotype frequency was increased in responders as compared to non-responders. For a list of the various systemic autoimmune diseases included, please refer to the paper directly. This analysis was run including patients with systemic lupus erythematosus (n = 144; significant result) and without including them (n = 60; non-significant result). SNP is described as being in the IL2-IL21 gene region.	Genotype GG is associated with increased response to rituximab in people with Autoimmune Diseases as compared to genotype GT.	GG	G
265	rs11100483	MAML3 (PA134953776)	perphenazine (PA450882)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to perphenazine in people with Schizophrenia.	A	G
266	rs5522	NR3C2 (PA242)	enalapril (PA449456)	The reduction in diastolic blood pressure (DBP) was significantly greater in patients with the TT genotype compared to the CC+CT genotype (p=0.009). Reduction is systolic blood pressure (SBP) was NOT significantly different between genotypes. Multiple linear regression analysis showed that significant predictors of DBP were rs5522 genotype, baseline DBP and wait:hip ratio. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased response to enalapril in people with Hypertension as compared to genotypes CC + CT.	TT	C
267	rs4696480	TLR2 (PA36550)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the UC cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotypes AA + AT.	TT	T
268	rs4696480	TLR2 (PA36550)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate.	Genotypes AT + TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	AT + TT	T
269	rs1816702	TLR2 (PA36550)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the CD cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype CC.	CT + TT	T
270	rs3804099	TLR2 (PA36550)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD, CD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.	CC + CT	T
271	rs3775291	TLR3 (PA36551)	Measles vaccines (PA164712887)	compared to both homozygous genotypes	Genotype TC is associated with decreased response to Measles vaccines as compared to genotype CC.	TC	C
272	rs2550948	SLC6A3 (PA311)	methylphenidate (PA450464)	For the genetic component, in the CGI-S model, a dominant effect in SLC6A3 rs2550948 was found with a significant improvement in the symptoms. Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Genotypes CC + CT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	CC + CT	C
273	rs274713	TENT4A (PA33523)	gemcitabine (PA449748)	Associated with longer overall survival (was not significantly associated with time to progression).	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	GG	T
274	rs1801394	"FASTKD3 (PA145148868),""MTRR (PA31277)"""	methotrexate (PA450428)	Non-response was classified by DAS28 >3.2 at two consecutive evaluations (minimum period of at least 6 months of MTX therapy).	Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	AA + AG	A
275	rs1801394	MTRR (PA31277)	methotrexate (PA450428)	Authors say this variant is associated with response in dominant model (minor allele/minor allele + minor/major vs major major and describe variant as A>G).	Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA.	AG + GG	A
276	rs1801394	MTRR (PA31277)	methotrexate (PA450428)	The A allele was independently associated with worse response using two distinct measures of response 1) the difference in Disease Activity Score 28 between baseline and 6 months later (deltaDAS28) and 2) the European League Against Rheumatism (EULAR) criteria. For DAS28, each A allele corresponded to 0.14 deltaDAS28 units in an additive model vs the G allele (indicating worse response assoc. with A allele). Using EULAR criteria the A allele also had an increased OR=1.39 for non-response (95% CI 1.11–1.75).	Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	A	A
277	rs2973049	GDNF (PA28644)	paroxetine (PA450801)	To ensure the accuracy of the results, multiple linear regression models were applied, and 3 SNPs were still identified as significant determinants of paroxetine clinical response (P rs 6265 = 0.001, P rs 2973049 = 0.011, and P rs 2216711 = 0.010). According to all of the analyses, the variability in paroxetine clinical response could be attributed to plasma concentration and SNPs.	Genotypes CT + TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotype CC.	CT + TT	T
278	rs2216711	GDNF (PA28644)	paroxetine (PA450801)	Patients were grouped by gender, the data revealed that the significant difference between A allele carriers in responder vs non-responder existed only in women (P=0.013) and not in men (P = 0.133). To ensure the accuracy of the results, multiple linear regression models were applied, and 3 SNPs were still identified as significant determinants of paroxetine clinical response (P rs 6265 = 0.001, P rs 2973049 = 0.011, and P rs 2216711 = 0.010). According to all of the analyses, the variability in paroxetine clinical response could be attributed to plasma concentration and SNPs.	Genotypes AA + AG is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype GG.	AA + AG	G
279	rs17382202	PDE4D (PA33130)	quetiapine (PA451201)	The number of T alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs17742120 and rs2164660.	Allele T is associated with increased response to quetiapine in people with Schizophrenia as compared to allele C.	T	C
280	rs1364043	HTR1A (PA192)	"fluvoxamine (PA449690),""milnacipran (PA164752812)"",""paroxetine (PA450801)"""	(no entry)	Genotype TT is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes GG + GT.	TT	T
281	rs6295	HTR1A (PA192)	"fluvoxamine (PA449690),""milnacipran (PA164752812)"",""paroxetine (PA450801)"""	"Caution: this is a C/G SNP in a gene on the minus strand. The authors state the association for the GG genotype (minor allele) assayed on positive chromosomal strand (ie. did not need to complement). Authors also stated ""We also pointed out the genotyping mis-definition of rs6295C/G in the previous four articles."""	Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.	GG	C
282	rs6295	HTR1A (PA192)	fluoxetine (PA449673)	Alleles reported as found in paper. Gene is on the negative strand association but it is unclear if this was taken into account when the genotype was describe in the article. Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment.	Genotype CC is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele G.	CC	C
283	rs6295	HTR1A (PA192)	clozapine (PA449061)	Patients with the GG genotype had a greater improvement on the Positive and Negative Symptoms Scale (PANSS), Negative Symptoms Subscale, as compared to those with the CC or CG genotypes. PANSS score was measured at baseline and then after 12 weeks of treatment.	Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CG.	GG	C
284	rs6295	HTR1A (PA192)	milnacipran (PA164752812)	depressive symptoms measured on Hamilton Rating Scale for Depression and outcome as change in symptoms, as measured 6 weeks after drug, following 10 days washout.	Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.	CC + CG	C
285	rs10042486	HTR1A (PA192)	"fluvoxamine (PA449690),""milnacipran (PA164752812)"",""paroxetine (PA450801)"""	(no entry)	Genotype CC is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	CC	C
286	rs10042486	HTR1A (PA192)	"amisulpride (PA162565877),""antipsychotics (PA452233)"",""olanzapine (PA450688)"",""quetiapine (PA451201)"",""risperidone (PA451257)"""	Response was measured by difference in PANSS scores between admission and discharge. Subjects with the TT genotype were more likely to improve on the PANSS total, positive and negative scores as compared to the CC + CT genotypes. Percentages of study participants taking each drug are as follow: risperidone (34%), olanzapine (24%), quetiapine (6%), amisulpiride (15%), and other antipsychotics (4%).	Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.	TT	C
287	rs17671591	HMGCR (PA189)	atorvastatin (PA448500)	Patients with the CT or TT genotype had a greater drop in low-density lipoprotein cholesterol (LDL-C) as compared to those with the CC genotype; no significant difference in basal levels or post-treatment levels were seen. Additionally, those with the CT or TT genotype had a greater increase in high-density lipoprotein cholesterol (HDL-C) as compared to those with the CC genotype; those with the CT or TT genotype also had a lower basal level of HDL-C as compared to those with the CC genotype. No significant differences in basal levels, post-treatment levels, or % change were seen when considering total cholesterol (TC) or triglycerides (TG). 10 mg/day atorvastatin for 4 weeks.	Genotypes CT + TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.	CT + TT	C
288	rs3846662	HMGCR (PA189)	hmg coa reductase inhibitors (PA133950441)	The percentage reduction in LDL-cholesterol upon statin treatment was significantly decreased in women with the AA genotype	Genotype AA is associated with decreased response to hmg coa reductase inhibitors in women with familial hypercholesterolemia as compared to allele G.	AA	A
289	rs11960832	SV2C (PA134888452)	olanzapine (PA450688)	Response was assessed by a change in the total Positive and Negative Syndrome Scale (PANSS) score. TT homozygotes had a smaller decrease or an increase in PANSS score compared to C allele carriers.	Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	TT	C
290	rs1232027	(no entry)	methotrexate (PA450428)	(no entry)	Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G.	A	G
291	rs2075685	XRCC4 (PA37423)	"fluorouracil (PA128406956),""Platinum compounds (PA164713176)"",""radiotherapy (PA166122986)"""	"1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. In multivariate analysis the number of risk alleles was significantly associated with survival (1-3 alleles HR 1.66 (95% CI 1.06-2.59) 3-6 alleles HR 2.28 (95% CI 1.28-4.03) P-value for trend = 0.001). Please note: the authors do not distinguish between distinct treatment regimens- simply ""chemotherapy""."	Allele T is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	T	G
292	rs495794	SRP19 (PA36124)	"citalopram (PA449015),""fluoxetine (PA449673)"",""paroxetine (PA450801)"",""sertraline (PA451333)"""	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	G	A
293	rs153549	REEP5 (PA134882361)	"citalopram (PA449015),""fluoxetine (PA449673)"",""paroxetine (PA450801)"",""sertraline (PA451333)"""	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The A allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the A allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the G allele."	Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	A	A
294	rs153560	REEP5 (PA134882361)	"citalopram (PA449015),""fluoxetine (PA449673)"",""paroxetine (PA450801)"",""sertraline (PA451333)"""	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	G	G
295	rs1050152	SLC22A4 (PA332)	imatinib (PA10804)	TT homozygotes had reduced time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotype TT is associated with decreased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	TT	C
296	rs1050152	SLC22A4 (PA332)	imatinib (PA10804)	Patients with the TT genotype had a decreased likelihood of achieving major molecular response (MMR) within 12 months, as compared to those with the CC or CT genotype. MMR was classified based on BCR-ABL to control gene transcript ratios, expressed on the International Scale; MMR was a ratio <= 0.1%.	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	TT	C
297	rs1050152	SLC22A4 (PA332)	imatinib (PA10804)	Patients with the TT genotype had a decreased likelihood of achieving major molecular response (MMR) within 12 months, as compared to those with the CC or CT genotype. MMR was classified based on BCR-ABL to control gene transcript ratios, expressed on the International Scale; MMR was a ratio <= 0.1%.	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	TT	C
298	rs1050152	SLC22A4 (PA332)	ustekinumab (PA166048654)	as measured by PASI75 at 4 months and adjusted for weight and FDR. Listed in table 2 as codominant method, CT as risk genotype, unclear what it was compared to.	Genotype CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	CT	C
299	rs2631372	SLC22A5 (PA333)	imatinib (PA10804)	Carriers of the G allele had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	CG + GG	G
300	rs2631367	SLC22A5 (PA333)	imatinib (PA10804)	Carriers of the G allele had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	CG + GG	C
301	rs1295686	IL13 (PA199)	Hepatitis vaccines (PA164712789)	The T allele increased the risk of non-immune response to hepatitis B vaccine. Hepatitis B vaccine at 0, 1 and 6 months standard schedule. Non-responders (n=24) were those who had insufficient anti-hepatitis B antibody levels (< 10 mIU/ml) after a 2nd round of revaccination. Responders (n=46) had anti-hepatitis B antibody levels >= 100 mIU/ml after the first standard 3-dose immunization. Significant in multivariable logistic regression analysis. Please note that alleles have been complemented to the plus chromosomal strand.	Allele T is associated with decreased response to Hepatitis vaccines as compared to allele C.	T	T
302	rs848	IL13 (PA199)	ustekinumab (PA166048654)	as measured by PASI75 at 4 months and adjusted for weight and FDR. Alleles were complemented.	Genotypes AA + AC is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC.	AA + AC	A
303	rs2303070	SPINK5 (PA37962)	glibenclamide (PA449782)	No allele was given for the association, so the minor allele from dbSNP at this location was used. Response to treatment was measured as reduction of HbA1c below 6.5% at 1-year of treatment.	Allele T is associated with increased response to glibenclamide in people with as compared to allele G.	T	G
304	rs2053044	ADRB2 (PA39)	ramipril (PA451223)	response assessed as reaching mean arterial blood pressure of 107 mmHg or less within 60 days of treatment	Genotypes AA + AG is associated with increased response to ramipril in people with Hypertension as compared to genotype GG.	AA + AG	A
305	rs1042711	ADRB2 (PA39)	atenolol (PA448499)	Either alone as a SNP or in combination with rs1042713 allele A and rs1042714 allele C as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele T is not associated with response to atenolol in people with Essential hypertension.	T	C
306	rs1042713	ADRB2 (PA39)	salmeterol (PA451300)	(no entry)	Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG.	AA	G
307	rs1042713	ADRB2 (PA39)	salmeterol (PA451300)	compared to response to montelukast treatment. Children homozygous for the Arg16 variant (genotype AA) were randomized to receive either fluticasone plus montelukast or seretide (salmeterol plus fluticasone) plus placebo for montelukast. School absences, bronchodilator usage, morning cough and wheeze, morning dyspnoea score, night wheeze and dyspnoea scores were all significantly higher in the salmeterol treated group compared to the montelukast treated group. FEV1 % predicted value was not significantly different between the two treatment groups.	Genotype AA is associated with decreased response to salmeterol in children with Asthma.	AA	G
308	rs1042713	ADRB2 (PA39)	benazepril (PA448561)	Refers to a cohort from Yuexi County in Anhui, China. Carriers of the G allele had a greater decrease in diastolic blood pressure in response to treatment with benazepril compared to AA homozygotes. Patients were treated for 15 days. Both the family-based association test (FBAT) and a multivariate linear regression analysis were used to test for statistical significance.	Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA.	AG + GG	G
309	rs1042713	ADRB2 (PA39)	atenolol (PA448499)	Either alone as a SNP or in combination with rs1042711 allele T and rs1042714 allele C as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele A is not associated with response to atenolol in people with Essential hypertension.	A	G
310	rs1042713	ADRB2 (PA39)	methacholine (PA165958382)	Patients with the AA genotype had lower log PC20 (provocative concentration of methacholine that causes a 20% fall in FEV1) compared to those with the GG genotype, indicating increased airway reactivity and an increased risk of worse asthma outcomes. Please note that this genotype was compared within African Americans, and between African Americans (AA genotype) and Whites (GG genotype). However, allele frequencies were the same between the two ethnicities in this population. African Americans n=45, Whites n=43.	Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG.	AA	G
311	rs1042713	ADRB2 (PA39)	tiotropium (PA164769056)	Response defined as improvement on the forced expiratory volume in 1 second (FEV1) by >=15% (or 200 ml) for at least 8 successive weeks after addition of tiotropium to conventional therapy.	Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG.	AA	G
312	rs1042713	ADRB2 (PA39)	"corticosteroids (PA10832),""selective beta-2-adrenoreceptor agonists (PA134687887)"""	(no entry)	Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG.	A	G
313	rs1042713	ADRB2 (PA39)	propranolol (PA451145)	Paper analyzes haplotypes given as amino acid change combinations as follows for rs1042713 and rs1042714 respectively: 1 - Arg/Gln (base A/G) 2- Gly/Glu (base G/C) 3- Gly/Gln (base G/G) Cirrhotic patients from hepB (51 patients) alcohol (7patients) cryptogeny (5 patients) and primary biliary cirrhosis (1 patient), with efficacy measured as change in vatical pressure after 7days of treatment. The 2/2 and 3/3 haplotypes both have A at rs1042713, which respond better than haplotype 1/1, with G at rs1042713. Compound heterozygotes are intermediate responders. See annotation: 1447959442	Genotype AA is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype GG.	AA	G
314	rs1042714	ADRB2 (PA39)	enalapril (PA449456)	Carriers of the G allele had a greater percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment.	Genotypes CG + GG are associated with increased response to enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.	CG + GG	G
315	rs1042714	ADRB2 (PA39)	atenolol (PA448499)	No significant difference in percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment was seen between genotypes.	Genotypes CG + GG are not associated with response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotype CC.	CG + GG	G
316	rs1042714	ADRB2 (PA39)	"atenolol (PA448499),""enalapril (PA449456)"""	Carriers of the G allele had a greater percent reduction in left ventricular mass index (LVMi) between baseline and after two years of treatment.	Genotypes CG + GG are associated with increased response to atenolol and enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.	CG + GG	G
317	rs1042714	ADRB2 (PA39)	carvedilol (PA448817)	Patients with the GG genotype had a greater percent increase in left ventricular ejection fraction between baseline and 12 months of treatment, as compared to those with the CC + CG genotypes.	Genotype GG is associated with increased response to carvedilol in people with Heart Failure as compared to genotypes CC + CG.	GG	G
318	rs1042714	ADRB2 (PA39)	atenolol (PA448499)	Either alone as a SNP or in combination with rs1042711 allele T and rs1042713 allele A as a haplotype. Neither this SNP nor any haplotype combination (haplotypes TGC, CGG, TGG, TAG and CAG were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele C is not associated with response to atenolol in people with Essential hypertension.	C	G
319	rs1800888	ADRB2 (PA39)	terbutaline (PA451616)	There were no homozygous variant subjects. The association was based on the fact that maximal HR increases were higher for WT (p-value=0.016) and QS2c (HR-corrected duration of electromechanical systole) shortening was increased for WT (p=0.022). When the data were analyzed with respect to sex, the authors found that sex was as significantly correlated with these measures as the variant, but that the variant and sex were not correlated with each other. The authors conclude this study supports the decreased survival rate of heterzygous individuals with congestive heart failure.	Genotype CT is associated with decreased response to terbutaline in healthy individuals as compared to genotype CC.	CT	C
320	rs3213094	IL12B (PA29785)	ustekinumab (PA166048654)	Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index.	Genotype CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	CT	C
321	rs2546890	IL12B (PA29785)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Moderate-to-severe plaque psoriasis. Patients were considered responders if they achieved a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI) (PASI75). PASI data was collected at 3 months, 6 months and 1 year. This variant is significantly associated with response at 3 months, 6 months and 1 year.	Genotypes AG + GG are associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	AG + GG	A
322	rs2546890	IL12B (PA29785)	"adalimumab (PA10004),""infliximab (PA452639)"""	as measured by PASI75 at 3 months.	Genotypes AA + AG is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype GG.	AA + AG	A
323	rs2546890	IL12B (PA29785)	etanercept (PA449515)	(no entry)	Genotypes AG + GG is associated with decreased response to etanercept in people with Psoriasis as compared to genotype AA.	AG + GG	A
324	rs2431697	PTTG1 (PA34033)	etanercept (PA449515)	(no entry)	Genotypes CC + CT is associated with decreased response to etanercept in people with Psoriasis as compared to genotype TT.	CC + CT	T
325	rs2290732	GABRA1 (PA28489)	carbamazepine (PA448785)	Patients with the AA and AG genotypes have increased tolerability to carbamazepine. Tolerability was assessed by retention rates, or the proportion of patients that continued to take carbamazepine for seizures over the previous 3 months. Patients were assessed every 3 months for 24 months. The retention rates for the AA + AG genotypes were significantly greater than the retention rate for the GG genotype during months 9 - 24 of treatment.	Genotypes AA + AG are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype GG.	AA + AG	A
326	rs265976	DRD1 (PA147)	clozapine (PA449061)	"The GT group improved the least compared to either the GG or the TT group. This is not significant after correction for multiple testing, but the authors state that it's not clear that this correction should be done, and that this is significant but exploratory and should be confirmed in a larger study. The association was found in African Americans but not in the Caucasian sample. Frequencies entered for ""cases"" vs. ""controls"" are for responders vs. nonresponders."	Genotype GT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes GG + TT.	GT	G
327	rs4867798	DRD1 (PA147)	methylphenidate (PA450464)	Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype TT.	CC + CT	T
328	rs686	DRD1 (PA147)	clozapine (PA449061)	This association was found in carriers of the DRD3 rs6280 AA genotype (gene-gene interaction analysis).	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	G	G
329	rs5326	DRD1 (PA147)	methylphenidate (PA450464)	Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.	CT + TT	C
330	rs5985	F13A1 (PA162)	photodynamic therapy (PA165984462)	Alleles given as reverse strand T and G. Change in measured best-correct visual acuity after 2 years of treatment.	Genotypes AA + AC are associated with decreased response to photodynamic therapy in people with Choroidal Neovascularization as compared to genotype CC.	AA + AC	C
331	rs9370867	MYLIP (PA134942677)	atorvastatin (PA448500)	Patients with with heterozygous familial hypercholesterolemia were treated with atorvastatin with the addition of ezetimibe in over half the patients. Patients carrying the AA genotype were more likely to achieve LDL-C levels of less than 130¿mg/dl after 1 year of treatment (75.0%) compared with patients with the GG and GA genotypes (34.5 and 34.8%, respectively; P=0.001). AA genotype had a greater LDL-C response compared with GG genotype. The presence of the G allele was associated with a greater odds of not achieving the LDL-C target in a multivariate model (OR = 2.08 per G allele, 95% confidence interval (CI) = 1.11- 3.90, P=0.02).	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	AA	A
332	rs1142345	TPMT (PA356)	mercaptopurine (PA450379)	(no entry)	Allele C is associated with exposure to mercaptopurine in children with Leukemia as compared to allele T.	C	T
333	rs7754840	CDKAL1 (PA134871999)	Dipeptidyl peptidase 4 (DPP-4) inhibitors (PA164712689)	The SNP was significantly associated with improved response to DPP-4 inhibitors (as assayed by reductions in HbA1c). Most of the patients were on combination anti-diabetic agent (ADA) therapy, but the relationship was only significant for regimens that included DPP-4 (alone or in combination with other ADAs).	Allele C is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele G.	C	G
334	rs7756992	CDKAL1 (PA134871999)	Dipeptidyl peptidase 4 (DPP-4) inhibitors (PA164712689)	The SNP was significantly associated with improved response to DPP-4 inhibitors (as assayed by reductions in HbA1c). Most of the patients were on combination anti-diabetic agent (ADA) therapy, but the relationship was only significant for regimens that included DPP-4 (alone or in combination with other ADAs).	Allele G is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele A.	G	A
335	rs6908425	CDKAL1 (PA134871999)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Moderate-to-severe plaque psoriasis. Patients were considered responders if they achieved a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI) (PASI75). PASI data was collected at 3 months, 6 months and 1 year. This variant was significantly associated with response at 6 months.	Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	CT + TT	T
336	rs2066911	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	A	G
337	rs2760118	ALDH5A1 (PA24702)	methadone (PA450401)	Patients carrying the T allele were at a higher risk of being a non-responder to methadone treatment as compared to those with the CC genotype. Responders defined as those who had negative results for illicit opioids in all of the last four urine tests. Nonresponders were those with two or more positive results in the last four urine tests. Responders also had a significantly higher mean methadone dose (p=0.001) and a mean number of months in the methadone maintenance treatment (MMT) program (p=0.009). However, when controlling for these two variables, the association between genotype and response remained statistically significant (p=0.0049).	Genotypes CT + TT is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to genotype CC.	CT + TT	C
338	rs6942227	(no entry)	lithium (PA450243)	(no entry)	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	A	A
339	rs116551936	(no entry)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.	AG	G
340	rs9380142	HLA-G (PA35083)	"capecitabine (PA448771),""fluorouracil (PA128406956)"""	The authors examined disease free survival (DFS) as well as overall survival (OS). The GG genotype was associated with decreased DFS and OS.	Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	A
341	rs2233945	PSORS1C1 (PA33919)	etanercept (PA449515)	The degree of response was determined by EULAR score. A significant association between rs2233945 and response to etanercept was seen at six months after beginning treatment. No significant association was seen at two years after beginning treatment. No significant associations were seen at either time point when response was measured as number of patients in remission or with low disease activity.	Allele C is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.	C	C
342	rs12191877	HLA-C (PA35057)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Moderate-to-severe plaque psoriasis. Patients were considered responders if they achieved a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI) (PASI75). PASI data was collected at 3 months, 6 months and 1 year. This variant was significantly associated with response at 3 months.	Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	CT + TT	C
343	rs13437088	HLA-B (PA35056)	etanercept (PA449515)	(no entry)	Genotype TT is associated with decreased response to etanercept in people with Psoriasis as compared to genotypes CC + CT.	TT	C
344	rs3828913	MICB (PA30812)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Patients with MICB major (CC) alleles had higher SVR rate (62.3%) than that of the patients with MICB minor (CA and AA) alleles (27.2%). A multivariate logistic model showed that the MICB major genotype (CC) was an independent factor contributing to SVR (OR, 4.47; 95% CI, 1.46-13.70; P=0.009), similar to the IL28B major genotype (rs8099917).	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	CC	C
345	rs1799964	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	"The frequency of the TT genotype was higher in those patients who were ""good responders"" to anti-TNF therapy, as compared to those who were ""poor and nonresponders"". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.06)."	Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CC + CT.	TT	T
346	rs1799724	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	A meta-analysis of 3 studies: in 1 study patients were treated with just infliximab (this study was not included in the genotype association analysis), in 1 study patients were treated with infliximab + adalimumab + etanercept, and in one study infliximab + rhTNFR-Fc. Patients with inflammatory diseases; Crohn's disease, Ankylosing spondylitis, psoriasis.	Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes CT + TT.	CC	C
347	rs1799724	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	"The frequency of the CC genotype was higher in those patients who were ""good responders"" to anti-TNF therapy, as compared to those who were ""poor and nonresponders"". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Please note that the T allele was significantly more frequent in those with ankylosing spondylitis as compared to healthy controls (p = 2.455 x 10^-7). Additionally, note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.20)."	Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CT + TT.	CC	C
348	rs1799724	TNF (PA435)	adalimumab (PA10004)	When in a haplotype with rs1800629 and rs361525. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate.	Genotype CC is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.	CC	C
349	rs1799724	TNF (PA435)	etanercept (PA449515)	Clinical efficacy assessed by percentage improvements (20, 50 or 70%) in disease activity according to the American College of Rheumatology (ACR) criteria at 12 weeks (i.e. ACR20, ACR50, ACR70). Patients who were ACR20 non-responders were compared against patients who were ACR70 responders. p-value adjusted for Korea Health Assessment Questionnaire (KHAQ) score at start of study and Patient's global assessment score at start of study. Please note that the p-value corrected for multiple testing (Bonferroni) is no longer significant (p=0.34).	Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC.	CT + TT	C
350	rs1799724	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	At week 24 of treatment, DAS28 was significantly lower in those with the TT genotype as compared to those who carried the C allele, although there was no significant difference in the remission rate.	Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	TT	C
351	rs1799724	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	(no entry)	Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele T.	C	C
352	rs1800629	TNF (PA435)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	(no entry)	Allele A is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to allele G.	A	G
353	rs1800629	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	A meta-analysis of 5 studies: in 3 studies patients were treated with just infliximab (one study not included in the genotype association analysis), in one study in patients were treated with infliximab + adalimumab + etanercept, and in one study infliximab + rhTNFR-Fc. Patients with inflammatory diseases; Crohn's disease, Ankylosing spondylitis, Psoriatic arthritis, psoriasis.	Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG.	GG	G
354	rs1800629	TNF (PA435)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	Response was defined as a DAS28 improvement of >=1.2 in some studies; other studies defined response using the ACR20. An ACR20 response corresponds to a decrease of at least 20% in the number of tender joints and the number of swollen joints, and an improvement of 20% in at least three of the following: the patient's assessment of pain, the patient's global assessment of disease status, the physician's global assessment of disease status, the patient's assessment of physical function, and C reactive protein.	Genotypes AG + GG is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype AA.	AG + GG	G
355	rs1800629	TNF (PA435)	infliximab (PA452639)	Good responders defined as patients whose disease activity score in 28 joints (DAS28) score improved by at least 1.2 at week 22 as compared to their DAS28 score before first infusion (EULAR criteria). Patients with the GG genotype were more likely to be good responders to infliximab treatment as compared to those with the AA or AG genotype. Additionally, those with the GG genotype had a higher mean DAS28 improvement as compared to those with the AA or AG genotype after 22 weeks.	Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	GG	G
356	rs1800629	TNF (PA435)	adalimumab (PA10004)	After 24 weeks of treatment, a greater percentage of those with the GG genotype were were responders to treatment, as compared to those with the AG genotype. Response classified according to the Disease Activity Score in 28 joints (DAS28). Additionally, those with the GG genotype had a greater DAS28 score improvement as compared to those with the AG genotype. No significant results were seen at week 8 or week 16 for either parameter, or when considering improvement using the American College of Rheumatology (ACR) definition at week 8, 16 or 24.	Genotype GG is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotype AG.	GG	G
357	rs1800629	TNF (PA435)	etanercept (PA449515)	A greater percentage of patients with the GG genotype were responders to treatment as compared to the AG genotype after 6 months and 1 year of treatment. Response assessed according to the Disease Activity Score in 28 joints (DAS28), where response was an improvement of >1.2. Additionally, those with the GG genotype had a higher mean DAS28 score improvement at 6 months, though this was a non-significant p-value. However, those with the GG genotype had a significantly higher mean DAS28 score improvement after 1 year of treatment. The authors note that 13 patients had received infliximab previously without success, which may have induced a bias in the study.	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG.	GG	G
358	rs1800629	TNF (PA435)	etanercept (PA449515)	"Patients with the AG and GG genotype had a greater decrease in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment, as compared to those with the AA genotype. Linear regression analysis, adjusted for baseline DAS28, among other factors. Additionally, patients with the AG and GG genotype were also more frequent in the group classified as having a ""good"" response according to the EULAR criteria, as compared to those with the AA genotype."	Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA.	AG + GG	G
359	rs1800629	TNF (PA435)	adalimumab (PA10004)	When in a haplotype with rs1799724 and rs361525. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate.	Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.	GG	G
360	rs1800629	TNF (PA435)	"adalimumab (PA10004),""infliximab (PA452639)"""	Response assessed after 24 weeks of treatment using the Bath Ankylosing Spondylitis Activity Index (BASDAI). Good response was a BASDAI improvement of >50% from baseline, moderate response an improvement of >=20% and <=50%, and non-response an improvement of <20%. No patients with the AA genotype were present in the population. Patients with the GG genotype had a larger improvement in BASDAI score (3.30 +/- 1.52) as compared to those with the AG genotype (1.21 +/- 0.39).	Genotype GG is associated with response to adalimumab and infliximab in people with Spondylitis, Ankylosing as compared to genotype AG.	GG	G
361	rs1800629	TNF (PA435)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	Response assessed after 24 weeks of treatment using the modified disease activity score (DAS28). Good response was a DAS28 improvement of >2.2 from baseline, moderate response an improvement of >=1.2 and <=2.2, and non-response as an improvement of <1.2. Patients with the GG genotype had the largest improvement in DAS28 score (2.72 +/- 0.70), following by those with the AG genotype (1.5 +/- 0.16) then those with the AA genotype (0.83 +/- 0.15). There was a significant difference in DAS28 improvement score between all genotypes.	Genotype GG is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	GG	G
362	rs1800629	TNF (PA435)	infliximab (PA452639)	Patients with the GG genotype had a significantly greater decrease in the Disease Activity Score in 28 joints (DAS28) score as compared to those with the AG genotype (no patients with the AA genotype were present in the cohort) after a mean of 24.8 months of treatment. The authors also noted a tendency of a better Health Assessment Questionnaire (HAQ) evolution (p=0.064), but no significant difference in radiological outcome (Sharp score).	Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG.	GG	G
363	rs1800629	TNF (PA435)	etanercept (PA449515)	When this genotype is combined with the rs1800896 CC genotype. Those with the GG-CC combination genotype were more likely to be responders to treatment, as compared to those with any other combination of genotypes. However, no significant difference in genotype frequencies was seen between responders and non-responders when considering the rs1800629 or 1800896 SNPs alone. Responders defined using the American College of Rheumatology (ACR) response criteria and response criteria based on the modified disease activity score (DAS)28 index. Non-responders failed to fulfill both these criteria.	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	GG	G
364	rs1800629	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	(no entry)	Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A.	G	G
365	rs361525	TNF (PA435)	adalimumab (PA10004)	When in a haplotype with rs1800629 and rs1799724. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate.	Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.	GG	G
366	rs361525	TNF (PA435)	infliximab (PA452639)	"Patients with the GG genotype were also more frequent in the group classified as having a ""good"" response according to the EULAR criteria, as compared to those with the AG genotype. Additionally, patients with the GG genotype had a greater decrease in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment, as compared to those with the AG genotype, but this was not significant in univariate linear regression analysis, adjusted for baseline DAS28, among other factors. No patients with the AA genotype present in the population."	Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG.	GG	G
367	rs361525	TNF (PA435)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	(no entry)	Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele A.	G	G
368	rs209474	(no entry)	lithium (PA450243)	(no entry)	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	A	A
369	rs3077	HLA-DPA1 (PA35062)	peginterferon alfa-2b (PA164784024)	Patients carrying GG genotype of rs3077 with low baseline HBV (<1000 IU/mL) had higher rate of achieving virological response.	Genotype GG is associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotypes AA + AG.	GG	A
370	rs6922548	PPARD (PA33557)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper)	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	G	A
371	rs1883322	PPARD (PA33557)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper, dbSNP changed designation of this allele from G/A to C/T at build 132)	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	C	C
372	rs2016520	PPARD (PA33557)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper, dbSNP changed designation of this allele from G/A to C/T at build 132)	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	C	C
373	rs3734254	PPARD (PA33557)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with data in pgkb, actual base not listed in paper)	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	T	C
374	rs3800373	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AA + AC.	CC	C
375	rs3800373	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotypes CC + AC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	CC + AC	C
376	rs3800373	FKBP5 (PA28162)	"citalopram (PA449015),""fluoxetine (PA449673)"",""mirtazapine (PA450522)"",""paroxetine (PA450801)"",""Selective serotonin reuptake inhibitors (PA164713257)"",""venlafaxine (PA451866)"""	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.	C	C
377	rs3800373	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotypes AC + CC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	AC + CC	C
378	rs1360780	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotype TT is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes CC + CT.	TT	T
379	rs1360780	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotypes TT + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype CC.	TT + CT	T
380	rs1360780	FKBP5 (PA28162)	"citalopram (PA449015),""fluoxetine (PA449673)"",""mirtazapine (PA450522)"",""paroxetine (PA450801)"",""Selective serotonin reuptake inhibitors (PA164713257)"",""venlafaxine (PA451866)"""	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.	T	T
381	rs1360780	FKBP5 (PA28162)	antidepressants (PA452229)	(no entry)	Genotype CC is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	CC	T
382	rs9471077	KIF6 (PA134920075)	"atorvastatin (PA448500),""pravastatin (PA451089)"""	(no entry)	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin.	AG + GG	A
383	rs9471077	KIF6 (PA134920075)	"atorvastatin (PA448500),""pravastatin (PA451089)"""	(no entry)	Genotype AA is not associated with increased response to atorvastatin or pravastatin.	AA	A
384	rs9462535	KIF6 (PA134920075)	"atorvastatin (PA448500),""pravastatin (PA451089)"""	(no entry)	Genotype CC is not associated with increased response to atorvastatin or pravastatin.	CC	C
385	rs9462535	KIF6 (PA134920075)	"atorvastatin (PA448500),""pravastatin (PA451089)"""	(no entry)	Genotypes AA + AC are associated with increased response to atorvastatin or pravastatin.	AA + AC	C
386	rs6458232	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study reported this variant as within the MDFI gene with alleles G/T. [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele A.	C	C
387	rs833061	VEGFA (PA37302)	cetuximab (PA10040)	(no entry)	Genotype TT is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes CC + CT.	TT	C
388	rs833061	VEGFA (PA37302)	pazopanib (PA165291492)	(no entry)	Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.	T	C
389	rs833061	VEGFA (PA37302)	"carfilzomib (PA166165203),""dexamethasone (PA449247)"",""lenalidomide (PA162363968)"""	"Authors indicate repose as CR/nCR/sCR but do not define these and non-response as VGPR and PR/SD (which assume to mean progression/stable disease). They also test ""minimum residual disease negativity"" MRD- as measure of response."	Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	CT + TT	C
390	rs1570360	VEGFA (PA37302)	"bevacizumab (PA130232992),""irinotecan (PA450085)"""	rs number not given in this paper. Found rs number for VEGF -1154 in PMID:17204151	Genotype GG is associated with decreased response to bevacizumab and irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	A
391	rs1570360	VEGFA (PA37302)	sildenafil (PA451346)	(no entry)	Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG.	AA	A
392	rs1570360	VEGFA (PA37302)	docetaxel (PA449383)	The GG genotype was found to be more frequent in non-responders (42.9%) than in patients responding to treatment (0%; complete or partial response).	Genotype GG is associated with decreased response to docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG.	GG	A
393	rs1570360	VEGFA (PA37302)	cetuximab (PA10040)	(no entry)	Genotype GG is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	A
394	rs2010963	VEGFA (PA37302)	"capecitabine (PA448771),""oxaliplatin (PA131285527)"""	The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). Response was observed in 21% of the patients with the -2578 (rs699947) CA genotype compared with 59% of the patients with CC + AA, P = 0.002, in 26% of the patients with the -460 (rs833061) CT genotype compared with 57% with CC = TT, P = 0.01, and in 27% of the patients with the 405 (rs2010963) GC genotype compared with 54% with GG + CC, P = 0.02.	Genotype CG is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + GG.	CG	C
395	rs2010963	VEGFA (PA37302)	"bevacizumab (PA130232992),""pegaptanib (PA164771236)"",""ranibizumab (PA164746012)"""	A lower percentage of patients with the CC genotype maintained visual acuity 1 year after the first anti-VEGF injection, as compared to those with the CG or GG genotype (Cochran-Armitage test). Additionally, multivariable logistic regression showed that the G allele was associated with an increased likelihood of maintaining visual acuity 1 year after the first injection both in all patients (n=83), and in patients who had their eyes treated with only a single initial treatment (n=65). Visual acuity was measured by the Landolt chart. Anti-VEGF treatments included bevacizumab (n=62), pegaptanib (n=3) or ranibizumab (n=18).	Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.	CC	C
396	rs2010963	VEGFA (PA37302)	pazopanib (PA165291492)	(no entry)	Allele G is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.	G	C
397	rs25648	VEGFA (PA37302)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""oxaliplatin (PA131285527)"""	Partial remissions and disease control rate was higher in patients with the CC genotype (p=0.04 and p=0.002, respectively), progression-free survival and overall survival were also higher in patients with the CC genotype.	Genotypes CT + TT are associated with decreased response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC.	CT + TT	C
398	rs25648	VEGFA (PA37302)	adalimumab (PA10004)	(no entry)	Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.	T	C
399	rs833069	VEGFA (PA37302)	ranibizumab (PA164746012)	Age-related macular degeneration. Patients with the CC or CT genotype had greater decreases in central subfield macular thickness (CSMT) between baseline and 3 or 6 months of treatment, as compared to those with the TT genotype. This indicates a better visual outcome. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT.	CC + CT	T
400	rs3025000	VEGFA (PA37302)	"bevacizumab (PA130232992),""ranibizumab (PA164746012)"""	Response was measured by mean change in visual acuity from baseline after 3, 6 and 12 months of treatment. Visual acuity was scored using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Carriers of the T allele had a significantly greater increase in visual outcome after 6 months of treatment, as compared to the CC genotype. No significant change was seen after 3 or 12 months of treatment after Bonferroni correction was used, which set the p-value at <0.007.	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	CT + TT	C
401	rs3025000	VEGFA (PA37302)	"bevacizumab (PA130232992),""ranibizumab (PA164746012)"""	Response was measured by mean change in visual acuity from baseline after 3, 6 and 12 months of treatment. Visual acuity was scored using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Patients were segregated into responders (gain of > or = 5 ETDRS letters), stable (gain or loss of < 5 ETDRS letters), or nonresponders (loss of > 5 ETDRS letters. Carriers of the T allele were more likely to be in the responders group than in the stable or nonresponders group after 3, 6 and 12 months of treatment.	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	CT + TT	C
402	rs3025039	VEGFA (PA37302)	"bevacizumab (PA130232992),""capecitabine (PA448771)"",""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	Response to treatment was determined by RECIST criteria.	Genotype TT is associated with decreased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.	TT	C
403	rs9369421	VEGFA (PA37302)	"carboplatin (PA448803),""taxanes (PA150481189)"""	Response refers to survival time. Please note, alleles have been complemented to the + chromosomal strand.	Genotypes CC + CT are associated with increased response to carboplatin and taxanes in women with as compared to genotype TT.	CC + CT	T
404	rs9394992	SLC29A1 (PA154)	"tipiracil hydrochloride (PA166171170),""trifluridine (PA451775)"""	The SNP was tested for association alone and with three other SNPs after univariate and multivariate analysis in a training (N= 52, Japan) and testing cohorts (N = 127, Italy). Although it remained significantly associated with progression-free and overall survival in univariate and multivariate analysis in the training cohort, it was not significant in the testing cohort.	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.	CT + TT	C
405	rs992160	CDC5L (PA26270)	gemcitabine (PA449748)	Associated with longer overall survival. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotypes CT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	CT + TT	C
406	rs2275913	IL17A (PA29794)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.	AA + AG	G
407	rs763780	IL17F (PA29800)	adalimumab (PA10004)	but this was only at 24-28 weeks. Response was a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI)	Genotype TT is associated with increased response to adalimumab in people with as compared to genotype CT.	TT	T
408	rs763780	IL17F (PA29800)	ustekinumab (PA166048654)	Response was a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI). However there were only 4 heterozygotes and no CC homozygotes in this treatment group.	Genotype TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CT.	TT	T
409	rs763780	IL17F (PA29800)	infliximab (PA452639)	Response was a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI). All seven heterozygotes responded to treatment and there were no CC homozygotes in this treatment group.	Genotype CT is associated with increased response to infliximab in people with Psoriasis as compared to genotype TT.	CT	T
410	rs41271330	BMP5 (PA25382)	escitalopram (PA10074)	12 weeks treatment. Patients were defined as responders if the decrease in both MADRS and Hamilton Depression Rating Scale total scores was at least 50%, and the score on the Clinical Global Impression improvement scale was 2 or less. Five clear responders and five clear non-responders for exome sequencing. Based on the results 38 markers were selected for further genotyping in remaining 116 Estonian patients with MDD. Out of the 38 marker 5 SNPs were selected that could distinguish the responders from the non-responders in the 116 Estonian MDD patients were further genotyped in the UK-based GENDEP sample set, comprising 394 MDD patients treated with escitalopram.	Allele A is associated with decreased response to escitalopram in people with Depressive Disorder, Major as compared to allele G.	A	G
411	rs7750468	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	G	G
412	rs2781659	ARG1 (PA24947)	selective beta-2-adrenoreceptor agonists (PA134687887)	(no entry)	Allele A is associated with increased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele G.	A	A
413	rs7772821	TAAR6 (PA134881141)	corticosteroids (PA10832)	Response was measured as percentile changes in the forced expiratory volume in 1s (%[INCREMENT]FEV1) after inhaled corticosteroid treatment in asthmatics. Pcorr= 0.002 in the codominant model, Pcorr= 0.03 in the dominant model, and Pcorr= 0.01 in the recessive model.	Genotype GG is associated with increased response to corticosteroids in people with Asthma as compared to genotypes GT + TT.	GG	T
414	rs2230926	TNFAIP3 (PA36593)	adalimumab (PA10004)	(no entry)	Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	T	T
415	rs2247408	PLAGL1 (PA33379)	olanzapine (PA450688)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele C is associated with response to olanzapine in people with Schizophrenia.	C	T
416	rs2234693	ESR1 (PA156)	leflunomide (PA450192)	rs9340799 and rs2234693 were in linkage disequilibrium: haplotype A-T was associated with better response and haplotype G-C with worse response.	Genotype TT is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotype CC.	TT	T
417	rs9340799	ESR1 (PA156)	leflunomide (PA450192)	rs9340799 and rs2234693 were in linkage disequilibrium: haplotype A-T was associated with better response and haplotype G-C with worse response.	Genotype AA is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.	AA	A
418	rs1799971	OPRM1 (PA31945)	morphine (PA450550)	(no entry)	Genotypes GG + AG are associated with increased dose of morphine as compared to genotype AA.	GG + AG	A
419	rs1799971	OPRM1 (PA31945)	naltrexone (PA450588)	(no entry)	Genotypes GG + AG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.	GG + AG	A
420	rs1799971	OPRM1 (PA31945)	morphine (PA450550)	Presence of the G allele was associated with higher pain scores in patients taking morphine. Otherwise healthy adolescents undergoing spinal fusion for scoliosis.	Genotypes AG + GG is associated with decreased response to morphine in children as compared to genotype AA.	AG + GG	A
421	rs1799971	OPRM1 (PA31945)	"acetaminophen (PA448015),""tramadol (PA451735)"""	Patients were receiving tramadol and acetaminophen as combination to relieve pain, specifically neuropathic pain associated with oxaliplatin treatment (as part of a FOLFOX or XELOX regimen) for adenocarcinoma.	Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG.	AA	A
422	rs1799971	OPRM1 (PA31945)	naltrexone (PA450588)	A significant association was seen between the G allele and the likelihood of achieving a level of non-hazardous drinking (defined as drinking less than 14 standard drinks and having nor heavy drinking days in one week). However, no significant main effect was observed between rs1799971, naltrexone and either the weekly sum of standard drinks or the number of heavy drinking days.	Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.	G	A
423	rs1799971	OPRM1 (PA31945)	fentanyl (PA449599)	(no entry)	Genotypes AG + GG are associated with increased response to fentanyl in women with Pain as compared to genotype AA.	AG + GG	A
424	rs1799971	OPRM1 (PA31945)	naltrexone (PA450588)	Carriers of the G allele have decreased relapse rates as compared to patients with the AA genotype. No difference seen in abstinence rates between different genotypes.	Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.	AG + GG	A
425	rs1799971	OPRM1 (PA31945)	opioids (PA452618)	Patients were treated with tramadol, morphine, fentanyl or sufentanil. Pain was measured using visual analog scale (VAS) scores. Patients with the AG genotype had higher pain scores on standard doses of opioids than patients with the AA genotype.	Genotype AG is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotype AA.	AG	A
426	rs1799971	OPRM1 (PA31945)	"Opioid anesthetics (PA164712948),""Other general anesthetics (PA164713083)"",""volatile anesthetics (PA166131630)"""	The GG genotype was significantly associated with a shorter recovery time from general anesthesia compared to the AA and AG genotypes.	Genotype GG is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes AA + AG.	GG	A
427	rs1799971	OPRM1 (PA31945)	ethanol (PA448073)	Subjects with the AG genotype showed significantly increased striatal dopamine release following administration of alcohol compared to AA subjects.	Genotype AG is associated with increased response to ethanol in men as compared to genotype AA.	AG	A
428	rs1799971	OPRM1 (PA31945)	nicotine (PA450626)	Women carrying the G allele experienced a reduced relative reinforcing value of nicotine compared to women with the AA genotype. There was a significant interaction of rs1799971 genotype and gender as this association was not observed in male participants.	Genotypes AG + GG are associated with decreased response to nicotine in women with Tobacco Use Disorder as compared to genotype AA.	AG + GG	A
429	rs1799971	OPRM1 (PA31945)	ethanol (PA448073)	Carriers of the G allele reported significantly higher vigor scores and significantly lower negative mood scores after drinking as compared with AA subjects.	Genotypes AG + GG are associated with increased response to ethanol as compared to genotype AA.	AG + GG	A
430	rs10485058	OPRM1 (PA31945)	methadone (PA450401)	Methadone patients with the AA genotype were less likely to have opioid-positive urine drug screens as compared to those with the AG and GG genotypes over 24 weeks. This SNP was not associated with response to buprenorphine treatment. A separate cohort of patients (CATS) was also analyzed; this cohort collected self-reported data on ever having had a relapse after a period of abstinence in opioid-dependent individuals. In this cohort, using an additive model, the A allele was found to be significantly associated with never having relapsed.	Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	AA	A
431	rs8191725	IGF2R (PA29701)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. This association was significant in the initial GWAS (in GALA II), but it was not significant in an attempted replication by imputation in silico in GALA I. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype AA.	AG	A
432	rs628031	SLC22A1 (PA329)	metformin (PA450395)	Significance given as part of stepwise analysis with age, BMI, treatment with lipid lowering agents and -43T>G (intron 1).	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	A	A
433	rs628031	SLC22A1 (PA329)	imatinib (PA10804)	Response = major molecular response (MMR) as defined by each individual study, 6 studies were analyzed, time frame was 6-24 months.	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	AA + AG	A
434	rs622342	SLC22A1 (PA329)	metformin (PA450395)	HbA1c(an assay of glucose control) was -0.68 % for each A allele of rs2289669.	Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.	CC	C
435	rs622342	SLC22A1 (PA329)	metformin (PA450395)	Additive model. Those with the C allele were less likely to respond to treatment with metformin compared to AA homozygotes. Responders defined as those in whom there was a decrease in glycated hemoglobin (HbA1c) fall by >=0.5% and non-responders as those in whom fasting glucose >180mg% and HbA1c fall by <1% at the end of 12 weeks of treatment.	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	AC + CC	C
436	rs2076828	SLC22A3 (PA330)	metformin (PA450395)	A healthy human cohort that was used to determine the effects of functional variants, including rs2076828, on metformin disposition and response. Carriers of the G allele had significantly smaller changes in their glucose AUC (mean ± S.D.; CC, -88 ± 40 mg/dl per hour; CG, -34 ± 51 mg/dl per hour; GG, -41 ± 72 mg/dl per hour) and significantly lower glucose AUC even before metformin dosing (mean ± S.D.; CC, 376 ± 62 mg/dl per hour; CG, 348 ± 55 mg/dl per hour; GG, 330 ± 41 mg/dl per hour; P < 0.05). Even after adjusting for the differences in glucose AUC before metformin dosing the variant remained significantly associated with metformin response (P < 0.05).	Allele G is associated with decreased response to metformin in healthy individuals as compared to allele C.	G	C
437	rs10455872	LPA (PA30432)	hmg coa reductase inhibitors (PA133950441)	Carriers of this variant respond to statins with a 5.9% smaller LDL-C lowering per minor allele compared with non-carriers.	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.	G	A
438	rs10455872	LPA (PA30432)	rosuvastatin (PA134308647)	The minor allele of this SNP is associated with decreased LDL-C reduction on rosuvastatin. The mean per allele effect was 6.2 mg/dL, corresponding to observed median LDL-C reductions of -55, -48, and -46 mg/dL for individuals with 0, 1, or 2 copies of the minor allele, respectively.	Genotypes AG + GG are associated with decreased response to rosuvastatin as compared to genotype AA.	AG + GG	A
439	rs10455872	LPA (PA30432)	hmg coa reductase inhibitors (PA133950441)	as part of a three SNP genetic risk score with rs2231142 in ABCG2 and rs2075650 in APOE. Associated allele not explicitly stated but methods reference Chasman et al., so used the associated allele from there [PMID:22331829].	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.	G	A
440	rs37973	GLCCI1 (PA38657)	glucocorticoids (PA452347)	as part of a two SNP predictive test of FEV1 change, which identified patients with good or poor steroid response (highest or lowest quartile, respectively). P values are for predictive performance of the test.	Allele G is associated with increased response to glucocorticoids in people with Asthma as compared to allele A.	G	G
441	rs16873129	RAPGEF5 (PA134902361)	antidepressants (PA452229)	Identity of minor allele not specified, so minor allele of dbSNP used here (C). Response considered to be successful with a 50% reduction at discharge of the Hamilton Rating Scale for Depression (HRSD17). Patients measured at admission and discharge, 4-6 weeks later. Specific antidepressants not listed.	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	C	T
442	rs1800797	IL6 (PA198)	peginterferon alfa-2a (PA164749390)	This association is as part of a haplotype which also includes rs1800796G and rs1800795G.	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele A.	G	A
443	rs1800796	IL6 (PA198)	peginterferon alfa-2a (PA164749390)	This association is as part of a haplotype which also includes rs1800797G and rs1800795G. This is a GC SNP so the listed associated allele may be incorrect.	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.	G	G
444	rs1800795	IL6 (PA198)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Obesity and the minus174G/C IL-6 gene promoter polymorphism predicted poor response to anti-TNF-a therapies [odds ratio for C(minus) carriers, obese: 2.00 confidence interval: 1.19 to 3.38; P=0.05].	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele C.	G	C
445	rs1800795	IL6 (PA198)	peginterferon alfa-2a (PA164749390)	This association is as part of a haplotype which also includes rs1800797G and rs1800796G. This is a GC SNP so the listed associated allele may be incorrect.	Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.	G	C
446	rs1800795	IL6 (PA198)	fenofibrate (PA449594)	Carriers of the C allele had a greater reduction in levels of interleukin-6 (IL-6; units = pg/ml) following 30 days of treatment, compared to those with the GG genotype.	Genotypes CC + CG are associated with increased response to fenofibrate in patients with a high risk of cardiovascular disease as compared to genotype GG.	CC + CG	C
447	rs1800795	IL6 (PA198)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	(no entry)	Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele C.	G	C
448	rs2270007	CRHR2 (PA26875)	citalopram (PA449015)	"This association is for response at week 4 but not at week 12. The allele associated with worse response is described as G. This is a G/C SNP, so this is ambiguous. The gene is on the negative chromosomal strand, so I am guessing that the authors meant negative chromosomal strand G (= positive chromosomal strand C). The OR entered is for increased risk of non-response. Authors note that Bonferroni correction was not done and that they think that it would be overly conservative to do so. p entered is not corrected; 7 SNPs were tested. Number of ""cases"" and ""controls"" entered are responders and non-responders."	Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	CC + CG	G
449	rs73294475	CRHR2 (PA26875)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation. This was assessed as a replication attempt for a previously reported association of a different CRHR2 SNP with response to bronchodilators. Bonferroni correction was performed according to the number of SNPs included that are within 50 kb up and downstream of CRHR2.	Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.	CT	T
450	rs2267715	CRHR2 (PA26875)	salbutamol (PA448068)	(no entry)	Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.	G	G
451	rs2284220	CRHR2 (PA26875)	salbutamol (PA448068)	(no entry)	Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.	G	G
452	rs7793837	CRHR2 (PA26875)	"salbutamol (PA448068),""selective beta-2-adrenoreceptor agonists (PA134687887)"""	(no entry)	Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	T	A
453	rs7793837	CRHR2 (PA26875)	"salbutamol (PA448068),""selective beta-2-adrenoreceptor agonists (PA134687887)"""	(no entry)	Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	T	A
454	rs255100	CRHR2 (PA26875)	salbutamol (PA448068)	The A allele of this variant is associated with reduced bronchodilator response in CAMP cohort. However, this association is not significant in the other two cohorts tested.	Allele A is associated with decreased response to salbutamol in people with Asthma as compared to allele T.	A	A
455	rs34548976	(no entry)	adrenergics, inhalants (PA10405)	For the discovery cohort, 351 children (ages 6–14 yr) with asthma (defined as physician-diagnosed asthma and =1 episode of wheeze in the previous yr) were recruited from households in San Juan (Puerto Rico). Replication of our findings for stress and BDR was attempted in 471 children with asthma (ages 7–15 yr) living in Rhode Island (n=229; 59 PR, 81 Dominican, and 89 non-Hispanic white children) and Puerto Rico (n=242) (Rhode Island Puerto Rico Asthma Center [RIPRAC] cohort). Finally, children with high child anxiety and BDR were assessed in 87 children (ages 12–17 yr) in the National Health and Nutrition Examination Survey (NHANES) in 2007–2010.	Allele T is associated with decreased response to adrenergics, inhalants in children with Asthma as compared to allele C.	T	C
456	rs2072183	NPC1L1 (PA31699)	hmg coa reductase inhibitors (PA133950441)	as measured by lesser reductions in LDL-C. These individuals were also more likely to start out with higher LDL-C before treatment. NPC1L1 is on the minus strand therefore alleles were complemented and shown here on plus chromosomal strand. Paper shows C as effect allele and also minor allele in European-ancestry individuals.	Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases and Hypercholesterolemia as compared to allele C.	G	G
457	rs2293347	EGFR (PA7360)	fluorouracil (PA128406956)	Response was defined as complete or partial response according to response evaluation criteria in solid tumors (RECIST); non-response was defined as no change or progressive disease. A greater percentage of those with the CC genotype were non-responders. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with decreased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT.	CC	C
458	rs1057868	POR (PA33532)	atorvastatin (PA448500)	Patients with the CT (POR *1/*28) or TT (POR *28/*28) genotypes had significantly lower percent mean reduction of total cholesterol and low-density lipoprotein cholesterol (LDLc) after 6 months of treatment as compared to those with the CC genotype (*1/*1). In multivariable linear regression adjusted for confounding factors, POR*28 genotype accounted for an estimated 8.3% and 7.3% of overall variability in % total cholesterol and LDLc reduction (p=0.001 and p=0.004, respectively).	Genotypes CT + TT is associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype CC.	CT + TT	C
459	rs2299214	GRM3 (PA28992)	antipsychotics (PA452233)	"Only in patients who were in the ""low severity group"" based on baseline severity score, using clinical global impressions (CGI) score. Within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the CC genotype were more prevalent in the CR group in all three cohorts. Note that this association did not withstand correction for multiple testing."	Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.	CC	C
460	rs2299214	GRM3 (PA28992)	risperidone (PA451257)	"Only in patients who were in the ""high severity group"" based on baseline severity score, using clinical global impressions (CGI) score. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the CC or CT genotype were more prevalent in the IR group. Note that this association did not withstand correction for multiple testing."	Genotypes CC + CT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotype TT.	CC + CT	C
461	rs724226	GRM3 (PA28992)	risperidone (PA451257)	(no entry)	Allele G is associated with increased response to risperidone in people with Schizophrenia.	G	A
462	rs6465084	GRM3 (PA28992)	antipsychotics (PA452233)	"Only in patients who were in the ""low severity group"" based on baseline severity score, using clinical global impressions (CGI) score. Within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the AA and AG genotype were more prevalent in the CR group in all three cohorts. Note that this association did not withstand correction for multiple testing."	Genotypes AG + GG is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype AA.	AG + GG	A
463	rs7787082	ABCB1 (PA267)	clozapine (PA449061)	Drug response was assessed using Clinical Global Impressions - Improvement (CGI-I) scores. Patients were classified as responders (CGI-I score of 1 or 2) or non-responders (CGI-I score greater than 3). The G allele was more frequently observed in non-responders than in responders. Please note this SNP is in linkage disequilibrium with rs10248420 (r-squared = 0.911).	Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.	G	G
464	rs10248420	ABCB1 (PA267)	clozapine (PA449061)	Drug response was assessed using Clinical Global Impressions - Improvement (CGI-I) scores. Patients were classified as responders (CGI-I score of 1 or 2) or non-responders (CGI-I score greater than 3). The A allele was more frequently observed in non-responders than in responders. Please note this SNP is in linkage disequilibrium with rs7787082 (r-squared = 0.911).	Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.	A	A
465	rs1922242	ABCB1 (PA267)	fluvastatin (PA449688)	Patients with the AA genotype had an increased change in LDL-C levels from baseline (change in HDL-C or triglycerides was not significantly different). Please note; alleles have been complemented to the plus strand. In the paper, A was reported as the less frequent allele - this has been complemented here to T.	Genotype AA is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AT.	AA	A
466	rs1128503	ABCB1 (PA267)	risperidone (PA451257)	Alleles complemented to plus chromosomal strand. Patients with the ABCB1 c.1236C>T, TT or CT genotypes had 4.7% lower ATEC scores than CC homozygotes	Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.	AA + AG	A
467	rs1128503	ABCB1 (PA267)	antipsychotics (PA452233)	Please note: this variant deviated from Hardy-Weinberg equilibrium in a pooled group of responders and non-responders. Alleles have been complemented to the plus chromosomal strand. Allele frequencies displayed significant differences in responders vs non-responders, however genotype frequencies were not significantly different (p=0.08).	Allele G is associated with increased response to antipsychotics in people with Schizophrenia.	G	A
468	rs1128503	ABCB1 (PA267)	simvastatin (PA451363)	Smaller reductions in total cholesterol and LDL cholesterol were seen in patients with the GG genotype compared to carriers of the A allele. No differences were seen in change in HDL-cholesterol or trigylcerides. Alleles have been complemented here to the plus chromosomal strand.	Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.	GG	A
469	rs1128503	ABCB1 (PA267)	rocuronium (PA164754992)	Patients with the AA genotype had longer clinical duration of the initial dose (p=0.031 for AA vs AG and p=0.026 for AA vs GG), longer clinical duration of the maintenance dose (p=0.022 for AA vs AG and p=0.014 for AA vs GG) and shorter recovery time (p=0.016 for AA vs AG and p=0.008 for AA vs GG) as compared to those with the AG or GG genotype. Multiple stepwise regression analysis showed that this variant was one of the best predictors of clinical duration in initial dose, and the best predictor of clinical duration of maintenance dose and recovery time. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to rocuronium as compared to genotypes AG + GG.	AA	A
470	rs1128503	ABCB1 (PA267)	imatinib (PA10804)	Meta-analysis with 5 studies. A significant finding only existed when considering Asian patients, not European or American patients, or all patients combined. Response assessed using major molecular response (MMR), cytogenetic response (CR) or complete cytogenetic response (CCR). Note that the exact number of individuals in the Asian subcohort was not provided, nor was the number of studies included in the subcohort meta-analysis - these values were calculated by PharmGKB from the paper but may not be accurate. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	GG	A
471	rs1128503	ABCB1 (PA267)	glucocorticoids (PA452347)	The GG genotype was more frequent in patients who were dependent on glucocorticoids as compared to those responsive to glucocorticoids. Responsiveness to glucocorticoids defined as patients who maintained complete or partial remission after glucocorticoid withdrawal. Dependence on glucocorticoids defined as patients in whom either steroids could not be reduced below the equivalent of prednisolone 10 mg/day within 3 months after therapy initiation without recurrent active disease, or relapse occurred within 3 months after the withdrawal of steroids. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to glucocorticoids in people with Crohn Disease.	GG	A
472	rs1128503	ABCB1 (PA267)	modafinil (PA450530)	Given as reverse strand C>T. Most of analysis conducted with haplotype (rs1128503, rs2032582, rs1045642), where CGC-TTT found improved treatment outcome with modafinil (compared to GCG-CGC and TTT-TTT and others).	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.	AG	A
473	rs1128503	ABCB1 (PA267)	"remifentanil (PA451232),""sevoflurane (PA451341)"""	The GG genotype was associated with a decreased visual analog scale score at 1, 2, 4, and 8 hours post-operative (all P<.05). The GG genotype was associated with shorter times of induction, respiration recovery, eyeopening, and extubation (all P<.05). Ramsay sedation scores were lower in the GG genotype (less sedation), while Face, Legs, Activity, Cry, Consolability scale (FLACC) scores were higher (increased pain) (both P<.05).	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	GG	A
474	rs1128503	ABCB1 (PA267)	tacrolimus (PA451578)	Patients with the AG or GG genotype had a significantly higher response rate and remission rate as compared to patients with the AA genotype. Those with the AG or GG genotype had a response rate of 73% and a remission rate of 63%, while those with the AA genotype had a response rate of 63% and a remission rate of 20%. There were also significant associations with partial ulcerative colitis disease activity score (p-DAI) and change in p-DAI. In multivariate analysis, this SNP was identified as an independent factor associated with remission (p=0.011). Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG are associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	AG + GG	A
475	rs1128503	ABCB1 (PA267)	imatinib (PA10804)	(no entry)	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	GG	A
476	rs1128503	ABCB1 (PA267)	clopidogrel (PA449053)	Patients with genotype GG showed decreased platelet inhibtion compared to genotypes AA+AG. The authors than link increased platelet inhibition to increased resistance to clopidogrel.	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.	AA + AG	A
477	rs1128503	ABCB1 (PA267)	risperidone (PA451257)	Alleles given as reverse strand C and T. Efficacy measured with reduction in PANSS total score reduced rate.	Genotypes AG + GG are not associated with response to risperidone in people with Schizophrenia as compared to genotype AA.	AG + GG	A
478	rs1128503	ABCB1 (PA267)	"propofol (PA451141),""remifentanil (PA451232)"""	Referred to as 1236 C>T in the paper. Please note that alleles have been complemented to the positive strand. Patients with the GG genotype were determined to have an increased response to propofol/remifentanil anesthesia compared to patients with the AA or AG genotypes as patients with the GG genotype had a decreased time of induction, respiration recovery, eye-opening and extubation in addition to reduced blood pressure and heart rate values, increased postsurgery analgesia (as determined by VAS score) and decreased postsurgery sedation (as determined by Ramsey score). However, GG patients also had increased FLACC score, indicating increased pain following extubation.	Genotype GG is associated with increased response to propofol and remifentanil in children as compared to genotypes AA + AG.	GG	A
479	rs1128503	ABCB1 (PA267)	methotrexate (PA450428)	Authors say this variant is associated with response in recessive model (minor allele/minor allele vs minor/major + major major and describe variant as G>A).	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.	AA	A
480	rs1128503	ABCB1 (PA267)	fentanyl (PA449599)	Please note that alleles have been complemented to the positive strand. Patients with the AA genotype had a lower odds ratio of requiring rescue medication compared to AG and GG patients.	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.	AA	A
481	rs1128503	ABCB1 (PA267)	tacrolimus (PA451578)	Patients with the AA genotype had a higher effectiveness of clinical treatment as compared to those with the AG or GG genotypes. Effective response included patients with complete or partial remission, and ineffective response included patients with no remission or recurrence.	Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.	AA	A
482	rs662	PON1 (PA33529)	simvastatin (PA451363)	Patients with the CC genotype had a significantly higher increase in HDL-cholesterol after treatment compared to patients with the TT genotype. Response of patients with the CT genotype was in between, closer to that of TT (not stats given). No differences between genotypes in change of triglyceride, total cholesterol or LDL-C were seen. Variant described as 192Q>R (here Q=allele T, R= allele C, complemented to the plus chromosomal strand).	Genotype CC is associated with increased response to simvastatin in people with Coronary Disease as compared to genotype TT.	CC	T
483	rs662	PON1 (PA33529)	"epirubicin (PA449476),""fluorouracil (PA128406956)"",""oxaliplatin (PA131285527)"""	Response refers to overall survival (OS). In the Kaplan–Meier analysis of OS genotypes of rs662 were associated with OS. In Cox regression analysis number of lesions as well as s662 genotype were independent predictors of OS. When comparing OS between the CC genotype and TT and CT genotypes there was no significant difference in OS (days) but when comparing between TT and CC only, the difference is significant (p=0.032). Please note: alleles have been complemented to the + strand.	Genotype CC is associated with increased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotypes CT + TT.	CC	T
484	rs17161788	CYP3A5 (PA131)	atorvastatin (PA448500)	Please note that this paper stated that CYP3A5*1D is defined by the rs17161788 SNP. However, the CYP nomenclature database and other papers note that CYP3A5*1D is defined by the rs15524 SNP. *1D/*1D (TT) compared to *1A/*1A+*1A/*1D (CC+CT). Percentage change in triglycerides, LDL-C, and HDL-C was significantly lower in patients with the TT genotype. However only in patients of non-African descent - this association was not seen in those of African descent.	Genotype TT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	TT	T
485	rs776746	CYP3A5 (PA131)	atorvastatin (PA448500)	*3C/*3C (CC) compared to *1A/*1A+*1A/*3C (TT+CT). Percentage change in triglycerides, LDL-C, and HDL-C was significantly lower in patients with the CC genotype. However only in patients of non-African descent - this association was not seen in those of African descent.	Genotype CC is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CT + TT.	CC	C
486	rs776746	CYP3A5 (PA131)	"atorvastatin (PA448500),""lovastatin (PA450272)"",""simvastatin (PA451363)"""	as measured by significantly lower total cholestrol and higher reductions in total cholesterol from baseline in patients with the *3/*3 (CC) genotype compared to those with the *1/*3 (CT) genotype after treatment. Percent reduction in LDL cholestrol was not statistically significant.	Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.	CC	C
487	rs776746	CYP3A5 (PA131)	atorvastatin (PA448500)	as measured by decreases in LDL-cholestrol. Please note; alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with increased response to atorvastatin as compared to genotype TT.	CC + CT	C
488	rs776746	CYP3A5 (PA131)	rosuvastatin (PA134308647)	as measured by achievement of their LDL cholesterol target (significance given for variants of either CYP3A5*1, 6986A>G, rs776746 and ABCG2; 421C>A, rs2231142).	Allele C is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele T.	C	C
489	rs776746	CYP3A5 (PA131)	clopidogrel (PA449053)	Frequency of CC+TC genotypes was significantly higher in clopidogrel-resistant patients than in clopidogrel-sensitive patients.	Genotypes CC + CT are associated with increased resistance to clopidogrel in people with Stroke as compared to genotype TT.	CC + CT	C
490	rs776746	CYP3A5 (PA131)	"docetaxel (PA449383),""paclitaxel (PA450761)"""	"Patients with complete and partial pathological response to neo-adjuvant taxanes were considered as responders while patients with static and progressive disease with neo-adjuvant taxanes were considered as non-responders. Authors considered the significance ""borderline"".(Complemented to represent on positive chromosomal strand)"	Genotype CC is associated with decreased response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.	CC	C
491	rs776746	CYP3A5 (PA131)	imatinib (PA10804)	Response = complete cytogenetic response (CCyR) as defined by each individual study, 4 studies were analyzed.	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.	C	C
492	rs4986910	CYP3A4 (PA130)	fluvastatin (PA449688)	as measured by increases in HDL-cholesterol. There were no patients with the GG genotype. Please note; alleles have been complemented to the plus chromosomal strand.	Genotype AG is associated with increased response to fluvastatin as compared to genotype AA.	AG	A
493	rs4646437	CYP3A4 (PA130)	cyclosporine (PA449167)	There was a significant difference in genotype frequency distribution between those who experienced biopsy-proven acute rejection and those who did not. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype AA.	AG + GG	G
494	rs2246709	CYP3A4 (PA130)	amlodipine (PA448388)	People who were carriers for the G allele were more likely to reach the target mean arterial pressure of <= 92 mm Hg when treated with amlodipine compared to AA homozygotes. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA.	AG + GG	A
495	rs2687116	CYP3A4 (PA130)	"carbamazepine (PA448785),""lamotrigine (PA450164)"",""phenytoin (PA450947)"",""primidone (PA451105)"",""valproic acid (PA451846)"""	(no entry)	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.	C	C
496	rs35599367	CYP3A4 (PA130)	simvastatin (PA451363)	A-variant allele was associated with reduced CYP3A4 activity. Response is determined as significance in increased reduction of total cholesterol or LDL cholesterol was reached after adjusting the model for potential confounding factors.	Allele A is associated with increased response to simvastatin in people with Chronic Disease as compared to genotype GG.	A	G
497	rs2740574	CYP3A4 (PA130)	amlodipine (PA448388)	Women who were carriers for the T allele were more likely to reach the target mean arterial pressure of <= 107 mm Hg when treated with amlodipine. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT are associated with increased response to amlodipine in women with Hypertension as compared to genotype CC.	CT + TT	C
498	rs2740574	CYP3A4 (PA130)	"carbamazepine (PA448785),""lamotrigine (PA450164)"",""phenytoin (PA450947)"",""primidone (PA451105)"",""valproic acid (PA451846)"""	(no entry)	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	C	C
499	rs2740574	CYP3A4 (PA130)	lumefantrine (PA165111722)	(no entry)	Allele T is associated with decreased response to lumefantrine in women with Malaria and Pregnancy as compared to allele C.	T	C
500	rs2740574	CYP3A4 (PA130)	buprenorphine (PA448685)	The paper analyzes the analgesic effect of buprenorphine. Please note that genotypes have been complemented to the positive strand.	Genotype TT is associated with increased response to buprenorphine in people with Ischemia and Pain as compared to genotype CC.	TT	C
501	rs2571598	ACHE (PA20)	rivastigmine (PA451262)	Response to rivastimine was assessed by the mini mental state examination (MMSE) at baseline and at 1, 3, 9 and 15 months after beginning therapy.	Genotype TT is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CC + CT.	TT	C
502	rs2227631	SERPINE1 (PA261)	"citalopram (PA449015),""fluoxetine (PA449673)"""	(as haplotype with rs1799889-G)	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	G	A
503	rs117986340	KMT2E (PA38568)	duloxetine (PA10066)	"Patients with the GG genotype had a greater % decrease in the Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline as compared to those with the GT genotype. Note that in the initial GWAS analysis, this variant only reached the ""suggestive"" (p<5E-5) threshold."	Genotype GG is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotype GT.	GG	G
504	rs78655421	CFTR (PA109)	ivacaftor (PA165950341)	24-week, placebo-controlled, double-blind, randomised clinical trial. Patients had the R117H variant and percentage of predicted forced expiratory volume in 1s (% predicted FEV1) of at least 40. Patients received either placebo or ivacaftor 150 mg every 12 hours for 24 weeks (1:1). The treatment difference in mean absolute change in % predicted FEV1 was 2.1 percentage points (p=0.2). But there were significant treatment differences in sweat chloride (-24.0 mmol/L, p<0.0001) and CFQ-R respiratory domain (8.4 points, p=0.009). In subgroup analyses, % predicted FEV1 improved in patients age 18 or older (p=0.01) but not 6-11 years old (favoring placebo, p=0.03). Patients' poly-T status was either 5T or 7T, and significant results for sweat chloride were seen for both types of poly-T status (p<0.0001 and p=0.0003, respectively)	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	AA + AG	G
505	rs78655421	CFTR (PA109)	ivacaftor (PA165950341)	Extension study of KONDUCT. Patients underwent a washout period then an interim analysis at 12 weeks. Placebo-to-ivacaftor and ivacaftor-to-ivacaftor groups showed % predicted FEV1 improvement (absolute change from post-washout baseline at week 12: placebo-to-ivacaftor 5.0 percentage points (p=0.0005), ivacaftor-to-ivacaftor 6.0 percentage points (p=0.006)). There was also improvement in CFQ-R respiratory domain.	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	AA + AG	G
506	rs78655421	CFTR (PA109)	ivacaftor (PA165950341)	R117H allele. Assessment of C-sweat in three cystic fibrosis patients. A R117H-7T/F508del patient and a R117H-7T/R117H-7T patient both showed increased C-sweat production when treated with ivacaftor. However, a R117H-5T/F508del patient did not have a C-sweat response to ivacaftor.	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	A	G
507	rs121909005	CFTR (PA109)	ivacaftor (PA165950341)	as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S549R-CFTR (rs121908757 allele C or rs121909005  allele G) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability, increased chloride transport and increased single channel current amplitude at 80mV.	Allele G is associated with response to ivacaftor.	G	T
508	rs121909005	CFTR (PA109)	ivacaftor (PA165950341)	S549R allele. It is unclear whether rs121908757 or rs121909005 is the causative variant. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.	Allele G is associated with response to ivacaftor in people with Cystic Fibrosis.	G	T
509	rs8191992	CHRM2 (PA111)	fluticasone/salmeterol (PA165290926)	"The ""major"" allele is associated with increased response. It is not clear whether that is A or T on the positive chromosomal strand."	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.	A	T
510	rs6962027	CHRM2 (PA111)	fluticasone/salmeterol (PA165290926)	"The ""major"" allele is associated with increased response. It is not clear whether that is A or T on the positive chromosomal strand."	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.	A	T
511	rs6962027	CHRM2 (PA111)	fluticasone/salmeterol (PA165290926)	"The ""major"" allele is associated with increased response. It is not clear whether that is A or T on the positive chromosomal strand."	Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.	A	T
512	rs2070744	NOS3 (PA254)	sildenafil (PA451346)	This effect was only seen in the subset of patients with post-operative ED rather than organic, clinical ED.	Genotypes CC + CT are associated with increased response to sildenafil in men with Erectile Dysfunction as compared to genotype TT.	CC + CT	C
513	rs2070744	NOS3 (PA254)	enalapril (PA449456)	Patients with the CC or CT genotypes showed significantly larger decreases in systolic and diastolic blood pressure as compared to patients with the TT genotype.	Genotypes CC + CT are associated with increased response to enalapril in people with Hypertension as compared to genotype TT.	CC + CT	C
514	rs17070785	CSMD1 (PA26947)	olanzapine (PA450688)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to olanzapine in people with Schizophrenia.	A	A
515	rs17570753	MCPH1 (PA30701)	perphenazine (PA450882)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to perphenazine in people with Schizophrenia.	A	T
516	rs11774231	(no entry)	perphenazine (PA450882)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele C is associated with response to perphenazine in people with Schizophrenia.	C	C
517	rs1495741	NAT2 (PA18)	iguratimod (PA166178387)	There are two places in the text where the variant is also referred to as rs1495742 but this appears to be a typo.	Genotypes AG + GG is associated with decreased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype AA.	AG + GG	G
518	rs320	LPL (PA232)	fenofibrate (PA449594)	Response was measured as the percentage of triglyceride lowering.	Genotype GG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes GT + TT.	GG	T
519	rs328	LPL (PA232)	pravastatin (PA451089)	as measured by decreases in total cholesterol.	Genotype GG is associated with increased response to pravastatin as compared to genotypes CC + CG.	GG	C
520	rs17060812	SLC39A14 (PA134863701)	nortriptyline (PA450657)	(no entry)	Allele C is associated with increased response to nortriptyline in people with Depression as compared to allele T.	C	C
521	rs1048101	ADRA1A (PA34)	nifedipine (PA450631)	This SNP was presented as Arg347Cys. Patients carrying the Cys allele had a better systolic blood pressure reduction as compared to patients homozygous for the Arg allele. A non-significant trend was found for diastolic blood pressure.	Genotypes AA + AG are associated with increased response to nifedipine in people with Hypertension as compared to genotype GG.	AA + AG	A
522	rs1546519	LYN (PA30498)	ziprasidone (PA451974)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to ziprasidone in people with Schizophrenia.	G	G
523	rs3808607	CYP7A1 (PA132)	atorvastatin (PA448500)	Alleles given as A and C. Response measured as reduction of LDL-C after 8 weeks of treatment with 10mg/day of atorvastatin.	Genotype TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes GG + GT.	TT	G
524	rs3758149	GGH (PA432)	methotrexate (PA450428)	(no entry)	Genotypes AA + AG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	AA + AG	G
525	rs1265138	RRM2B (PA34866)	"cladribine (PA449027),""cytarabine (PA449177)"""	More patients with a complete response after the first induction therapy were seen in the AA genotype group. No multiple testing adjustments were performed: 7 SNPs were investigated.	Genotype AA is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	AA	A
526	rs13266634	SLC30A8 (PA134915546)	repaglinide (PA451234)	(no entry)	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	CT + TT	C
527	rs13266634	SLC30A8 (PA134915546)	"insulin recombinant (PA164744571),""zinc acetate (PA451961)"""	The aim of the study was to determine whether zinc supplements improved insulin response in people with the CT+TT genotypes as compared to people with the CC genotypes. After being administered insulin without zinc, fasting characteristics were similar across genotypes except for C-peptide:insulin ratio, insulin AUC at 5 and 10 minutes, which were significantly lower in the CC genotype group. The proinsulin:insulin ratio at 5 and 10 minutes after insulin and glucose as well as the C-peptide:insulin ratio at 5 and 10 minutes after insulin and glucose were also lower in the CC genotype group compared to the CT+TT genotype group. People with the CT+TT genotypes had significantly improved responses to insulin when it was supplemented with zinc acetate as compared to CC genotypes.	Genotypes CT + TT is associated with increased response to insulin recombinant and zinc acetate in healthy individuals as compared to genotype CC.	CT + TT	C
528	rs6983267	(no entry)	Platinum compounds (PA164713176)	Study looking at SNPs in long non-coding RNA, but with SNPs assessed from genomic DNA.	Genotypes GG + GT are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype TT.	GG + GT	G
529	rs2114358	PVT1 (PA34053)	glatiramer acetate (PA449760)	Significant for responders vs non-responders after multiple testing correction.	Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	G
530	rs1799998	CYP11B2 (PA134)	"benazepril (PA448561),""imidapril (PA452640)"""	Carriers of the A allele had greater reductions in diastolic blood pressure after 6 weeks of treatment compared to GG homozygotes. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG are associated with increased response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	AA + AG	A
531	rs1799998	CYP11B2 (PA134)	candesartan (PA448765)	A positive response was defined as a diastolic blood pressure of < 85 mmHg after 4 weeks of treatment. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to candesartan in people with Hypertension as compared to genotypes AA + AG.	GG	A
532	rs10975641	GLDC (PA28716)	"citalopram (PA449015),""escitalopram (PA10074)"""	"Be careful- GC SNP. The paper states that the minor allele was assoc with decreased odds for remission(in the original cohort), and from dbSNP freq/orientation of fastA compared to Golden path, I believe G on the + chr strand to be the minor allele. For the STAR*D study, remission was not found to be significantly associated; the significant association was with ""the binary phenotype ""response""""."	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.	G	C
533	rs10739150	(no entry)	atenolol (PA448499)	in black patients. Black participants with rs10739150 GG, TG, and TT genotypes had a BP response of -8.7/-7.2,-4.6/-4.8, and 1.4/-1.5 mmHg, respectively, after atenolol monotherapy.	Genotypes GG + GT are associated with increased response to atenolol in people with Hypertension as compared to genotype TT.	GG + GT	T
534	rs17584499	PTPRD (PA34013)	pioglitazone (PA450970)	Patients with the CC genotype showed significantly greater decreases in postprandial plasma glucose levels after 3 months of pioglitazone treatment. However, changes in other biochemical measures were not significant.	Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	CC	C
535	rs4742610	PTPRD (PA34013)	"trandolapril (PA451737),""verapamil (PA451868)"""	This was associated with resistant hypertension in whites and Hispanics in the international verapamil SR trandolapril study (meta-analysis P=3.2×10-5).	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.	T	C
536	rs12346562	(no entry)	atenolol (PA448499)	The A allele of SNP rs12346562 was associated with better DBP response to atenolol, but with less pronounced response to hydrochlorothiazide. White participants with rs12346562 AA, AC, and CC genotypes had mean DBP responses of -15.0,-11.2, and -9.4 mmHg to atenolol (P=3.2x10-6, b=-2.4 mmHg per A allele).	Genotypes AA + AC is associated with increased response to atenolol in people with Hypertension as compared to genotype CC.	AA + AC	C
537	rs12346562	(no entry)	hydrochlorothiazide (PA449899)	The A allele of SNP rs12346562 was associated with better DBP response to atenolol, but with less pronounced response to hydrochlorothiazide. White participants with rs12346562 AA, AC, and CC genotypes had mean DBP responses of -3.8,-3.8, and -5.6 mmHg to atenolol (P=0.0018, b=1.55 mmHg per A allele).	Genotypes AA + AC is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.	AA + AC	C
538	rs6475448	MLLT3 (PA30852)	montelukast (PA450546)	Patients who were homozygous for rs6475448 showed markedly increased mean d forced expiratory volume (FEV1) from baseline after 8 weeks of montelukast. The largest increase was observed for Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol (LOCCS); the rs6475448-AA genotype was associated with a LS-mean delta FEV1 of 344 mL vs. -4.66 mL for rs6475448-GG genotype. Study Cohort: Discovery cohort (N=133): American Lung Association Asthma Clinical Research Center (ALA-ACRC)-supported trials, the Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial (LOCCS) and Effectiveness of Low Dose Theophylline as Add On Therapy for the Treatment of Asthma (LODO) trials. Replication cohort (N=184): Childhood Asthma Research and Education (CARE) Network- Characterizing the Response to a LT Receptor Antagonist and an Inhaled Corticosteroid and Pediatric Asthma Controller Trial (CLIC and PACT)	Genotype AA is associated with increased response to montelukast in people with Asthma as compared to genotype GG.	AA	G
539	rs774359	C9orf72 (PA134908144)	ustekinumab (PA166048654)	as measured by PASI75 at 4 months and adjusted for weight and FDR.	Genotypes CC + CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype TT.	CC + CT	T
540	rs6151031	ALDH1A1 (PA24692)	"cyclophosphamide (PA449165),""doxorubicin (PA449412)"""	(no entry)	Genotype CTGGTGAGGAGAGAACC/del is associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.	CTGGTGAGGAGAGAACC/del	C
541	rs10465180	NTRK2 (PA31818)	clozapine (PA449061)	The association remained significant after permutation.	Genotype CC is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CT + TT.	CC	C
542	rs2769605	(no entry)	"lithium (PA450243),""valproic acid (PA451846)"""	(no entry)	Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.	CC	C
543	rs17461620	TUT7 (PA134971144)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C	C
544	rs238	(no entry)	"diuretics (PA151249535),""hydrochlorothiazide (PA449899)"",""Thiazides, plain (PA164713347)"""	The association was significant in PEAR + GERA, but not in NORDIL (in which the effect was opposite, though small) or in the 3-study meta-analysis. Observations: 3.11 mm Hg decrease in reduction of systolic blood pressure per A allele in PEAR + GERA, 0.45 mm Hg greater reduction in systolic blood pressure per A allele in NORDIL and 2.22 mm Hg decrease in reduction of systolic blood pressure per A allele in PEAR + GERA + NORDIL.	Allele A is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A	A
545	rs1800975	XPA (PA368)	Platinum compounds (PA164713176)	Only significant within the squamous cell carcinoma subtype patients (i.e. not significant in overall cohort of non-small-cell lung cancer patients with stage IIIA/IIIB or stage IV). Platinum-based doublets consisting of cisplatin or carboplatin plus gemcitabine, vinorelbine, taxane or pemetrexed. Response defined as complete or partial response; non-response defined as stable disease or progression disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	CC	T
546	rs2230808	ABCA1 (PA24373)	fenofibrate (PA449594)	Patients with the CC genotype had a greater small high-density lipoprotein (HDL) particle concentration (units = umol/L) and a greater total HDL particle concentration after fenofibrate treatment for 3 weeks, as compared to patients with the TT genotype.	Genotype CC is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	CC	T
547	rs2230806	ABCA1 (PA24373)	fenofibrate (PA449594)	Patients with the CT genotype had a greater small high-density lipoprotein (HDL) particle concentration (units = umol/L) after fenofibrate treatment for 3 weeks, as compared to patients with the CC genotype.	Genotype CT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	CT	C
548	rs2230806	ABCA1 (PA24373)	fenofibrate (PA449594)	Patients with the TT genotype had a greater total high-density lipoprotein (HDL) particle concentration (units = umol/L) after fenofibrate treatment for 3 weeks, as compared to patients with the CC genotype.	Genotype TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	TT	C
549	rs2487032	(no entry)	clopidogrel (PA449053)	This variant is associated with decreased Cmax, decreased AUC of clopidogrel, decreased H4 concentration, and decreased antiplatelet effects of clopidogrel with a higher PRU.	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	A	G
550	rs2770150	TLR4 (PA36552)	Pertussis vaccines (PA164713160)	Patients with the GG genotype had a lower pertussis toxin-specific immunoglobulin G (PT-IgG) titer following whole-cell pertussis vaccination as compared to those with the AG genotype. The IgG antibody titer against PT correlates with protection against disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to Pertussis vaccines in children as compared to genotype AG.	GG	A
551	rs5030728	TLR4 (PA36552)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for all cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype GG.	AA + AG	G
552	rs4986790	TLR4 (PA36552)	Pertussis vaccines (PA164713160)	10-year follow-up for a booster dose of acellular pertussis vaccine. Original vaccine given at 3, 4, 5 and 24 months old. No pertussis had occurred in any patients at this 10-year point. The fold increase in antibody response to pertussis toxin after vaccination was significantly lower in subjects with the AG or GG genotypes as compared to those with the AA genotype (wild-type); 55% vs 86%, respectively.	Genotype AA is associated with increased response to Pertussis vaccines in children as compared to genotypes AG + GG.	AA	A
553	rs1554973	CNPY4 (PA162382618)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.	CC + CT	T
554	rs3761847	TRAF1 (PA36708)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	using either the absolute change in DAS28 or the proportion of good responders and non-responders as outcomes. The G allele is also a susceptibility factor for RA related to TNF signaling.	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	G	G
555	rs430397	HSPA5 (PA29504)	Platinum compounds (PA164713176)	Resistance was measured by comparing responders (patients with complete or partial response) with non-responders (stable or progressive disease). Please note that alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased resistance to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	TT	C
556	rs1544105	FPGS (PA167)	methotrexate (PA450428)	(no entry)	Genotypes TT + CT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	TT + CT	C
557	rs10901080	ASS1 (PA162376926)	hydroxyurea (PA449942)	Patients with plateau fetal hemoglobin (HbF) levels below 20% were considered ‘HU nonresponders’, while patients with plateau HbF levels rising over 20% were considered ‘HU responders’.	Allele T is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele G.	T	G
558	rs1611115	DBH (PA136)	levodopa (PA450213)	Not corrected for multiple testing. The CT/TT group had decrease odds of having cocaine-positive urine (odds ratio=0.127, 95% confidence interval 0.026¿0.633) under levodopa treatment, whereas for placebo, the odds of having cocaine-positive urine increased over time (odds ratio=1.65, 95% confidence interval 1.399¿1.948). For CC genotype, however, the treatment by time interaction was not significant (F1,86=0.00, P=0.991).	Genotypes CT + TT are associated with increased response to levodopa in people with Cocaine-Related Disorders as compared to genotype CC.	CT + TT	T
559	rs1611115	DBH (PA136)	naltrexone (PA450588)	Veterans. Two-thirds had a lifetime history of major depressive disorder, 37% had a lifetime history of post-traumatic stress disorder. 65% took SSRIs and 39% took anticonvulsants. 84-day treatment period. Patients who carried the T allele had more abstinence from heavy drinking days as compared to those with the CC genotype. Note that heavy drinking days was defined as more than four standard drinks in a day.	Genotypes CT + TT is associated with increased response to naltrexone in men with Alcoholism as compared to genotype CC.	CT + TT	T
560	rs982003	CACNB2 (PA88)	antipsychotics (PA452233)	Patients with the CC genotype had a greater decrease in Positive and Negative Syndrome Scale (PANSS)-negative scores over a period of 12 months as compared to those with the TT genotype. No significant association was seen when comparing the CT vs TT genotype. Significance was set at p<3.45E-6. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.	CC	C
561	rs3810950	CHAT (PA26448)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	G	G
562	rs4838392	CHAT (PA26448)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	G	A
563	rs12246528	CHAT (PA26448)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	G	G
564	rs1786929	(no entry)	"fluticasone propionate (PA449686),""montelukast (PA450546)"""	Patients with the AA or AG genotype had an increase in forced expiratory volume in the first second of expiration (FEV1), as compared to those with the TT genotype who had a decrease in FEV1. FEV1 was measured before treatment and 4 weeks later. This result was significant for a subgroup of atopic asthma patients (n = 189, p = 0.027), but not a subgroup of nonatopic asthma patients (n = 84, p = 0.161). Please note that this SNP was also found to be significantly associated with severity of asthma. Alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype GG.	AA + AG	A
565	rs10997242	CTNNA3 (PA27010)	antidepressants (PA452229)	Identity of minor allele not specified, so minor allele of dbSNP used here. Response considered to be successful with a 50% reduction at discharge of the Hamilton Rating Scale for Depression (HRSD17). Patients measured at admission and discharge, 4-6 weeks later. Specific antidepressants not listed.	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	C	T
566	rs4148947	CHST3 (PA26503)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper, since frequencies are close have low confidence in this allele assignment)	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	T	T
567	rs4148950	CHST3 (PA26503)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper)	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	A	G
568	rs1871450	CHST3 (PA26503)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with data in pgkb, actual base not listed in paper)	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	A	G
569	rs12418	CHST3 (PA26503)	"docetaxel (PA449383),""thalidomide (PA451644)"""	(allele inferred by frequency comparison with dbSNP, actual base not listed in paper)	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	A	G
570	rs35793	KCNMA1 (PA220)	quetiapine (PA451201)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to quetiapine in people with Schizophrenia.	G	C
571	rs12248560	CYP2C19 (PA124)	clopidogrel (PA449053)	CYP2C19*17 heterozygotes (CT) compared to homozygouse wildtype patients (CC), as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients by two-sided unpaired wilcoxon test (p=0.0001). CYP2C19*17 (genotyped rs12248560 C>T) was not mentioned in the results for the multiple linear regression model, though CYP2C19*17 carrier status was said to be an independent variable for platelet reactivity index in the statistical analysis section (but p value not given).	Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	CT	C
572	rs12248560	CYP2C19 (PA124)	phenazepam (PA166180939)	Patients with the CC or CT genotypes had a greater reduction in anxiety scores compared to patients with the TT genotype.	Genotypes CC + CT are associated with increased response to phenazepam in men with Alcohol-Related Disorders as compared to genotype TT.	CC + CT	C
573	rs4986893	CYP2C19 (PA124)	clopidogrel (PA449053)	(no entry)	Genotype AA is associated with decreased response to clopidogrel.	AA	G
574	rs4986893	CYP2C19 (PA124)	clopidogrel (PA449053)	as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients. Patients with one (p=0.001) or two (p<0.001) loss-of-function alleles (CYP2C19*2 (genotyped rs4244285 G>A) or CYP2C19*3 (genotyped rs4986893 G>A)) had a significantly increased platelet reactivity index compared to those without loss-of-function alleles. [stat_test: multiple linear regression model]	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	A	G
575	rs4244285	CYP2C19 (PA124)	"aspirin (PA448497),""clopidogrel (PA449053)"""	These patients had coronary arterial stenting. The comparison was that ADP-induced ex vivo platelet aggregation was higher in (AA + AG) compared to GG, but the template does not accomodate this. *2 SNP. [stat_test: chi-square]	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	A	G
576	rs4244285	CYP2C19 (PA124)	"aspirin (PA448497),""clopidogrel (PA449053)"""	The prevalance of High Platelet Reactivity (HPR) was higher in (AA + AG) compared to GG, but the template doesn't accomodate this. *2 SNP. [stat_test: chi-square]	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	A	G
577	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	(no entry)	Genotype AA is associated with decreased response to clopidogrel.	AA	G
578	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients. Patients with one (p=0.001) or two (p<0.001) loss-of-function alleles (CYP2C19*2 (genotyped rs4244285 G>A) or CYP2C19*3 (genotyped rs4986893 G>A)) had a significantly increased platelet reactivity index compared to those without loss-of-function alleles. [stat_test: multiple linear regression model]	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	A	G
579	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	Patients undergoing elective coronary stenting.	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	AA + AG	G
580	rs4244285	CYP2C19 (PA124)	"aspirin (PA448497),""clopidogrel (PA449053)"""	OR of 3.43 is for the occurrence of stent thrombosis, and OR of 2.70 is for the combination of stent thrombosis and cardiac mortality within a 6 month followup period. The stents eluted sirolimus or paclitaxel.	Genotypes AA + AG is associated with decreased response to aspirin and clopidogrel in people with percutaneous coronary interventions and drug-eluting stents as compared to genotype GG.	AA + AG	G
581	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	This was based upon measuring the rate of high on-treatment platelet reactivity.	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	AA + AG	G
582	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	These were patients undergoing percutaneous coronary intervention. Carriers of the A allele at rs4244285(determining *2) showed significantly increased residual platelet aggregation after a 600 mg loading dose of clopidogrel when compared to non-carriers. Patients were also typed for the main variants which determine *3 and *17. Patients also were dosed with 500 mg aspirin and 70 u/kg body weight unfractionated heparin prior to PCI. Patients were classified as having low or high residual platelet aggregation and the comparison was between those with low and high RPA.	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	AA + AG	G
583	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	AA + AG	G
584	rs4244285	CYP2C19 (PA124)	"clopidogrel (PA449053),""prasugrel (PA154410481)"",""ticagrelor (PA165374673)"""	This variant annotation is part of an Rx annotation, which compared personalized anti-platelet therapy to empiric treatment. Patients undergoing personalized therapy were given prasugrel if they carried 1 or 2 copies of the CYP2C19*2 allele and clopidogrel if they did not. Patients not receiving personalized therapy received ticagrelor.	Allele A is associated with response to clopidogrel, prasugrel and ticagrelor in people with Acute coronary syndrome.	A	G
585	rs4244285	CYP2C19 (PA124)	cyclophosphamide (PA449165)	This variant (CYP2C19*2) was independently associated with treatment failure and influenced the effects of GSTP1 and CYP3A5*3.	Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA.	AG + GG	G
586	rs4244285	CYP2C19 (PA124)	"cyclophosphamide (PA449165),""doxorubicin (PA449412)"""	(no entry)	Genotypes AA + AG are associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.	AA + AG	G
587	rs4244285	CYP2C19 (PA124)	clopidogrel (PA449053)	This variant is associated with decreased H4 concentration, and decreased antiplatelet effects of clopidogrel with a higher PRU.	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	AA + AG	G
588	rs1799853	CYP2C9 (PA126)	sulfonamides, urea derivatives (PA10390)	(no entry)	Genotype TT is associated with increased response to sulfonamides, urea derivatives.	TT	C
589	rs1799853	CYP2C9 (PA126)	irbesartan (PA450084)	Subjects were part of the Swedish Irbesartan Left Ventricular Hypertrophy Investigation (SILVHIA). This study analyzed data for subjects who were either randomized to 50 mg/day atenolol (N= 53) or 150 mg/day irbesartan (N=49) over 12 weeks. If diastolic blood pressure (DBP) remained greater than 90 mmHg at 6 weeks doses were doubled. At 12 weeks 67% of patients treated with irbesatran had to receive a 300 mg dose. By the end of the study, mean dose diastolic blood pressure (DBP) and systolic blood pressure (SBP) were assessed between the CYP2C9 *1/*2 (rs1799853 CT) genotype as compared to the CYP2C9 *1/*1 (rs1799853 CC) genotype. At the end of 12 weeks there was a significant decrease in DBP in those with the CT genotype as compared to the CC genotype but no significant difference in SBP. There were insufficient numbers of subjects with the *3 allele (rs1057910 C) (*1/*3, *2/*3, *3/*3) and so it was not analyzed.	Genotype CT is associated with increased response to irbesartan in people with Hypertension as compared to genotype CC.	CT	C
590	rs1057910	CYP2C9 (PA126)	sulfonamides, urea derivatives (PA10390)	(no entry)	Genotype CC is associated with increased response to sulfonamides, urea derivatives.	CC	A
591	rs717620	ABCC2 (PA116)	"atorvastatin (PA448500),""simvastatin (PA451363)"""	or switching to a different drug. Analysis of atorvastatin alone was not significant.	Allele T is associated with decreased dose of atorvastatin and simvastatin.	T	C
592	rs717620	ABCC2 (PA116)	antiepileptics (PA143485705)	This SNP was also part of haplotype associated with response/resistance.	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	CT + TT	C
593	rs717620	ABCC2 (PA116)	tamoxifen (PA451581)	Efficacy was measured as disease-free survival in breast cancer patients with distant metastasis of bone, lung, or liver. No patients had the TT genotype.	Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.	CT	C
594	rs717620	ABCC2 (PA116)	antiepileptics (PA143485705)	The authors observed that the ABCC2 variant c.-24C>T was associated with a significantly increased risk of AED resistance (TT+CT vs CC: OR=1.24, 95%CI=1.06-1.46, p=0.009; TT vs CT+CC: OR=1.90, 95%CI=1.31-2.76, p=0.0008; T vs C: OR=1.27, 95%CI=1.11-1.46, p=0.0006).	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	CT + TT	C
595	rs717620	ABCC2 (PA116)	atorvastatin (PA448500)	The authors saw that in the overall cohort, which included men and women, total cholesterol (TC), HDL-C, LDL-C, and triglycerides (TG) decreased significantly 4 weeks after beginning treatment. However, the only parameter that was significantly associated with genotype was TG, which decreased, but only in men. In women, there was no genotype effect.	Genotypes CT + TT are associated with decreased response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.	CT + TT	C
596	rs717620	ABCC2 (PA116)	simvastatin (PA451363)	as measured by HDL-C increase this was also significant in subset of women. Alleles complemented to plus chromosomal strand.	Genotypes CT + TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype CC.	CT + TT	C
597	rs3740066	ABCC2 (PA116)	antiepileptics (PA143485705)	This SNP was also part of haplotype associated with response/resistance.	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	CT + TT	C
598	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	Each additional G allele led to a significantly increased change in mean response time variability for the flanker interference task (see the paper for information on this measurement). Increased changes with each additional G allele were also seen for the sustained attention task (see paper), but these did not reach the corrected statistical significance level (p=0.0034). p-values were corrected for baseline ADHD Rating Scale IV (ARS) score, age, sex and IQ. Patients were treated with methylphenidate for 12 weeks.	Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	CG + GG	G
599	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002).	Genotype CC is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CG + GG.	CC	G
600	rs1800544	ADRA2A (PA35)	Selective serotonin reuptake inhibitors (PA164713257)	**Please note that this variant was reported by the authors as being in the DRD4 gene. This variant is in the ADRA2A gene according to dbSNP**. A combination of neuroendocrine factors, some clinical characteristics and rs1800544 polymorphisms predicted 74.8% of the SSRI response and 65.5% of SSRI remission. Reported as responders have significantly more CG genotype than non-responders to SSRI therapy.	Genotype CG is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CC + GG.	CG	G
601	rs1800544	ADRA2A (PA35)	milnacipran (PA164752812)	depressive symptoms measured on Hamilton Rating Scale for Depression and outcome as change in symptoms, as measured 6 weeks after drug, following 10 days washout.	Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.	CC + CG	G
602	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	ADHD Rating Scale-IV (ARS) and CGI-I are used to analyze response. A “good” response was defined as an improvement from the baseline ARS score after treatment with MPH of >= 50%, and an improvement in the CGI-I score after treatment with MPH of 1 or 2 points, whereas a “poor” response was defined as an improvement in the ARS scores of < 50% and a CGI-I score in the range of 3–7 points. Comparison of the response to MPH treatment between the subjects with and without the ADRA2A G/G genotype revealed that the response to MPH treatment was significantly associated with the G/G genotype.	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG.	GG	G
603	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	Primary outcome measure was the parent-rated inattentive subscale of the Swanson, Nolan, and Pelham Scale version IV. There was a significant interaction effect between the presence of the G allele and treatment over time for the SNAP-IV inattentive scores during the 3 months of treatment (n = 106; F2,198 = 4.30; P = .02). From baseline to the first and third months of treatment, individuals with the G allele achieved greater reduction of inattentive scores than individuals without this allele p=0.01.	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	G	G
604	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	It is assumed that the alleles are reported in the paper as being on the positive strand.	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	G	G
605	rs1800544	ADRA2A (PA35)	methylphenidate (PA450464)	In the ANCOVA model considering SNAP-IV baseline inattentive scores as a co- variate, a significant effect of the G allele on SNAP-IV inattentive scores at 4 weeks of treatment [CG=GG genotypes: mean score (SD)=0.673 (0.290); CC genotype: mean score (SD)=0.902 (0.424); n=59; F=6.14; p=0.016] was detected.	Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	CG + GG	G
606	rs1800545	ADRA2A (PA35)	atenolol (PA448499)	Patients with the GG genotype had a greater change in left ventricular mass between baseline and after 12 weeks of treatment, compared to other genotypes.	Genotype GG is associated with increased response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.	GG	G
607	rs7903146	TCF7L2 (PA36394)	sulfonamides, urea derivatives (PA10390)	(no entry)	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	TT	C
608	rs12255372	TCF7L2 (PA36394)	sulfonamides, urea derivatives (PA10390)	(no entry)	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	TT	G
609	rs290487	TCF7L2 (PA36394)	repaglinide (PA451234)	(no entry)	Genotype TT is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	TT	C
610	rs12415607	CASP7 (PA26091)	"docetaxel (PA449383),""gemcitabine (PA449748)"",""paclitaxel (PA450761)"",""Platinum compounds (PA164713176)"",""vinorelbine (PA451881)"""	Patients with the AA and AC genotypes had increased overall survival time compared to those with the CC genotype.	Genotypes AA + AC are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	AA + AC	C
611	rs12415607	CASP7 (PA26091)	"paclitaxel (PA450761),""Platinum compounds (PA164713176)"""	Patients with the AA and AC genotypes had increased overall survival time compared to those with the CC genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AC are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	AA + AC	C
612	rs7921977	CASP7 (PA26091)	"docetaxel (PA449383),""gemcitabine (PA449748)"",""paclitaxel (PA450761)"",""Platinum compounds (PA164713176)"",""vinorelbine (PA451881)"""	No significant difference in progression-free survival was seen between patients with the CC genotype and those with the TT genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is not associated with response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	CC	C
613	rs7921977	CASP7 (PA26091)	"docetaxel (PA449383),""gemcitabine (PA449748)"",""paclitaxel (PA450761)"",""Platinum compounds (PA164713176)"",""vinorelbine (PA451881)"""	Patients with the CT genotype had reduced progression-free survival compared to those with the TT genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CT is associated with decreased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	CT	C
614	rs2227310	CASP7 (PA26091)	"docetaxel (PA449383),""gemcitabine (PA449748)"",""paclitaxel (PA450761)"",""Platinum compounds (PA164713176)"",""vinorelbine (PA451881)"""	Patients with the CG and GG genotypes had increased overall survival time compared to those with the CC genotype. p-value remained significant after Bonferroni correction for multiple testing.	Genotypes CG + GG are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	CG + GG	C
615	rs2227310	CASP7 (PA26091)	"paclitaxel (PA450761),""Platinum compounds (PA164713176)"""	Patients with the CG and GG genotypes had increased overall survival time compared to those with the CC genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes CG + GG are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	CG + GG	C
616	rs4353229	CASP7 (PA26091)	"docetaxel (PA449383),""gemcitabine (PA449748)"",""paclitaxel (PA450761)"",""Platinum compounds (PA164713176)"",""vinorelbine (PA451881)"""	Patients with the CC and CT genotypes had increased overall survival time compared to those with the TT genotype. p-value remained significant after Bonferroni correction for multiple testing. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	CC + CT	T
617	rs4353229	CASP7 (PA26091)	"paclitaxel (PA450761),""Platinum compounds (PA164713176)"""	Patients with the CC and CT genotypes had increased overall survival time compared to those with the TT genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes CC + CT are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	CC + CT	T
618	rs1127687	CASP7 (PA26091)	"gemcitabine (PA449748),""Platinum compounds (PA164713176)"""	Patients with the AA and AG genotypes had reduced progression-free survival compared to those with the GG genotype. This was a stratified analysis of only people taking gemcitabine, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AG are associated with decreased response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
619	rs1127687	CASP7 (PA26091)	"paclitaxel (PA450761),""Platinum compounds (PA164713176)"""	Patients with the AA and AG genotypes had reduced progression-free survival compared to those with the GG genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AG are associated with decreased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
620	rs1801253	ADRB1 (PA38)	metoprolol (PA450480)	The CC (Arg389) homozygous genotype was strongly associated with the DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele.	Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.	C	G
621	rs1801253	ADRB1 (PA38)	metoprolol (PA450480)	The authors used the dose of metoprolol prescribed, the resting heart rate and survival analysis to determine drug response. They do not report on the Ser49Gly (rs1801252) in this study.	Allele C is not associated with increased response to metoprolol in people with Heart Failure as compared to allele G.	C	G
622	rs1801253	ADRB1 (PA38)	"atenolol (PA448499),""carvedilol (PA448817)"",""diltiazem (PA449334)"",""metoprolol (PA450480)"",""verapamil (PA451868)"""	Reported as Gly389 carriers being more likely to respond favorably to ventricular rate control therapy and requiring the lowest doses of rate control medication compared to Arg389Arg (60 % vs 51 %). GC SNP; be careful. Gly corresponds to G on the + strand. [stat_test: chi square].	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	CG + GG	G
623	rs1801253	ADRB1 (PA38)	metoprolol (PA450480)	Patients with the CC genotype (homozygous for Arg389) had a more significant decrease in systolic blood pressure, diastolic blood pressure, and mean arterial pressure than patients with the GG genotype (homozygous for Gly389). Patients with the CG genotype (heterozygous for Gly389Arg) had less of a decrease than patients with the CC genotype, but more of a decrease than patients with the GG genotype. There was no significant difference between patients with the different genotypes in regards to heart rate. This SNP was also studied in conjunction with rs1801252. However, the influence from rs1801252 is small compared to the influence from rs1801253. This study showed that patients with one or more G allele did not respond to metoprolol and were classified as non-responders, while patients homozygous for the C allele had a good response and thus are labeled good responders.	Genotype CC is associated with increased response to metoprolol in people with Essential hypertension as compared to genotypes CG + GG.	CC	G
624	rs1801253	ADRB1 (PA38)	metoprolol (PA450480)	This SNP was studied in conjunction with rs61767072, in the ADRA2C gene. When treated with metoprolol, patients that had Arg389Arg/del-carrier genotypes had a significantly greater increase in ejection fraction as compared to patients with any other genotype (Arg389Arg/Ins/Ins, Gly389-carrier/del-carrier, or Gly389-carrier/Ins/Ins). The authors also suggest that the ADRB1 polymorphism is less strongly associated with the level of sympathetic nervous system activation than the ADRA2C polymorphism.	Genotype CC is associated with increased response to metoprolol in people with Heart Failure as compared to genotypes CG + GG.	CC	G
625	rs1801253	ADRB1 (PA38)	metoprolol (PA450480)	This SNP was presented as ADRB1 Arg389Gly. Subjects were given dobutamine with and without metoprolol pre-treatment in order to evaluate this SNPs effect on responsiveness to beta-blocker treatment. The increase in fractional shortening (FS) due to dobutamine was greater in subjects homozygous for the Arg allele as compared to Gly carriers. Similarly, subjects homozygous for the Arg allele showed significant blunting of dobutamine-induced increase of FS when pre-treated with metoprolol, down to levels comparable to untreated Gly carriers. Gly carriers saw very little blunting of the effects due to dobutamine when pre-treated with metoprolol.	Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotypes CG + GG.	CC	G
626	rs1801253	ADRB1 (PA38)	dobutamine (PA449381)	Healthy male individuals with the CC genotype had a greater increase in fractional shortening (FS) after cumulative doses of dobutamine, compared to G allele carriers. Response in FS was compared by calculating the area under the curve (AUC) of the dose-response relationship of GG and GC+CC. The AUC of the dose-response curves for GG and GC+CC were significantly different.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	CC	G
627	rs1801253	ADRB1 (PA38)	dobutamine (PA449381)	Patients with the CC genotype had significantly greater increases in systolic blood pressure (mmHg) upon cumulative doses of dobutamine, compared to carriers of the G allele. Dobutamine was given as a continuous infusion of increasing doses: 10, 20, 30 and 40 ug/kg/min. Significant differences in systolic blood pressure between genotypes were seen at 30 and 40 ug/kg/min doses only.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	CC	G
628	rs1801253	ADRB1 (PA38)	bucindolol (PA165945764)	This SNP was mainly referred to as an Arg>Gly amino acid change at position 389, with the Arg amino acid resulting in better patient outcome. This study was interested in the effect of this SNP in tandem with rs61767072. Patients homozygous for the Arg amino acid showed significantly less occurrences of all cause mortality, cardiac transplant, or heart failure hospitalizations as compared to other patients. Patients carrying the Gly amino acid but were homozygous for the wildtype allele at rs61767072 responded worse than those that were homozygous for wildtype allele at this SNP, but much better than patients carrying the variant allele at both SNPs. Patients carrying the variant allele at both SNPs and were treated with bucindolol had worse outcomes than those that were given a placebo.	Genotype CC is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes CG + GG.	CC	G
629	rs1801253	ADRB1 (PA38)	atenolol (PA448499)	Either alone as a SNP or in combination with rs1801252 allele A as a haplotype. Neither this SNP nor any haplotype combination (haplotypes AG and GC were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele C is not associated with response to atenolol in people with Essential hypertension.	C	G
630	rs1801253	ADRB1 (PA38)	dobutamine (PA449381)	Response defined as heart rate and renin responses to dobutamine. In a multi-variant analysis genotype was an significant contributor to change in heart rate (p=0.011). ADRB1 Arg389 homozygous had a three-fold greater response in heart rate and renin response compared with Gly389 homozygotes.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotype GG.	CC	G
631	rs1801253	ADRB1 (PA38)	"Beta Blocking Agents (PA164712535),""flecainide (PA449646)"""	The association was only found in patients with coadministration of ß-blockers compared to no ß-blocker use. Coadministered ß-blockers were carvedilol (n = 55), bisoprolol (n = 13), atenolol (n = 9), nadolol (n=4), metoprolol (n=3), and propranolol (n=3).	Allele G is associated with decreased response to Beta Blocking Agents and flecainide in people with Tachycardia as compared to allele C.	G	G
632	rs10490924	ARMS2 (PA162376896)	bevacizumab (PA130232992)	as determined by lower changes in visual acuity score. TG heterozygotes seemed to have higher changes than GG homozygotes. This variant was not associated with significant difference in central retinal thickness or max. lesion thickness.	Genotype TT is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	TT	G
633	rs10490924	ARMS2 (PA162376896)	bevacizumab (PA130232992)	Patients with the GT and TT genotype had greater improvements in visual acuity (using a Snellen eye exam chart then converted to a logarithm of the minimal angle of resolution value) between baseline and 6 months of treatment, as compared to those with the GG genotype. Patients with the TT genotype had the greatest visual acuity improvement, followed by the GT and then the GG genotype. No significant differences were seen when considering improvement over 12 months of treatment.	Genotypes GT + TT are associated with increased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	GT + TT	G
634	rs1931704	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	A	G
635	rs2237892	KCNQ1 (PA223)	repaglinide (PA451234)	Patients with the CT and TT genotypes had a greater decrease in postprandial plasma glucose (PPG) levels between baseline and after 8 weeks of treatment, compared to those with the CC genotype.	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	CT + TT	C
636	rs2237895	KCNQ1 (PA223)	repaglinide (PA451234)	Patients with the AC and CC genotypes had a greater increase in postprandial serum insulin levels between baseline and after 8 weeks of treatment, compared to those with the AA genotype.	Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	AC + CC	A
637	rs2237897	KCNQ1 (PA223)	gliclazide (PA10892)	Fasting plasma glucose (FPG) had a greater reduction in CT and TT subjects vs CC and a higher rate of treatment success was found in T carriers.	Genotypes CT + TT are associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	CT + TT	C
638	rs2898950	RRM1 (PA298)	"cladribine (PA449027),""cytarabine (PA449177)"""	Less patients with a complete response after the first induction therapy were seen in the AA genotype group. No multiple testing adjustments were performed: 7 SNPs were investigated.	Genotypes AC + CC is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.	AC + CC	A
639	rs1561876	RRM1 (PA298)	"cladribine (PA449027),""cytarabine (PA449177)"""	The GG genotype (reported as CC in the paper) was associated with lower intracellular cytarabine levels at day 1 of therapy, inferior response after the first course of remission induction therapy, poor event-free survival and a greater risk of relapse. No multiple testing adjustments were performed: 7 SNPs were investigated.	Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	GG	G
640	rs11030918	RRM1 (PA298)	gemcitabine (PA449748)	"The CT is associated with improved response to gemcitabine therapy only when it is part of a haplotype with AC at rs12806698. 65.5% of patients with the CT/AC haplotype at rs11030918 and rs12806698 were ""responders"" (were in complete or partial remission) while 42.6% of all other haplotypes combined were responders. Non-responders had stable or progressive disease."	Genotype CT is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + TT.	CT	T
641	rs12806698	RRM1 (PA298)	"carboplatin (PA448803),""gemcitabine (PA449748)"""	"Patients with the AC genotype had the longest duration of progression free survival (30.7 weeks) compared to patients with the AA (24.7 weeks) or CC (23.3 weeks) genotypes. There was no difference in ""chemotherapy response"" between groups. Chemotherapy response was classified as either partial response (PD), stable disease (SD), or progressive disease (PD)."	Genotype AC is associated with increased response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	AC	C
642	rs12806698	RRM1 (PA298)	gemcitabine (PA449748)	"The AC genotype is associated with improved response to gemcitabine therapy only when it is part of a haplotype with CT at rs11030918. 65.5% of patients with the CT/AC haplotype at rs11030918 and rs12806698 were ""responders"" (were in complete or partial remission) while 42.6% of all other haplotypes combined were responders. Non-responders had stable or progressive disease."	Genotype AC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	AC	C
643	rs2284449	RRM1 (PA298)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the TT genotype at rs2284449 (RRM1) alone, an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin.	Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung.	TT	T
644	rs232043	RRM1 (PA298)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the AA genotype at rs232043 (RRM1) alone, an association was found when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin.	Genotype AA is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	AA	G
645	rs720106	RRM1 (PA298)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	The authors analyzed the effect of genotypes on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). Although no association was found between overall survival and the TT genotype at rs720106 (RRM1) alone, an association was found when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin, but not in patients treated with taxane/cisplatin.	Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	TT	T
646	rs9937	RRM1 (PA298)	gemcitabine (PA449748)	Patients with the AA genotype had shorter progression free survival than patients with either the AG or the GG genotype. However, tumor response to therapy did not significantly differ between genotype groups. This study presented this SNP as rs3177016, but dbSNP has merged that rsID with rs9937. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001).	Genotype AA is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	AA	A
647	rs2499984	OR52J3 (PA32416)	lithium (PA450243)	Quantitative trait analysis of long-term treatment response scale comparing all three genotypes - GA was associated with response between GG and AA.	Genotype GG is associated with increased response to lithium in people with Bipolar Disorder as compared to genotype AA.	GG	A
648	rs11042725	ADM (PA24580)	paroxetine (PA450801)	not associated for but not to fluoxetine or citalopram	Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC.	CC	C
649	rs7937567	GALNT18 (PA134950929)	cisplatin (PA449014)	This SNP was significantly associated with complete pathologic response in the discovery cohort, but not the replication cohort.	Genotype GG is associated with increased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	GG	G
650	rs77149876	(no entry)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.	CT	T
651	rs5219	KCNJ11 (PA217)	repaglinide (PA451234)	(no entry)	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	T	T
652	rs5219	KCNJ11 (PA217)	gliclazide (PA10892)	"Patients with the TT genotype (referred to by its amino acids, ""KK"" in the paper) were significantly more likely to attain the standard fasting glucose level as compared to patients with the CC or CT genotypes. Significant after adjustment for age, gender and body mass index (BMI) at baseline. Patients received gliclazide for 16 weeks."	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	TT	T
653	rs5219	KCNJ11 (PA217)	sulfonamides, urea derivatives (PA10390)	The CT genotype was associated with increased response to sulfonylureas (a greater than or equal to 7% decrease in Hb1Ac levels at least 3 months after beginning treatment).	Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.	CT	T
654	rs10501087	BDNF-AS (PA134953249)	antipsychotics (PA452233)	The C allele is associated with increased odds of resistance to antipsychotic treatment. Resistance was assessed by whether patients were taking clozapine, since clozapine is indicated for patients poorly responsive or resistant to first-line treatments.	Genotypes CC + CT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype TT.	CC + CT	T
655	rs7124442	BDNF (PA31891)	citalopram (PA449015)	The association was with worse treatment outcome over 6 weeks and this applied particularly to anxious depression, for which p = 0.003.	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotypes CC + CT.	TT	C
656	rs6265	BDNF (PA31891)	antidepressants (PA452229)	(no entry)	Genotype CT is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + TT.	CT	C
657	rs6265	BDNF (PA31891)	paroxetine (PA450801)	Remained significant after Bonferroni correction.	Genotype TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	TT	C
658	rs6265	BDNF (PA31891)	citalopram (PA449015)	The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression.	Genotype CC is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype TT.	CC	C
659	rs6265	BDNF (PA31891)	antipsychotics (PA452233)	The T allele is associated with increased odds of resistance to antipsychotic treatment. Resistance was assessed by whether patients were taking clozapine, since clozapine is indicated for patients poorly responsive or resistant to first-line treatments. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype CC.	CT + TT	C
660	rs6265	BDNF (PA31891)	paroxetine (PA450801)	Patients were grouped by gender, the data revealed that the significant difference between G allele carriers in responder vs non-responder existed only in women (P = 0.019) and not in men (P = 0.255). To ensure the accuracy of the results, multiple linear regression models were applied, and 3 SNPs were still identified as significant determinants of paroxetine clinical response (P rs 6265 = 0.001, P rs 2973049 = 0.011, and P rs 2216711 = 0.010). According to all of the analyses, the variability in paroxetine clinical response could be attributed to plasma concentration and SNPs.	Genotypes CC + CT is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype TT.	CC + CT	C
661	rs6265	BDNF (PA31891)	olanzapine (PA450688)	The CC genotype (referred to as Val/Val in the paper) was associated with an increased likelihood of response to olanzapine treatment, as compared to those with the CT or TT genotype (Val/Met or Met/Met). Response defined as at least a 50% reduction in the initial Positive and Negative Syndrome Scale (PANSS) total and subscale scores after 8 weeks of treatment. Significant results were seen for the PANSS total and PANSS positive subscale scores, but not for PANSS negative or PANSS general psychopathology scores.	Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	CC	C
662	rs6265	BDNF (PA31891)	methylphenidate (PA450464)	A significant association at the Bonferroni-corrected level was found between the relative frequency of CGI-S 1 or 2 status post-treatment and homozygosity of the Val allele of the BDNF Val66Met polymorphism (p=0.0002)	Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.	CC	C
663	rs11030104	BDNF (PA31891)	antipsychotics (PA452233)	The G allele is associated with increased odds of resistance to antipsychotic treatment. Resistance was assessed by whether patients were taking clozapine, since clozapine is indicated for patients poorly responsive or resistant to first-line treatments. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype AA.	AG + GG	A
664	rs7103411	BDNF (PA31891)	citalopram (PA449015)	The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression.	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype CC.	TT	C
665	rs1967554	"BDNF (PA31891),""BDNF-AS (PA134953249)"""	methadone (PA450401)	"This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for ""increased risk of poorer response"". There were 23 nonresponders and 68 responders."	Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.	C	A
666	rs11030118	"BDNF (PA31891),""BDNF-AS (PA134953249)"""	methadone (PA450401)	"This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for ""increased risk of poorer response"". There were 23 nonresponders and 68 responders."	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.	G	G
667	rs2030324	BDNF (PA31891)	methadone (PA450401)	"This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for ""increased risk of poorer response"". There were 23 nonresponders and 68 responders."	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.	G	A
668	rs11030119	BDNF (PA31891)	methadone (PA450401)	"This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for ""increased risk of poorer response"". There were 23 nonresponders and 68 responders."	Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.	G	G
669	rs1800169	"CNTF (PA26683),""ZFP91-CNTF (PA162409715)"""	iloperidone (PA161199368)	as measured by various different assessments of drug response (PANSS, BPRS, and CGI scores were all significantly different)	Genotype GG is associated with increased response to iloperidone in people with Schizophrenia as compared to genotypes AA + AG.	GG	G
670	rs619586	MALAT1 (PA134935778)	Platinum compounds (PA164713176)	Study looking at SNPs in long non-coding RNA, but with SNPs assessed from genomic DNA.	Genotypes AG + GG are associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to genotype AA.	AG + GG	A
671	rs1695	GSTP1 (PA29028)	"cyclophosphamide (PA449165),""epirubicin (PA449476)"",""fluorouracil (PA128406956)"""	Significant when combined with the GSTT1 non-null genotype.	Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	A	A
672	rs1695	GSTP1 (PA29028)	"cyclophosphamide (PA449165),""epirubicin (PA449476)"""	(no entry)	Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	AA + AG	A
673	rs1695	GSTP1 (PA29028)	"fluorouracil (PA128406956),""oxaliplatin (PA131285527)"""	Increased likelihood of a better response rate in those with AG or GG genotype compared to AA.	Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	AG + GG	A
674	rs1695	GSTP1 (PA29028)	anthracyclines and related substances (PA130620651)	(no entry)	Allele A is associated with increased response to anthracyclines and related substances in women with Breast Neoplasms as compared to allele G.	A	A
675	rs1695	GSTP1 (PA29028)	dimethyl fumarate (PA166152838)	(no entry)	Genotype GG is associated with decreased response to dimethyl fumarate in people with Psoriasis as compared to genotypes AA + AG.	GG	A
676	rs948854	GAL (PA28529)	"antidepressants (PA452229),""benzodiazepine derivatives (PA10402)"",""mirtazapine (PA450522)"",""Selective serotonin reuptake inhibitors (PA164713257)"""	This was specific to premenopausal women(not seen in postmenopausal women or in men). The same allele was associated with more severe vegetative but not cognitive depressive symptoms. Patients were on a variety of therapies, with the three largest groups being SSRIs,Tricyclics, and Mirtazapine.	Allele C is associated with decreased response to antidepressants, benzodiazepine derivatives, mirtazapine or Selective serotonin reuptake inhibitors in women Depressive Disorder, Major as compared to allele T.	C	C
677	rs61734430	FOLR3 (PA28211)	pemetrexed (PA10810)	Patients with one or more T alleles had an increased likelihood of disease progression at mid-treatment radiological evaluation, as compared to those with the CC genotype.	Genotypes CT + TT is associated with decreased response to pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype CC.	CT + TT	C
678	rs3758785	GPR83 (PA28927)	hydrochlorothiazide (PA449899)	Heterozygotes had intermediate response and pattern was the same for both SBP and DBP.	Genotype GG is associated with decreased response to hydrochlorothiazide in people with essential hypertension as compared to genotype AA.	GG	A
679	rs3758785	GPR83 (PA28927)	candesartan (PA448765)	Heterozygotes had intermediate response and pattern was the same for both SBP and DBP.	Genotype GG is associated with increased response to candesartan in people with Essential hypertension as compared to genotype AA.	GG	A
680	rs74973995	(no entry)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype AA.	AG	A
681	rs568910	CASP1 (PA26083)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	A	A
682	rs1503391	CARD16 (PA164717628)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	A	A
683	rs1792774	CARD16 (PA164717628)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C	C
684	rs187238	IL18 (PA29802)	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""interferons (PA451999)"",""peginterferon alfa-2a (PA164749390)"",""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This association is for patients infected with viral genotype 1. Treatment was with 48 weeks of standard interferon-alpha-2a or interferon-alpha-2b plus ribavirin or pegylated interferon-alpha and ribavirin. The allele associated with non-response is not entirely clear, since this is a GC SNP. Paper reports G associated with higher rate of non-response. Gene is on the negative chromosomal strand, so it's likely that the allele associated (with decreased response) on the positive chromosomal strand is C.	Allele C is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	C	C
685	rs1946518	IL18 (PA29802)	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""interferons (PA451999)"",""peginterferon alfa-2a (PA164749390)"",""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This association is for patients infected with viral genotype 1. Treatment was with 48 weeks of standard interferon-alpha-2a or interferon-alpha-2b plus ribavirin or pegylated interferon-alpha and ribavirin.	Allele T is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	T	T
686	rs1946518	IL18 (PA29802)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	When comparing responders vs. non- and partial-responders. Patients with the TT genotype had increased response as compared to patients with the GG genotype, and patients with the GT + TT genotype had increased response as compared to patients with the GG genotype. However, no association was seen when compared GT vs GG, and no association was seen for any genotype when considering responders vs. non-responders.	Genotypes GT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.	GT + TT	T
687	rs1800497	ANKK1 (PA134872551)	risperidone (PA451257)	(no entry)	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	A	G
688	rs1800497	ANKK1 (PA134872551)	aripiprazole (PA10026)	A1/A1 (AA) vs A2/A2 (GG) and A1/A2 (AA) vs A2/A2 were statistically significant for PANSS positive score (positive symptoms). Assumed TaqA1 = allele A, TaqA2 = allele G, though the specific alleles were not reported in this study.	Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.	AA + AG	G
689	rs1800497	"ANKK1 (PA134872551),""DRD2 (PA27478)"""	prochlorperazine (PA451114)	Patients with the AA or AG genotypes had an increased incidence of nausea when treated with prochlorperazine for opioid-induced nausea and vomiting as compared to patients with the GG genotype.	Genotypes AA + AG are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype GG.	AA + AG	G
690	rs6277	DRD2 (PA27478)	aripiprazole (PA10026)	This was significant for the PANSS excitement subscale - patients with the GG genotype had a higher PANSS excitement score and thus poor response to aripiprazole compared to patients with the AA genotype after 4 weeks of treatment. GA vs AA was not statistically significant (p=0.92 PANSS excitement score).	Genotype GG is associated with decreased response to aripiprazole in people with Schizophrenia as compared to genotype AA.	GG	G
691	rs6277	DRD2 (PA27478)	nicotine (PA450626)	"Please note that alleles have been complemented to the positive strand. Male subjects with the AA genotype had a higher perception score of ""feel the effects"" of nicotine with 5ug/kg nicotine, while male subjects with the AA or AG genotypes had higher ""feel the effects"" scores with 10ug/kg. Male subjects with the AA genotype had decreased fatigue and increased anger in the mood scoring compared to male subjects with the AG or GG genotypes. There was no significant association between this variant and physiological responses to nicotine, performance task responses or nicotine reinforcement."	Allele A is associated with increased response to nicotine in men as compared to allele G.	A	G
692	rs1076560	DRD2 (PA27478)	olanzapine (PA450688)	The associations were evaluated in conjunction with rs6314 in the HTR2A gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype	Genotypes AA + AC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotype CC.	AA + AC	C
693	rs1076560	DRD2 (PA27478)	rasagiline (PA164764584)	Efficacy was measured with peak reduction in total UPDRS scores at 12 weeks. Patients were randomly assigned to delayed or early start of rasagiline, at 1 mg or 2 mg daily. Patients with Parkinson's symptoms that progressed were given appropriate therapy and withdrawn from the study.	Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.	CC	C
694	rs2283265	DRD2 (PA27478)	rasagiline (PA164764584)	Efficacy was measured with peak reduction in total UPDRS scores at 12 weeks. Patients were randomly assigned to delayed or early start of rasagiline, at 1 mg or 2 mg daily. Patients with Parkinson's symptoms that progressed were given appropriate therapy and withdrawn from the study.	Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.	CC	C
695	rs1079597	DRD2 (PA27478)	amisulpride (PA162565877)	Korean; differences measured after at least 6 weeks treatment; treatment response defined as a reduction of at least 30% from the baseline.	Allele C is associated with increased response to amisulpride in people with Schizophrenia as compared to allele T.	C	C
696	rs1079597	DRD2 (PA27478)	prochlorperazine (PA451114)	Patients with the CT or TT genotypes had an increased incidence of nausea when treated with prochlorperazine for opioid-induced nausea and vomiting as compared to patients with the CC genotype.	Genotypes CT + TT are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype CC.	CT + TT	C
697	rs1799732	DRD2 (PA27478)	antipsychotics (PA452233)	in a meta-analysis.	Genotype DEL is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG.	DEL	A
698	rs1799732	DRD2 (PA27478)	chlorpromazine (PA448964)	[stat_test:T1 by CLUMP; 2 d.f.] Ascertained by Improvement on the overall Brief Psychiatry Rating Scale.	Genotype GG is associated with increased response to chlorpromazine in people with Schizophrenia as compared to genotypes DELDEL + GDEL.	GG	A
699	rs1799732	DRD2 (PA27478)	bupropion (PA448687)	At end of treatment. Not significant at 6 month follow-up (p=0.08).	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del.	GG	A
700	rs1799732	DRD2 (PA27478)	nicotine (PA450626)	At end of treatment. Not significant at 6 month follow-up (p=0.31).	Genotypes G/del + del/del is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.	G/del + del/del	A
701	rs1799978	DRD2 (PA27478)	risperidone (PA451257)	(no entry)	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	T	T
702	rs2514218	DRD2 (PA27478)	clozapine (PA449061)	as measured by change in brief psychiatric rating scale (BPRS)	Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.	T	C
703	rs2514218	DRD2 (PA27478)	"aripiprazole (PA10026),""risperidone (PA451257)"""	Patients with the CC genotype had a greater reduction in symptoms over 12 weeks of treatment with either aripiprazole or risperidone.	Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	CC	C
704	rs1150226	HTR3A (PA29555)	clozapine (PA449061)	As part of a haplotype: The A-C-C haplotype composed by rs2276302-rs1062613-rs1150226 was associated with better response (responder frequency 71.3%; non-responder frequency 57.9%, [chi]2=5.48; P=0.01; permutated P=0.04) whereas the G-T-T haplotype was nominally associated with worse response (responder frequency 5.9%; non-responder frequency 12.9%, [chi]2=3.98; P=0.04; permutated P=0.07).	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	G	A
705	rs1062613	HTR3A (PA29555)	clozapine (PA449061)	As part of a haplotype: The A-C-C haplotype composed by rs2276302-rs1062613-rs1150226 was associated with better response (responder frequency 71.3%; non-responder frequency 57.9%, [chi]2=5.48; P=0.01; permutated P=0.04) whereas the G-T-T haplotype was nominally associated with worse response (responder frequency 5.9%; non-responder frequency 12.9%, [chi]2=3.98; P=0.04; permutated P=0.07)	Allele C is associated with increased response to clozapine in people with Schizophrenia as compared to allele T.	C	T
706	rs1062613	HTR3A (PA29555)	clozapine (PA449061)	Response was defined as a Brief Psychiatric Rating Scale (BPRS) total score of less than or equal to 35. Patients with the T allele had an increased likelihood of response to clozapine.	Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.	T	T
707	rs2276302	HTR3A (PA29555)	clozapine (PA449061)	As part of a haplotype: The A-C-C haplotype composed by rs2276302-rs1062613-rs1150226 was associated with better response (responder frequency 71.3%; non-responder frequency 57.9%, [chi]2=5.48; P=0.01; permutated P=0.04) whereas the G-T-T haplotype was nominally associated with worse response (responder frequency 5.9%; non-responder frequency 12.9%, [chi]2=3.98; P=0.04; permutated P=0.07).	Allele A is associated with increased response to clozapine in people with Schizophrenia as compared to allele G.	A	G
708	rs2276302	HTR3A (PA29555)	clozapine (PA449061)	Response was defined as a Brief Psychiatric Rating Scale (BPRS) total score of less than or equal to 35. Patients with the G allele had an increased likelihood of response to clozapine.	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	G	G
709	rs964184	APOA1 (PA49)	fenofibrate (PA449594)	Patients with the G allele had a greater increase in high-density lipoprotein (HDL) cholesterol and triglyceride (TG) level between baseline and either 3 weeks or 8 weeks of fenofibrate treatment, as compared to those with the C allele. Two cohorts were used: the discovery cohort came from the National Heart, Lung and Blood Institute GOLDN study population, and the replication cohort came from the Pharmacogenetics of Hypertriglyceridemia in Hispanics (HyperTG) study. Participants from the GOLDN study received fenofibrate treatment for 3 weeks, participants from HyperTG received it for 8 weeks. Differences in the discovery study population were significant after correction for multiple testing.	Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C.	G	G
710	rs3135506	APOA5 (PA24888)	fenofibrate (PA449594)	No significant differences in the change of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), C-reactive protein (CRP), very low density lipoprotein (VLDL) size (units = nm) or high density lipoprotein (HDL) size based on genotype was seen, between baseline and 3 weeks of fenofibrate treatment.	Genotypes CG + GG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	CG + GG	G
711	rs3135506	APOA5 (PA24888)	fenofibrate (PA449594)	Carriers of the C allele had greater decreases in plasma triglyceride (TG) and high-density lipoprotein (HDL) levels over 3 weeks of treatment, as compared to GG homozygotes.	Genotypes CC + CG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG.	CC + CG	G
712	rs3135506	APOA5 (PA24888)	fenofibrate (PA449594)	Carriers of the G allele had a significantly greater decrease in triglyceride (TG) levels and a significantly greater increases in high density lipoprotein cholesterol (HDL-C) levels and in low density lipoprotein size (units = nm) between baseline and 3 weeks of fenofibrate treatment, compared to CC homozygotes.	Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	CG + GG	G
713	rs662799	APOA5 (PA24888)	atorvastatin (PA448500)	Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand.	Genotype AA is associated with increased response to atorvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.	AA	G
714	rs662799	APOA5 (PA24888)	simvastatin (PA451363)	Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand.	Genotype AA is associated with increased response to simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.	AA	G
715	rs662799	APOA5 (PA24888)	rosuvastatin (PA134308647)	Subjects were randomized to receive one of three dose-adjusted statins (N = 65 rosuvastatin, N= 65 atorvastatin, N= 65 simvastatin) and cholesterol (HDL, LDL), triglycerides and free-fatty acids (FFA) were compared between groups before and after statin treatment. Please note: alleles have been complemented to the + chromosomal strand.	Genotype AA is associated with increased response to rosuvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.	AA	G
716	rs533556	SIK3 (PA165543631)	hmg coa reductase inhibitors (PA133950441)	although this was not confirmed in the replication study.	Genotype AA is associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype CC.	AA	A
717	rs1954787	GRIK4 (PA28976)	antidepressants (PA452229)	Meta-analysis combining 5 studies.	Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	CC	T
718	rs1954787	GRIK4 (PA28976)	antidepressants (PA452229)	Meta-analysis combining 5 studies.	Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	C	T
719	rs8177374	TIRAP (PA134972842)	ustekinumab (PA166048654)	Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate.	Genotypes CT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	CT + TT	C
720	rs2238032	CACNA1C (PA83)	"losartan (PA450268),""nifedipine (PA450631)"",""nitrendipine (PA146096020)"""	Response was classified as having a minimum of three blood pressure (BP) measurements of less than 140 systolic and 90 diastolic, and no more than one hypertensive BP measurement (> 140/90) over at least 6 months of treatment. All other patients were classified as non-responders.	Genotype TT is associated with increased response to losartan, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.	TT	T
721	rs2238032	CACNA1C (PA83)	"amlodipine (PA448388),""felodipine (PA449591)"""	Response was classified as having a minimum of three blood pressure (BP) measurements of less than 140 systolic and 90 diastolic, and no more than one hypertensive BP measurement (> 140/90) over at least 6 months of treatment. All other patients were classified as non-responders.	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.	TT	T
722	rs2238032	CACNA1C (PA83)	calcium channel blockers (PA10407)	Response was classified as having a minimum of three blood pressure (BP) measurements of less than 140 systolic and 90 diastolic, and no more than one hypertensive BP measurement (> 140/90) over at least 6 months of treatment. All other patients were classified as non-responders.	Genotype TT is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes GG + GT.	TT	T
723	rs2239128	CACNA1C (PA83)	calcium channel blockers (PA10407)	Response was classified as having a minimum of three blood pressure (BP) measurements of less than 140 systolic and 90 diastolic, and no more than one hypertensive BP measurement (greater then 140 systolic and 90 diastolic). All other patients were classified as non-responders. Patients were treated for at least 6 months.	Allele C is associated with increased response to calcium channel blockers in people with Hypertension as compared to allele T.	C	T
724	rs2239128	CACNA1C (PA83)	"amlodipine (PA448388),""felodipine (PA449591)"""	Response was classified as having a minimum of three blood pressure (BP) measurements of less than 140 systolic and 90 diastolic, and no more than one hypertensive BP measurement (greater then 140 systolic and 90 diastolic). All other patients were classified as non-responders. Patients were treated for at least 6 months.	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.	C	T
725	rs2239128	CACNA1C (PA83)	nimodipine (PA450633)	Participants with the CC genotype showed significantly decreased systolic blood pressure following nimodipine administration compared to participants with the CT genotype. There was no significant association between this variant and diastolic blood pressure.	Genotype CC is associated with increased response to nimodipine in healthy individuals as compared to genotype CT.	CC	T
726	rs767455	TNFRSF1A (PA36609)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	The TT genotype was associated with a better response after 3 months of treatment with anti-TNFalpha drugs. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	TT	T
727	rs767455	TNFRSF1A (PA36609)	"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"""	Patients with the TT genotype had poorer response to the anti-TNFalpha drugs after 3 months of treatment. Response to therapy was assessed according to EULAR response criteria. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	TT	T
728	rs767455	TNFRSF1A (PA36609)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Significantly more patients with the homozygous TT genotype achieved a good response according to EULAR criteria (European League Against Rheumatism) after 3 months of treatment compared to patients who carried the C allele (p=0.011). Additionally, after 6 months of treatment, remission of disease or low disease activity was more frequently observed in patients with the TT genotype as compared to those with the CC genotype (p=0.04). Please note that alleles have been complemented to the plus chromosomal strand.	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.	TT	T
729	rs4149570	TNFRSF1A (PA36609)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and CD cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes AC + CC.	AA	A
730	rs2301339	GNB3 (PA176)	atenolol (PA448499)	Women with the GG genotype had greater decreases in diastolic blood pressure (DBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to AA homozygotes. No significant results were seen in men (data not shown).	Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotype AA.	GG	G
731	rs2301339	GNB3 (PA176)	atenolol (PA448499)	GG homozygotes had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to A allele carriers. No significant results were seen for diastolic blood pressure.	Genotype GG is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes AA + AG.	GG	G
732	rs2301339	GNB3 (PA176)	atenolol (PA448499)	Women with the GG genotype had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to carriers of the A allele. No significant results were seen in men (data not shown).	Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AA + AG.	GG	G
733	rs5443	GNB3 (PA176)	sumatriptan (PA451566)	This is in Whites(Germans). There were not enough TT people for a significant conclusion.	Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC.	CT	C
734	rs5443	GNB3 (PA176)	sildenafil (PA451346)	(no entry)	Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT.	TT	C
735	rs5443	GNB3 (PA176)	atenolol (PA448499)	CC homozygotes had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to T allele carriers. No significant results were seen for diastolic blood pressure.	Genotype CC is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes CT + TT.	CC	C
736	rs5443	GNB3 (PA176)	atenolol (PA448499)	Women with the CC genotype had greater decreases in diastolic blood pressure (DBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to TT homozygotes. No significant results were seen in men (data not shown).	Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotype TT.	CC	C
737	rs5443	GNB3 (PA176)	atenolol (PA448499)	Women with the CC genotype had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to carriers of the T allele. No significant results were seen in men (data not shown).	Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes CT + TT.	CC	C
738	rs5443	GNB3 (PA176)	antidepressants (PA452229)	(no entry)	Genotypes CC + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	CC + CT	C
739	rs5443	GNB3 (PA176)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	TT homozygotes had reduced urinary excretion of sodium chloride and calcium, and reduced volume of urinary excretion, compared to CC homozygotes, during the 24 hours after drug administration.	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.	TT	C
740	rs5443	GNB3 (PA176)	clonidine (PA449051)	Exclusively male participants. Increased response for T allele carriers was shown by: greater reductions in plasma norepinephrine levels, systolic blood pressure and total peripheral resistance, greater increases in serum growth hormone and electromechanical systole (QS2c) duration, and slowing of pulse wave velocity, as compared to those with the CC genotype. Changes in these measurements were assessed between baseline and a varied number of hours (indicated in the study parameters).	Genotypes CT + TT are associated with increased response to clonidine in healthy individuals as compared to genotype CC.	CT + TT	C
741	rs5443	GNB3 (PA176)	clonidine (PA449051)	Carriers of the T allele were more likely to respond to clonidine treatment as compared to CC homozygotes. Responders were defined as those with a 20% decrease in body weight and a 20% increase in urine sodium volume after 3 months of treatment.	Genotypes CT + TT are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype CC.	CT + TT	C
742	rs5443	GNB3 (PA176)	telmisartan (PA451605)	(no entry)	Genotype TT is associated with decreased response to telmisartan in people with Essential hypertension as compared to genotypes CC + CT.	TT	C
743	rs5443	GNB3 (PA176)	"hydralazine (PA449894),""isosorbide dinitrate (PA450125)"""	Fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT (African American Heart Failure Trial) improved outcomes in TT genotype, but did not improve outcomes in CC or CT. Outcomes were composite score (death, hospital stay for heart failure), quality of life, and event-free survival.	Genotype TT is associated with increased response to hydralazine and isosorbide dinitrate in people with Heart Failure as compared to genotypes CC + CT.	TT	C
744	rs5443	GNB3 (PA176)	amlodipine (PA448388)	As measured by reduction in diastolic blood pressure	Genotype TT is not associated with response to amlodipine in people with Essential hypertension as compared to genotypes CC + CT.	TT	C
745	rs5443	GNB3 (PA176)	sibutramine (PA451344)	Patients with the CC genotype and treated with sibutramine experienced greater weight loss than patients with the CT or TT genotypes. The authors note that the study was underpowered to adequately analyze effects of the TT genotype.	Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT.	CC	C
746	rs2058878	GRIN2B (PA28980)	acamprosate (PA10344)	Tag SNPs (518 total) were selected within genes associated with alcoholism as well as genes encoding enzymes involved in glycine metabolism, glycine transporters, subunits of glycine receptors, NMDA receptors, genes involved in glutamate reuptake, synthesis or degradation and genes with reported associations with acamprosate treatment outcomes in human or animal studies. The length of time to first alcohol use “survival analysis method” was used to examine associations between clinical variables and genetic markers with efficacy of acomprasate (its ability to length the duration of abstinence from alcohol). The analyses were replicated in a subset of 110 participants from PREDICT, a double-blind randomized controlled trial that compared treatment outcomes including length of abstinence among alcohol- dependent subjects of German descent recruited from inpatient facilities and treated with acamprosate, naltrexone or placebo for 3 months. The strongest association finding, was for the A allele at rs2058878 A allele, which remained significantly associated with longer abstinence even after Bonferroni correction for the number of SNPs included in the analyses (P = 4.6 × 10 - 5, corrected P = 0.024).	Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T.	A	T
747	rs3794271	SLCO1C1 (PA37815)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Whether response was better with which allele was not stated, however looking at genotype frequencies the G allele is associated with increased likelihood of not responding, whereas A increased likelihood of a good response; n=31 genotype GG: 16% good, 39% moderate, 45% none. n=151 genotype AG: 27% good, 44% moderate, 28.5% none. n=131 with genotype AA: 44% good, 13% moderate, 15% none.	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	G	G
748	rs3794271	SLCO1C1 (PA37815)	infliximab (PA452639)	Whether response was better with which allele was not stated, however looking at genotype frequencies the G allele is associated with increased likelihood of not responding, whereas A increased likelihood of a good response.	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A.	G	G
749	rs3794271	SLCO1C1 (PA37815)	etanercept (PA449515)	Whether response was better with which allele was not stated, however looking at genotype frequencies the G allele is associated with increased likelihood of not responding, whereas A increased likelihood of a good response.	Allele G is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.	G	G
750	rs3794271	SLCO1C1 (PA37815)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Carriers of the G allele had a higher response to anti-TNF agents as compared to those with the AA genotype. Response assessed through change in Psoriasis Area and Severity Index (PASI) between baseline and 12-14 weeks of treatment.	Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	AG + GG	G
751	rs3794271	SLCO1C1 (PA37815)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	The presence of the G allele was associated with a reduced response to anti-TNF treatment. Response measured as the absolute change in Disease Activity Score for 28 joints (DAS28) between weeks 0 and 12 of anti-TNF treatment.	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA.	AG + GG	G
752	rs4149117	SLCO1B3 (PA35844)	imatinib (PA10804)	When analyzed in combination with rs7311358. The rs7311358 AA + AG genotypes and the rs4149117 GG + GT genotypes were associated with a higher probability of not responding to the standard dose of imatinib. Additionally, the frequency of the rs7311358 GG genotype and the rs4149117 TT genotype (analyzed together) was higher in the responder group (63.8%) as compared to the non-responder group (44.7%) (p=0.042). Lastly, the frequency of the TT genotype was increased in non-responders who achieved complete molecular response (CMR) as compared to those who did not (100% vs 41.9%, p=0.026) independently of rs7311358. Responders defined as having complete cytogenetic response (CCyR), and non-responders as not having CCyR with the initial dose, or who relapsed during treatment and required higher doses.	Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	GG + GT	T
753	rs7311358	SLCO1B3 (PA35844)	imatinib (PA10804)	When analyzed in combination with rs4149117. The rs7311358 AA + AG genotypes and the rs4149117 GG + GT genotypes were associated with a higher probability of not responding to the standard dose of imatinib. Additionally, the frequency of the rs7311358 GG genotype and the rs4149117 TT genotype (analyzed together) was higher in the responder group (63.8%) as compared to the non-responder group (44.7%) (p=0.042). Lastly, the frequency of the GG genotype was higher in non-responders who achieved complete molecular response (CMR) as compared to those who did not (100% vs 41.9%, p=0.026) independently of rs4149117. Responders defined as having complete cytogenetic response (CCyR), and non-responders as not having CCyR with the initial dose, or who relapsed during treatment and required higher doses.	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	AA + AG	G
754	rs4149036	SLCO1B1 (PA134865839)	atorvastatin (PA448500)	as measured by decreases in triglycerides.	Genotypes AC + CC are associated with increased response to atorvastatin as compared to genotype AA.	AC + CC	C
755	rs2306283	SLCO1B1 (PA134865839)	"capecitabine (PA448771),""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"""	Patients were split into two groups based on treatment. One group received irinotecan, fluorouracil, and leucovorin, and the other group received irinotecan and capecitabine. Patients carrying the A allele showed significantly greater rapid response rate, progression free survival, and irinotecan-related time to treatment failure as compared to patients with the GG genotype. In addition, when combined with rs1051266, patients carrying the A allele for this SNP and homozygous for the G allele at rs1051266 had significantly higher rapid response rates than patients with any other combination of genotypes.	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	AA + AG	A
756	rs2306283	SLCO1B1 (PA134865839)	rocuronium (PA164754992)	Patients with the AA genotype had lower clinical duration of the initial dose (p=0.000 for AA vs AG and AA vs GG), lower clinical duration of the maintenance dose (p=0.011 for AA vs AG and p=0.025 for AA vs GG) and shorter recovery time (p=0.038 for AA vs AG and p=0.043 for AA vs GG) as compared to those with the AG or GG genotype. However, this allele was no longer significant in multivariable stepwise regression analysis.	Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.	AA	A
757	rs2306283	SLCO1B1 (PA134865839)	atorvastatin (PA448500)	Response measured as reduction of LDL-C after 8 weeks of treatment with 10mg/day of atorvastatin.	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	AA	A
758	rs2306283	SLCO1B1 (PA134865839)	atorvastatin (PA448500)	Patients with the AG and GG genotype had a greater percent increase in high-density lipoprotein cholesterol (HDL-C) levels as compared to those with the AA genotype. However, no significant differences in percent changes between genotypes were seen for total cholesterol (p=0.81), low density lipoprotein cholesterol (LDL-C; p=0.27) or triglycerides (p=0.30). Patients were treated with atorvastatin for 4 weeks at 10 mg/day.	Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	AG + GG	A
759	rs4149056	SLCO1B1 (PA134865839)	fluvastatin (PA449688)	as measured by increases in HDL-cholestrol.	Genotype TT is associated with increased response to fluvastatin as compared to genotypes CC + CT.	TT	T
760	rs4149056	SLCO1B1 (PA134865839)	pravastatin (PA451089)	as determined by a smaller reduction in total cholestrol in patients with the CT genotype compared to the TT genotype. Changes in LDL-C, HDL-C and triglycerides were not significantly different.	Genotype CT is associated with decreased response to pravastatin in people with Coronary Stenosis as compared to genotype TT.	CT	T
761	rs4149056	SLCO1B1 (PA134865839)	simvastatin (PA451363)	Patients treated with simvastatin and harbouring the SLCO1B1 521C allele were less likely to achieve the treatment goal at the 5-year follow-up.	Genotypes CC + CT is associated with decreased response to simvastatin in people with Dyslipidaemia as compared to genotype TT.	CC + CT	T
762	rs4149056	SLCO1B1 (PA134865839)	rosiglitazone (PA451283)	as measured by HbA1c reduction.	Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.	C	T
763	rs4149056	SLCO1B1 (PA134865839)	hmg coa reductase inhibitors (PA133950441)	as measured by plasma LDL-c.	Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.	C	T
764	rs4149056	SLCO1B1 (PA134865839)	methotrexate (PA450428)	Evidence of minimal residual disease at 78 days was higher in CC genotype vs. CT + TT.	Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	CC	T
765	rs4149056	SLCO1B1 (PA134865839)	conjugated estrogens (PA164754789)	Women with the CT genotype had a significantly increased reduction in night sweats following hormonal therapy than women with the TT genotype.	Genotype CT is associated with increased response to conjugated estrogens in women with Menopause as compared to genotype TT.	CT	T
766	rs4149056	SLCO1B1 (PA134865839)	fluvastatin (PA449688)	Response was determined as lower percentage change in total cholesterol (WMD: - 2.98; 95% CI: - 5.12 to - 0.84; P = 0.006, with no evidence of heterogeneity) and LDL (WMD: - 5.58; 95% CI: - 10.64 to - 0.52; P = 0.031, with significant heterogeneity).	Genotype TT is associated with decreased response to fluvastatin as compared to genotypes CC + CT.	TT	T
767	rs2900478	SLCO1B1 (PA134865839)	hmg coa reductase inhibitors (PA133950441)	Carriers of this variant respond to statins with a 1.6% smaller LDL-C lowering effect per minor allele compared with non-carriers.	Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.	A	T
768	rs61764370	KRAS (PA30196)	"capecitabine (PA448771),""cetuximab (PA10040)"",""oxaliplatin (PA131285527)"""	C allele carriers (there were no homozygotes) had a statistically significantly higher rate of complete response (CR) after neoadjuvant therapy and a trend for better 5-year progression-free survival (PFS) and overall survival. Both CR and survival outcomes were independent of the use of cetuximab. Patients received neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab	Genotype AC is associated with increased response to capecitabine, cetuximab and oxaliplatin in people with Rectal Neoplasms as compared to genotype AA.	AC	A
769	rs1540339	VDR (PA37301)	selective beta-2-adrenoreceptor agonists (PA134687887)	(no entry)	Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to allele T.	C	C
770	rs2239179	VDR (PA37301)	selective beta-2-adrenoreceptor agonists (PA134687887)	(no entry)	Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T.	C	T
771	rs773123	ERBB3 (PA27846)	"carboplatin (PA448803),""docetaxel (PA449383)"",""trastuzumab (PA451743)"""	When compared to women who received different treatment regimens. Response was defined as likelihood of achieving relapse-free survival.	Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	A	A
772	rs2069502	CDK4 (PA102)	somatropin recombinant (PA451446)	Response to growth hormone treatment assessed by 1-month insulin-like growth factor-I (IGF-I) generation. Multiple test correction was done for 1182 SNPs. Corrected p values was given.	Genotype CC is associated with decreased response to somatropin recombinant in children with Turner Syndrome as compared to genotypes CT + TT.	CC	C
773	rs2270777	CDK4 (PA102)	somatropin recombinant (PA451446)	Response to growth hormone treatment assessed by 1-month insulin-like growth factor-I (IGF-I) generation. Multiple test correction was done for 1171 SNPs. Corrected p values was given.	Genotype TT is associated with increased response to somatropin recombinant in children with growth hormone deficiency as compared to genotypes CC + CT.	TT	C
774	rs10877012	CYP27B1 (PA27099)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is not significantly associated with sustained virological response (SVR).	Allele T is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	T	G
775	rs10877012	CYP27B1 (PA27099)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype was associated with sustained virological response (SVR).	Genotypes GT + TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	GT + TT	G
776	rs12231740	SLC16A7 (PA35819)	methotrexate (PA450428)	Authors say this variant is associated with non-response in allelic model (minor vs major and describe variant as C>T).	Allele T is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.	T	C
777	rs3763980	SLC16A7 (PA35819)	methotrexate (PA450428)	Authors say this variant is associated with non-response in allelic model (minor allele vs major and describe variant as T>A).	Allele A is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.	A	A
778	rs2430561	IFNG (PA29674)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and CD cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease and Inflammatory Bowel Diseases as compared to genotype TT.	AA + AT	T
779	rs2069705	IFNG (PA29674)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	(no entry)	Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	G	G
780	rs61747221	BEST3 (PA162377503)	hydrochlorothiazide (PA449899)	(no entry)	Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	AA + AG	G
781	rs17109924	LGR5 (PA28894)	fluorouracil (PA128406956)	Patients who received 5-fluorouracil-based adjuvant chemotherapy and underwent surgery, who carried at least one C allele, had significantly increased time to tumor recurrence as compared to those with the TT genotype. No association was seen for patients who only underwent surgery (p=0.728; n=208).	Genotypes CC + CT is associated with increased response to fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	CC + CT	T
782	rs4570625	TPH2 (PA128747823)	fluoxetine (PA449673)	Please note the association was only significant using the GAF/CGAS scale as outcome measure. Effect of HTR1B rs130058 on clinical improvement was measured by differences in scores obtained in GAF/CGAS, CDI, OCI-CV, SCARED, CGI-S, and CGI-I scales after fluoxetine treatment. For the other scales the results were not significantly different between the genotypes.	Genotype TT is associated with increased response to fluoxetine in children with Mental Disorders as compared to genotypes GG + GT.	TT	G
783	rs10879346	TPH2 (PA128747823)	antidepressants (PA452229)	(no entry)	Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	C	C
784	rs1487278	TPH2 (PA128747823)	"mirtazapine (PA450522),""venlafaxine (PA451866)"""	(no entry)	Allele C is associated with increased response to mirtazapine and venlafaxine in people with Depression as compared to genotype TT.	C	T
785	rs7968606	ANKS1B (PA128394692)	amisulpride (PA162565877)	Symptoms and improvement were assessed with the PANSS general after 6 weeks of treatment. No statistically significant difference was seen in positive, negative, or total scores.	Genotype CC is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CT + TT.	CC	C
786	rs11065987	(no entry)	hydrochlorothiazide (PA449899)	rs11065987 was selected as a representative SNP of rs11065987, rs653178, rs10774625 and rs11066301, all of which are in high linkage disequilibrium with each other. The A allele of rs11065987 was associated with a greater decrease in both systolic and diastolic blood pressure following treatment with hydrochlorothiazideas compared to the GG genotype.	Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	AA + AG	A
787	rs5888	SCARB1 (PA97)	atorvastatin (PA448500)	as measured by a larger % change in total cholesterol, LDL-C, ApoB and ApoB/apoAI ratio. When analysed in women and men seperately, a significant association was only seen in women. Alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	AA	A
788	rs1412125	HMGB1 (PA188)	Platinum compounds (PA164713176)	Responders defined as complete or partial remission, non-responders defined as progressive or stable disease. 236 patients had non-small cell lung cancer and 102 had small cell lung cancer. However, when correcting for multiple testing using the false detection rate correction, this SNP did not remain significant (p=0.066).	Genotype CC is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotypes CT + TT.	CC	C
789	rs585719	(no entry)	citalopram (PA449015)	This was only true in African Americans and was attributed to LD with rs76665058. No TT were seen in this cohort.	Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC.	CT	C
790	rs6314	HTR2A (PA193)	antidepressants (PA452229)	19% tricyclics;17% mirtazapine;14% SSRI; 13% electroconvulsive therapy;13% repetitive transcranial magnetic stimulation; 24% combinations. The improvement was in HAMD-17 score.	Genotypes AG + GG are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	AG + GG	G
791	rs6314	HTR2A (PA193)	olanzapine (PA450688)	The associations were evaluated in conjunction with rs1076560 in the DRD2 gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype	Genotype GG is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	GG	G
792	rs7997012	HTR2A (PA193)	antidepressants (PA452229)	Meta-analysis with 11 studies.	Genotypes AG + GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	AG + GG	A
793	rs6313	HTR2A (PA193)	antidepressants (PA452229)	Meta-analysis with 11 studies. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	GG	G
794	rs6311	HTR2A (PA193)	risperidone (PA451257)	as measured by decrease in ATEC score. Alleles complemented to plus chromosomal strand.	Genotypes CT + TT are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype CC.	CT + TT	C
795	rs6311	HTR2A (PA193)	fluvoxamine (PA449690)	The association was only found for fluvoxamine treatment not treatment with paroxetine.	Genotype CC is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	CC	C
796	rs6311	HTR2A (PA193)	ustekinumab (PA166048654)	as measured by PASI75 at 4 months and adjusted for weight and FDR.	Genotypes CT + TT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC.	CT + TT	C
797	rs9535826	ATP7B (PA73)	Platinum compounds (PA164713176)	"using a dominant model the authors conclude that the G allele at rs9535826 is associated with increased response (""responders"") to platinum therapy."	Allele G is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele T.	G	T
798	rs9535828	ATP7B (PA73)	Platinum compounds (PA164713176)	"using a dominant model the authors conclude that the A allele at rs9535828 is associated with increased response (""responders"") to platinum therapy."	Allele A is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele G.	A	G
799	rs9561765	ABCC4 (PA397)	imatinib (PA10804)	Patients with the AG genotype had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months.	Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.	AG	G
800	rs11568658	ABCC4 (PA397)	latanoprost (PA164774763)	Primary outcome was % change in intraocular pressure (%delta IOP). % delta IOP= ((Baseline IOP values - IOP values posttreatment) / Baseline IOP values × 100 %.)	Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC.	AC	C
801	rs9585618	NALCN (PA162396840)	ziprasidone (PA451974)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele C is associated with response to ziprasidone in people with Schizophrenia.	C	T
802	rs17655	ERCC5 (PA27851)	platinum (PA150595617)	significant in subset of Asian studies. GG+GC vs. CC was not significant. G vs C was trend.	Genotype GG is associated with increased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	GG	G
803	rs1315115	NPAS3 (PA134968746)	risperidone (PA451257)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: the allele was reported as C (though this gene is found on the plus chromosomal strand). It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to risperidone in people with Schizophrenia.	G	G
804	rs177852	TTC6 (PA134868995)	hydrochlorothiazide (PA449899)	Participants were from the PEAR-1 black cohort. This association was associated with DBP response.	Genotypes CC + CT is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype TT.	CC + CT	C
805	rs2273623	PPM1A (PA33603)	nortriptyline (PA450657)	Effect was apparent after 5 weeks of treatment.	Genotype AA is associated with decreased response to nortriptyline in people with Depression as compared to genotypes AG + GG.	AA	A
806	rs944050	ESR2 (PA27886)	gemcitabine (PA449748)	Associated with longer time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype TT is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.	TT	T
807	rs2776546	(no entry)	"diuretics (PA151249535),""hydrochlorothiazide (PA449899)"",""Thiazides, plain (PA164713347)"""	The association was with diastolic blood pressure response. Observations: 3.24 mm Hg greater reduction of diastolic blood pressure per A allele in PEAR + GERA, 0.88mm Hg greater reduction in diastolic blood pressure per A allele in NORDIL and 2.22 mm Hg greater reduction of diastolic blood pressure per A allele in PEAR + GERA + NORDIL.	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	A	C
808	rs2401863	TDP1 (PA421)	irinotecan (PA450085)	(no entry)	Genotype GG is associated with increased response to irinotecan in people with Colorectal Neoplasms as compared to genotypes GT + TT.	GG	G
809	rs77441273	SLC24A4 (PA35854)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. This association was significant in the initial GWAS (in GALA II). In an attempted replication by imputation in silico in GALA I, there was a consistent direction of effect in Puerto Ricans, but the result was not significant. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.	AG	G
810	rs1799722	BDKRB2 (PA80)	enalapril (PA449456)	Patients with the CC or CT genotypes showed significantly larger decreases in systolic and diastolic blood pressure as compared to patients with the TT genotype.	Genotype TT is associated with decreased response to enalapril in people with Hypertension as compared to genotypes CC + CT.	TT	C
811	rs12050217	BDKRB1 (PA79)	perindopril (PA450877)	Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes.	Genotypes AA + AG is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype GG.	AA + AG	A
812	rs861539	XRCC3 (PA37422)	"cisplatin (PA449014),""docetaxel (PA449383)"",""irinotecan (PA450085)"""	"Response was ""time to progression"" and length of survival."	Genotype AA is associated with decreased response to cisplatin, docetaxel and irinotecan in people with Stomach Neoplasms as compared to genotypes AG + GG.	AA	G
813	rs861539	XRCC3 (PA37422)	Platinum compounds (PA164713176)	CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes.	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
814	rs2494732	AKT1 (PA24684)	risperidone (PA451257)	(no entry)	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	TT	T
815	rs2494752	AKT1 (PA24684)	"carboplatin (PA448803),""cisplatin (PA449014)"""	Subjects heterozygous for this variant showed significantly shorter progression free survival as compared to patients homozygous for either allele. Odds ratio below is for disease progression.	Genotype AG is associated with decreased response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + GG.	AG	A
816	rs3803300	AKT1 (PA24684)	risperidone (PA451257)	(no entry)	Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	CT	T
817	rs6494223	CHRNA7 (PA114)	"donepezil (PA449394),""galantamine (PA449726)"",""rivastigmine (PA451262)"""	In patients with mild Alzheimer's disease only (baseline Mini-Mental State Examination (MMSE) score >= 20); in patients with moderate to severe Alzheimer's (MMSE <20) no significant results were seen (p=0.73). Adjusted for gender, age, baseline MMSE, and presence of the APOE E4 allele. After 6 months of treatment with cholinesterase inhibitors, those with the T allele were more likely to be a responder to treatment, as compared to those without the T allele. A responder was defined as a patient who showed improvement or no deterioration in cognition comparing MMSE scores at baseline with MMSE scores after 6 months. The authors note in the Discussion section that after 24 months of treatment, no significant association was seen.	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	T	C
818	rs4646	CYP19A1 (PA27091)	"anastrozole (PA448432),""letrozole (PA450196)"",""tamoxifen (PA451581)"""	Median follow up time was 96 months and the association was with disease free survival (DFS). Overall there was no difference in DFS by genotype, however when women were split into the pre-menopausal and post-menopausal group, an association was seen between the AA genotype and DFS, but in opposite directions. The AA genotype was associated with shorter DFS in the post-menopausal women and longer DFS in the pre-menopausal women when compared to the AC and CC genotypes (87 months in pre-menopausal AA women, and 48.7 months in pre-menopausal AC+CC women). Chemotherapy included Cyclophosphamide, Doxorubicin/epirubicin and Fluoracil or Doxorubicin, Cyclophosphamide with/without docetaxel, Cyclophosphamide, Epirubicin or Doxorubicin, Cyclophosphamide followed by Docetaxel or weekly Paclitaxel, CAF (Cyclophosphamide, Doxorubicin/Epirubicin and Fluoracil) followed by Docetaxel or weekly Paclitaxel treatment and others, 10 (2.5%) remained unknown.	Genotype AA is associated with increased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to genotypes AC + CC.	AA	A
819	rs4646	CYP19A1 (PA27091)	"anastrozole (PA448432),""letrozole (PA450196)"",""tamoxifen (PA451581)"""	Median follow up time was 96 months and the association was with disease free survival (DFS). Overall there was no difference in DFS by genotype, however when women were split into the pre-menopausal and post-menopausal group, an association was seen between the AA genotype and DFS, but in opposite directions. The AA genotype was associated with shorter DFS in the post-menopausal women and longer DFS in the pre-menopausal women when compared to the AC and CC genotypes (13.7 months in post-menopausal AA women, and 56.3 months in post-menopausal AC+CC women). Chemotherapy included Cyclophosphamide, Doxorubicin/epirubicin and Fluoracil or Doxorubicin, Cyclophosphamide with/without docetaxel, Cyclophosphamide, Epirubicin or Doxorubicin, Cyclophosphamide followed by Docetaxel or weekly Paclitaxel, CAF (Cyclophosphamide, Doxorubicin/Epirubicin and Fluoracil) followed by Docetaxel or weekly Paclitaxel treatment and others, 10 (2.5%) remained unknown.	Genotype AA is associated with decreased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	AA	A
820	rs4646	CYP19A1 (PA27091)	tamoxifen (PA451581)	Women were on tamoxifen (n=250) or on unnamed aromatase inhibitors (n=37). Disease free survival was compared at 62.7 weeks and 55.6 weeks follow-up for all women for all women, though different week comparisons were used for each significant association that was found. This association was significant in all women combined and the pre-menopausal subset, but not the post-menopausal subset. The AA genotype was associated with poorer disease free survival in post-menopausal women (p=0.005).	Genotypes AA + AC are associated with increased response to tamoxifen in women with Breast Neoplasms as compared to genotype CC.	AA + AC	A
821	rs4646	CYP19A1 (PA27091)	tamoxifen (PA451581)	Women were on tamoxifen (n=250) or on unnamed aromatase inhibitors (n=37). Disease free survival was compared at 62.7 weeks and 55.6 weeks follow-up for all women for all women, though different week comparisons were used for each significant association that was found. This association was significant in all women combined and the pre-menopausal subset, but had different directions of association in post- and pre-menopausal women.	Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	AA	A
822	rs1800588	LIPC (PA230)	fluvastatin (PA449688)	as measured by increases in HDL-cholestrol.	Genotypes CC + CT are associated with increased response to fluvastatin as compared to genotype TT.	CC + CT	C
823	rs1800588	LIPC (PA230)	simvastatin (PA451363)	as measured by increases in HDL-cholestrol. Levels in patients with genotype CC were in between that of the CT genotype (highest) and TT (lowest).	Genotype CT is associated with increased response to simvastatin as compared to genotype TT.	CT	C
824	rs1800588	LIPC (PA230)	pravastatin (PA451089)	as determined by greater increases in HDL-cholesterol in patients with the T allele compared to genotype CC. This variant was described as -514C/T.	Genotypes CT + TT are associated with increased response to pravastatin in people with Hypercholesterolemia as compared to genotype CC.	CT + TT	C
825	rs2606345	CYP1A1 (PA27092)	antiepileptics (PA143485705)	Bonferroni-corrected significance level was p<0.017. The AA genotype (as well as the A allele) was overrepresented in female poor responders to antiepileptic drugs. Poor responders were those who had one or more seizures during the 10 months of analysis of patients taking antiepileptics (the study period was a year, but the first 2 months were excluded to allow drugs to reach steady-state levels). Note that no significant results were seen when considering males (n=194, p=0.627) or the total population (n=351, p=0.072). The A allele was found to lower CYP1A1 promoter activity by 70-80%.	Genotype AA is associated with decreased response to antiepileptics in women with Epilepsy as compared to genotypes AC + CC.	AA	C
826	rs762551	CYP1A2 (PA27093)	nevirapine (PA450616)	Nevirapine was given as part of HAART therapy. Efficacy was determined based on CD4 count.	Genotype CC is associated with increased response to nevirapine in people with HIV as compared to genotypes AA + AC.	CC	C
827	rs2290573	ULK3 (PA134908392)	imatinib (PA10804)	"52% Major Cytogenetic Response as compared to 89%. When broken into ""Caucasian"" vs. ""non-Caucasian"", the results were significant in the Caucasian group and the trend was consistent in the non-Caucasian group but there were not enough subjects for the results to attain significance."	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	GG	G
828	rs16969968	"CHRNA3 (PA113),""CHRNA5 (PA26491)"""	nicotine (PA450626)	Participants with the AA or AG genotypes were significantly more likely to respond to nicotine replacement therapy (NRT) than participants with the GG genotype.	Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.	AA + AG	G
829	rs7170769	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study reported this variant as within the SLCO3A1 gene and alleles A/ G. [stat_test: chi squared allele test]	Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	T	C
830	rs4932551	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study reported this variant as within the SLCO3A1 gene and alleles C/G - the allele conferring increased response to treatment is not clear. [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele G.	C	G
831	rs9597	UBE2I (PA37134)	"cisplatin (PA449014),""irinotecan (PA450085)"""	No GG homozygotes were observed.	Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	CG	C
832	rs1967309	ADCY9 (PA30)	dalcetrapib (PA166131581)	Part of the dal-OUTCOMES and dal-PLAQUE-2 studies. Outcome was mean change in cholesterol efflux. Patients with the AG genotype had intermediate response.	Genotype AA is associated with increased response to dalcetrapib in people with as compared to genotype GG.	AA	A
833	rs144315541	ADCY9 (PA30)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation. This was assessed as a replication attempt for a previously reported association of a different ADCY9 SNP with response to bronchodilators. Bonferroni correction was performed according to the number of SNPs included that are within 50 kb up and downstream of ADCY9.	Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.	AG	G
834	rs6498169	CLEC16A (PA162382340)	glatiramer acetate (PA449760)	Significant for responders vs non-responders plus intermediate responders after multiple testing correction.	Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	G
835	rs7405404	(no entry)	lithium (PA450243)	(no entry)	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	T	T
836	rs1799801	ERCC4 (PA27850)	Platinum compounds (PA164713176)	Platinum-based doublets consisting of cisplatin or carboplatin plus gemcitabine, vinorelbine, taxane or pemetrexed. Response defined as complete or partial response; non-response defined as stable disease or progression disease.	Genotype TT is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	TT	T
837	rs246240	ABCC1 (PA244)	methotrexate (PA450428)	ABCC1 rs246240 G carrier is associated with increased risk of non-response to methotrexate.	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	AG + GG	A
838	rs3784864	ABCC1 (PA244)	methotrexate (PA450428)	ABCC1 rs3784864 G carrier is associated with increased risk of non-response to methotrexate.	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	AG + GG	G
839	rs35592	ABCC1 (PA244)	methotrexate (PA450428)	(no entry)	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.	TT	T
840	rs2238476	ABCC1 (PA244)	methotrexate (PA450428)	(no entry)	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.	GG	G
841	rs28364006	ABCC1 (PA244)	methotrexate (PA450428)	(no entry)	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	GG	A
842	rs212091	ABCC1 (PA244)	"lamivudine (PA450163),""lopinavir (PA450264)"",""ritonavir (PA451260)"",""zidovudine (PA451954)"""	Patients with the CC or CT genotype had an increased risk of virological failure virological failure (detectable viral load despite 48 weeks of highly active antiretroviral therapy (HAART) treatment), as compared to those with the TT genotype.	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV as compared to genotype TT.	CC + CT	T
843	rs12917707	UMOD (PA37199)	cyclosporine (PA449167)	In death-censored adjusted multivariate analysis, the presence of the DONOR T allele was associated with a significantly lower hazard ratio for graft loss. No significant results were seen when looking at RECIPIENT genotype. Additionally, no significant results were found for blood pressure, serum creatinine or acute graft rejections 1 year after transplantation. No association with graft survival was found in Kaplan-Meier analysis (0.65).	Genotypes GT + TT is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype GG.	GT + TT	G
844	rs3024530	IL4R (PA29832)	pitrakinra (PA165983754)	Subjects with the AA genotype have a reduced frequency of asthma exacerbations compared to those with the AG + GG genotypes.	Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.	AA	A
845	rs1805015	IL4R (PA29832)	Hepatitis vaccines (PA164712789)	The C allele was associated with a protective immune response, that is, a lower chance of being a non-responder to hepatitis B vaccine. Hepatitis B vaccine at 0, 1 and 6 months standard schedule. Non-responders (n=24) were those who had insufficient anti-hepatitis B antibody levels (< 10 mIU/ml) after a 2nd round of revaccination. Responders (n=46) had anti-hepatitis B antibody levels >= 100 mIU/ml after the first standard 3-dose immunization. Significant in multivariable logistic regression analysis.	Allele C is associated with increased response to Hepatitis vaccines as compared to allele T.	C	T
846	rs8832	IL4R (PA29832)	pitrakinra (PA165983754)	Subjects with the GG genotype have a reduced frequency of asthma exacerbations and nocturnal awakenings compared to those with the AA + AG genotypes. There is a significant dose-response relationship for both of these phenotypes in subjects with the GG genotype.	Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.	GG	A
847	rs1029489	IL4R (PA29832)	pitrakinra (PA165983754)	Subjects with the GG genotype have a reduced frequency of asthma exacerbations compared to those with the AA + AG genotypes. There is also a significant dose-response relationship for this phenotype in subjects with the GG genotype.	Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.	GG	A
848	rs3093390	IL21R (PA29821)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The significance of this association did not reach genome-wide significance. This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C	C
849	rs2359612	VKORC1 (PA133787052)	phenprocoumon (PA450921)	The time to achieve the target INR was strongly dependent on this variant. Carriers of the AA genotype reached an INR of 2-3 after a mean time of 3.2 days (n = 5), AG carriers after 4.4 days (n = 27), and GG carriers after 6.5 days (n = 15).	Genotypes AA + AG is associated with increased response to phenprocoumon as compared to genotype GG.	AA + AG	A
850	rs9934438	VKORC1 (PA133787052)	acenocoumarol (PA452632)	VKORC1 wild-type patients were found to be at an increased risk of subtherapeutic anticoagulation when compared to patients carrying at least one copy of the variant allele. This effect was present during the first 3 months of therapy. This risk is increased if the patient is also wild-type for the CYP2C9 gene, though VKORC1 had a greater effect on the risk of underanticoagulation. Similarly, patients carrying variants of the VKORC1 gene had a higher risk of overanticoagulation.	Genotype GG is associated with decreased response to acenocoumarol as compared to genotypes AA + AG.	GG	G
851	rs9923231	VKORC1 (PA133787052)	"acenocoumarol (PA452632),""warfarin (PA451906)"""	This = VKORC1*2. The 5 low responders were all CC. Required doses were (CC + CT): 5.9+/-1.9 mg and TT: 4.1+/-3.3 mg.	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	CC + CT	C
852	rs9923231	VKORC1 (PA133787052)	acenocoumarol (PA452632)	Subjects with the T allele were found to have lower factor VII levels and higher INR changes when compared to subjects with the C allele. This SNP is reported to be in complete linkage disequilibrium with rs9934438.	Allele T is associated with increased response to acenocoumarol in healthy individuals as compared to allele C.	T	C
853	rs9923231	VKORC1 (PA133787052)	warfarin (PA451906)	Patients in this study were treated with low dose (1-2mg/day) warfarin. This SNP was presented as VKORC1 -1639 G>A. Prothrombin time (INR) was significantly different among genotype groups and was observed as follows: AA>AG>GG. When VKORC1 was analyzed in tandem with CYP2C9, it was found that those patients with the highest number of variants (VKORC1 A alleles and CYP2C9 *3 alleles) also had the highest INR measurements as compared to patients wildtype for both genes (GG VKORC1 genotype and CYP2C9 *1/*1) who had the lowest INR measurements.	Genotype TT is associated with increased response to warfarin as compared to genotypes CC + CT.	TT	C
854	rs9923231	VKORC1 (PA133787052)	warfarin (PA451906)	The authors evaluated the effects of the alleles in patients who had left ventricular assist devices implanted and were on warfarin. Patients were evaluated in two periods: immediately after LVAD implantation (period 1) immediately prior to hospital discharge (period 2).	Genotype CT is associated with increased dose of warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.	CT	C
855	rs9923231	VKORC1 (PA133787052)	warfarin (PA451906)	The authors evaluated the effects of the alleles in patients who had left ventricular assist devices implanted and were on warfarin. Patients were evaluated in two periods: immediately after LVAD implantation (period 1) immediately prior to hospital discharge (period 2). Times in therapeutic range (TTR) was used as a measure of efficacy. Warfarin sensitivity index (WSI) is defined as the mean prothrombin time-international normalized ratio (PT-INR) divided by the mean daily warfarin dosage, and is indicative of reactivity to anticoagulation by warfarin.	Genotype CT is associated with decreased response to warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.	CT	C
856	rs9939609	FTO (PA152208656)	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""ribavirin (PA451241)"""	(no entry)	Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV as compared to genotype TT.	AA + AT	T
857	rs2242446	SLC6A2 (PA310)	venlafaxine (PA451866)	Response assessed as remission, defined as MADRS score =<10 at the end of treatment.	Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	CC	C
858	rs3785143	SLC6A2 (PA310)	atomoxetine (PA134688071)	The T allele was associated with being a non-responder to atomoxetine treatment. Children were given the drug for 8 - 12 weeks. Response was defined as at least a 25% decrease from baseline on the ADHD-RS-IV total score. No association was seen with remission. Multiple test correction still gave a significant p-value (p=0.0416).	Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	T	C
859	rs12708954	SLC6A2 (PA310)	atomoxetine (PA134688071)	(no entry)	Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	A	C
860	rs5569	SLC6A2 (PA310)	methylphenidate (PA450464)	Compared the response of MPH between the patients with G/G genotype and those without G/G genotype, 41 (71.9%) patients with G/G genotype showed good response, whereas only 27 (46.4%) patients without G/G genotype showed good response (P=0.008). Association found for both ADHD rating scale-IV scores or Clinical Global Impression-Severity scores.	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	GG	G
861	rs5569	SLC6A2 (PA310)	methylphenidate (PA450464)	Post hoc least significant difference comparisons suggested that subjects with both G/G and G/A genotypes showed greater symptom reductions (7.15 ± 4.25 and 6.94 ± 5.60) than those with A/A genotypes (2.13 ± 4.29) (p < .01). Response was measured using the ADHD RS-IV scale.	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	AG + GG	G
862	rs5569	SLC6A2 (PA310)	methylphenidate (PA450464)	(no entry)	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	GG	G
863	rs71647871	CES1 (PA107)	clopidogrel (PA449053)	The average inhibition of P2Y12 -mediated platelet aggregation 0-12 h after clopidogrel intake was 19% higher in the c.428G/A carriers than in noncarriers (P=0.036) suggesting the antiplatelet effect of clopidogrel was enhanced in subjects with the CES1 c.428G/A genotype.	Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.	CT + TT	C
864	rs1529927	SLC12A3 (PA321)	"bumetanide (PA448682),""furosemide (PA449719)"",""torasemide (PA451733)"""	CC homozygotes had increased urinary excretion of sodium chloride and potassium, as compared to GG homozygotes, during the 24 hours after drug administration.	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.	CC	C
865	rs247616	(no entry)	hmg coa reductase inhibitors (PA133950441)	GWAS study.	Allele T is associated with increased response to hmg coa reductase inhibitors as compared to allele C.	T	C
866	rs708272	CETP (PA108)	atorvastatin (PA448500)	Response as measured by a higher elevation in HDL cholestrol. A larger reduction in Triglycerides and CETP mass reduction was seen in patients with the GG genotype but were not significant. Genotypes were compared. The elevation in patients with the AA genotype was minimal, indicating that these patients are unlikely to benefit from atorvastatin treatment. Taq1 cut = B1 = allele G, no Taq1 site = B2 = allele A.	Genotype GG is associated with increased response to atorvastatin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	GG	G
867	rs708272	CETP (PA108)	lovastatin (PA450272)	as measured by decreases in LDL-cholestrol. Patients with the AA genotype had levels in between that of patients with the AG (highest decrease) or GG (lowest decrease) genotype. Please note; this variant was described as Taq1B in the CETP gene.	Genotype AG is associated with increased response to lovastatin as compared to genotype GG.	AG	G
868	rs1532624	CETP (PA108)	hmg coa reductase inhibitors (PA133950441)	(no entry)	Genotype AA is associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype CC.	AA	C
869	rs5882	CETP (PA108)	simvastatin (PA451363)	as measured by a greater decrease in TG levels and a greater increase in HDL-C levels (please note that total cholesterol and LDL level changes did not differ significantly). Variant described as CETP I405V (I= allele A, V= allele G).	Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to allele G.	A	G
870	rs8050896	(no entry)	risperidone (PA451257)	The number of T alleles present in a patient was negatively associated with CGI-S score.	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele A.	T	A
871	rs1800566	NQO1 (PA31744)	"epirubicin (PA449476),""fluorouracil (PA128406956)"",""oxaliplatin (PA131285527)"""	Response refers to survival (progression free and overall). rs1800566 AG/AA genotype was an independent predictive factor of poor PFS. Please note: the alleles reported here are complemented to the + chromosomal strand.	Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.	AA + AG	G
872	rs3784943	CDH13 (PA26287)	amphetamine (PA448408)	"The authors reported that ""amphetamine (vs. placebo) effects were significantly greater on ""Feel Drug"" ratings (p < 0.05) and marginally greater on ""Feel High"" ratings and systolic blood pressure (p < 0.10) in G/A + G/G genotypes than A/A genotypes. The G allele was more common among Asian than other racial groups."" Patients with the risk allele may have greater risk of psychostimulant abuse liability."	Genotypes AG + GG is associated with increased response to amphetamine as compared to genotype AA.	AG + GG	A
873	rs391300	SRR (PA37877)	metformin (PA450395)	(no entry)	Genotypes CC + CT are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.	CC + CT	T
874	rs224534	TRPV1 (PA37329)	acetaminophen (PA448015)	Volunteers who had a higher pain threshold with acetaminophen treatment compared to placebo were designated as responders.	Genotypes AA + AG is associated with increased response to acetaminophen in healthy individuals as compared to genotype GG.	AA + AG	G
875	rs6065	GP1BA (PA178)	aspirin (PA448497)	A good responder group was defined as having a CEPI-CT > 250s, and a poor responder group as having a CEPI-CT < 250s.	Genotypes CT + TT are associated with increased response to aspirin in men as compared to genotype CC.	CT + TT	C
876	rs1042522	TP53 (PA36679)	"cisplatin (PA449014),""paclitaxel (PA450761)"""	Association reported for 72 ProPro and Arg/Pro (Pro is interpreted as C on coding strand, gene is on minus strand, and therefore risk allele is given as G on plus strand as shown above)	Genotypes CG + GG are associated with decreased response to cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	CG + GG	G
877	rs1042522	TP53 (PA36679)	"capecitabine (PA448771),""paclitaxel (PA450761)"""	Outcomes were response rate, progression free survival, and overall survival. Alleles given as Pro/Arg, which Pro (G on + strand) associated with worse response.	Genotype GG is associated with decreased response to capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.	GG	G
878	rs1042522	TP53 (PA36679)	oxaliplatin (PA131285527)	Patients receiving FOLFOX (oxaliplatin+fluorouracil+leucovorin) with or without bevacizumab. No significant association with progression-free survival or overall survival was seen.	Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	CG + GG	G
879	rs1979277	SHMT1 (PA35753)	"bevacizumab (PA130232992),""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"""	(no entry)	Allele A is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.	A	G
880	rs12943590	SLC47A2 (PA162403847)	metformin (PA450395)	OR is given for likelihood of being non-responder.	Genotypes AA + AG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	AA + AG	G
881	rs11869731	ASIC2 (PA24433)	lithium (PA450243)	P value for quantitative trait analysis of long-term treatment response scale comparing all three genotypes. Please note: the ACCN1 gene is found on the minus chromosomal strand. The G allele was reported in this study as the minor allele - genotype GG was associated with response to lithium. Here we give the association with the complementary C allele on the plus chromosomal strand.	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG.	CC	G
882	rs4795893	CCL2 (PA130413151)	risperidone (PA451257)	Patients with the AA or AG genotype had a greater reduction in total Positive and Negative Symptom Scores (PANSS), as well as on the Positive and General subscales, at week 4 of risperidone treatment, as compared to those with the GG genotype. No significant results were seen when considering the Negative subscale. Additionally, significant results were only seen for one of the two cohorts studied, a population from Henan; no significant results were in a population from Shanghai (n=113).	Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	AA + AG	G
883	rs4795893	CCL2 (PA130413151)	antipsychotics (PA452233)	In low severity schizophrenia patient subgroup	Allele G is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele A.	G	G
884	rs2857657	CCL2 (PA130413151)	risperidone (PA451257)	Patients with the GG genotype had a greater reduction in Positive and Negative Symptom Scores (PANSS), specifically the Positive subscale, at weeks 4 and 8 of risperidone treatment, as compared to those with the CC and CG genotype. No significant results were seen when considering the Negative or General subscales, or the total PANSS score reduction. Additionally, significant results were only seen for one of the two cohorts studied, a population from Shanghai; no significant results were in a population from Henan (n=95).	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	GG	G
885	rs4586	CCL2 (PA130413151)	risperidone (PA451257)	Patients with the CC or CT genotype had a greater reduction in total Positive and Negative Symptom Scores (PANSS), as well as on the Positive and General subscales, at week 4 of risperidone treatment, as compared to those with the TT genotype. No significant results were seen when considering the Negative subscale. Additionally, significant results were only seen for one of the two cohorts studied, a population from Henan; no significant results were in a population from Shanghai (n=113).	Genotypes CC + CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	CC + CT	T
886	rs4586	CCL2 (PA130413151)	antipsychotics (PA452233)	In low severity schizophrenia patient subgroup	Allele T is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele C.	T	T
887	rs2872507	ORMDL3 (PA32821)	fluticasone propionate (PA449686)	as measured by increase in FEV1. This was significant in the whole group and in atopic asthmatics but not non-atopic asthmatics. (NB: allele frequencies are from table 2 and is from larger numbers of patients than those that had FEV1 phenotypes)	Genotypes AA + AG are associated with increased response to fluticasone propionate in children with Asthma as compared to genotype GG.	AA + AG	G
888	rs2314339	"NR1D1 (PA31748),""THRA (PA36507)"""	lithium (PA450243)	Authors note that the comparison by genotype(CT+TT vs CC) rather than by allele was not significant after Bonferroni correction. OR listed below is for non-improvement or worsening in carriers of the T allele.	Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.	T	C
889	rs2071427	"NR1D1 (PA31748),""THRA (PA36507)"""	lithium (PA450243)	This result is for the combination of this SNP with rs6438552 GG. People with this genotype combination had a 75% chance of being in the Li-responsive group. People with rs2071427 CC/rs6438552 AA had a 44% response rate. Those with 2 or 3 favorable alleles had responses on a gradient between these two results.	Genotype TT is associated with increased response to lithium in people with Bipolar Disorder.	TT	C
890	rs2071427	"NR1D1 (PA31748),""THRA (PA36507)"""	lithium (PA450243)	(no entry)	Allele T is not associated with response to lithium in people with Bipolar Disorder as compared to allele C.	T	C
891	rs2269457	"NR1D1 (PA31748),""THRA (PA36507)"""	lithium (PA450243)	(no entry)	Allele T is not associated with response to lithium in people with Bipolar Disorder as compared to allele C.	T	T
892	rs12941497	NR1D1 (PA31748)	lithium (PA450243)	(no entry)	Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.	A	G
893	rs2071570	NR1D1 (PA31748)	lithium (PA450243)	(no entry)	Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele C.	A	C
894	rs4796793	STAT3 (PA337)	interferons (PA451999)	IFN-alpha. Careful- GC SNP. Based on dbSNP population frequencies in Asians(and orientation of dbSNP exemplar sequence and FastA sequence compared to + Golden Path strand), I reversed the designations used in the article, but I'm not completely sure this is correct. Also, the p I've entered is not adjusted for multiple testing, and if adjusted: 0.0039 * 423(for tested SNPs) = 1.6. [stat_test: pearson's chi square]	Genotype GG is associated with increased response to interferons in people with Carcinoma, Renal Cell as compared to genotypes CC + CG.	GG	G
895	rs739645	CRHR1 (PA26874)	fluticasone propionate (PA449686)	The minor allele is reported to be associated with increased response. dbSNP lists C as the minor allele in a CEU panel.	Allele C is associated with increased response to fluticasone propionate in people with Asthma as compared to allele A.	C	T
896	rs1876829	CRHR1 (PA26874)	fluticasone propionate (PA449686)	The minor allele is reported to be associated with increased response. dbSNP lists G as the minor allele in a CEU panel.	Allele G is associated with increased response to fluticasone propionate in people with Asthma as compared to allele A.	G	T
897	rs17250932	TBX21 (PA36362)	Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)	When comparing responders vs. non-responders. However, no significant association was seen when comparing the CT vs TT genotype, or the CC + CT vs TT genotype. Additionally, no association was seen for any genotype when considering responders vs. non- and partial-responders.	Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.	CC	T
898	rs1800012	COL1A1 (PA35041)	etidronic acid (PA449548)	in term of increase of femoral neck bone mineral density (BMD)	Genotypes AA + AC are associated with decreased response to etidronic acid in people with Bone Diseases, Metabolic as compared to genotype CC.	AA + AC	C
899	rs967676	CA10 (PA25985)	"fluticasone propionate (PA449686),""montelukast (PA450546)"""	ONLY in patients with atopic asthma phenotype - results were not significant when considering those with nonatopic asthma (n = 84, p = 0.207) or when considering atopic and nonatopic asthma patients together (n = 288, p = 0.293). Patients with the CC or CT genotype had a higher increase in forced expiratory volume in the first second of expiration (FEV1) as compared to those with the TT genotype. FEV1 was measured before treatment and 4 weeks later. Please note that this SNP was also found to be significantly associated with risk for asthma and severity of asthma. Alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype TT.	CC + CT	T
900	rs2429427	TANC2 (PA142670837)	calcium channel blockers (PA10407)	Increased response as determined by a greater decrease in both systolic and diastolic blood pressure.	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype AA.	GG	G
901	rs4341	ACE (PA139)	pravastatin (PA451089)	as measured by decreases in total cholesterol.	Genotypes CG + GG are associated with increased response to pravastatin as compared to genotype CC.	CG + GG	G
902	rs4359	ACE (PA139)	ramipril (PA451223)	This SNP was also reported as ACE C17888T. This SNP was in linkage disequilibrium with rs4344, D' = .88. Patients homozygous for this SNP (CC or TT) responded to ACE inhibitor treatment (reached target blood pressure) faster than patients heterozygous (CT) for this SNP.	Genotypes CC + TT are associated with increased response to ramipril in people with Hypertension as compared to genotype CT.	CC + TT	T
903	rs4791040	PRKCA (PA33759)	"diuretics (PA151249535),""hydrochlorothiazide (PA449899)"",""Thiazides, plain (PA164713347)"""	The association was with diastolic blood pressure response. It did not reach genome-wide significance when only PEAR + GERA were analyzed, but this SNP was selected for replication in NORDIL and this association was significant. Observations: 4.46 mm Hg decreased reduction of diastolic blood pressure per T allele in PEAR + GERA, 3.30 mm Hg decreased reduction of diastolic blood pressure per T allele in NORDIL, and 4.17 mm Hg decreased reduction of diastolic blood pressure per T allele in PEAR + GERA + NORDIL.	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T	T
904	rs16960228	PRKCA (PA33759)	"diuretics (PA151249535),""hydrochlorothiazide (PA449899)"",""Thiazides, plain (PA164713347)"""	Observations: 4.46 mm Hg increased reduction of diastolic blood pressure per A allele in PEAR + GERA, 3.26 mm Hg increased reduction of diastolic blood pressure per A allele in NORDIL, and 4.16 mm Hg increased reduction of diastolic blood pressure per A allele in PEAR + GERA + NORDIL.The association did not reach genome-wide significance when only PEAR + GERA were analyzed, but this SNP was selected for replication in NORDIL and here the association reached significance. It did not reach genome-wide significance in the meta-analysis of PEAR + GERA + NORDIL. It was then tested for replication in the GENRES and Milan cohorts, reaching significance in GENRES but not in the Milan cohort.	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	A	G
905	rs329007	RALBP1 (PA34199)	"bevacizumab (PA130232992),""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"""	Patients were receiving treatment with bevacizumab + FOLFIRI (fluorouracil, leucovorin, irinotecan). Patients with the GG genotype had a significantly lower tumor response rate according to the RECIST criteria. However, when the p-value was adjusted for multiple testing, it was no longer significant (p=0.63). When considering only tumors on the left-sided colon and rectum, this SNP was also associated with tumor response rate.	Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	G
906	rs4483927	HRH4 (PA134982275)	risperidone (PA451257)	Patients with the TT genotype had a smaller reduction in positive, negative, general and total PANSS (Positive and Negative Syndrome Scale) scores after 4 and 8 weeks of treatment as compared to those with the GG or GT genotype. At 4 weeks, the TT genotype showed a significantly smaller reduction for all scores; at 8 weeks, it only showed a significantly smaller reduction for the positive and total scores. Please note that either ANOVA or Kruskal-Wallis tests were used, so all genotypes were compared against each other, and no post-hoc test information was provided.	Genotype TT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotypes GG + GT.	TT	G
907	rs16973410	(no entry)	lithium (PA450243)	Quantitative trait analysis of long-term treatment response scale comparing all three genotypes.	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CT + TT.	CC	C
908	rs9952628	SKOR2 (PA165429121)	perphenazine (PA450882)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele G is associated with response to perphenazine in people with Schizophrenia.	G	G
909	rs75982813	NEDD4L (PA31534)	atenolol (PA448499)	(no entry)	Allele A is not associated with response to atenolol in people with Hypertension as compared to allele G.	A	A
910	rs75982813	NEDD4L (PA31534)	hydrochlorothiazide (PA449899)	If the p for the dominant model (0.0239) is adjusted for 4 SNPs tested, it is 0.092 and the association does not reach significance. Blood pressure reduction for the heterozygote (AG) is less than for either of the homozygotes for both systolic and diastolic blood pressure.	Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.	AG + GG	A
911	rs520210	NEDD4L (PA31534)	citalopram (PA449015)	GWAS. Responders to antidepressant treatment had a higher frequency of the A allele as compared to non-responders. Responders were patients that showed a 50% or greater reduction, from baseline to final visit, in the self-report 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR). Participants who did not meet this criteria were non-responders. Patients had to complete at least 6 weeks of treatment with citalopram to be included.	Allele A is associated with increased response to citalopram in people with Depression as compared to allele G.	A	G
912	rs4149601	NEDD4L (PA31534)	hydrochlorothiazide (PA449899)	AG and GG patients had significantly greater reduction in Systolic and in Diastolic Blood pressure than those with AA genotype. As this association was tested as a replication attempt, p was not adjusted for multiple testing as it was for the other SNPs in this study. A significant association was also seen between the haplotype rs4149601G/rs292449C and greater response to hydrachlorothiazide in Whites.	Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.	AG + GG	G
913	rs4149601	NEDD4L (PA31534)	"Aldosterone antagonists (PA164712326),""amiloride (PA448368)"""	This was true for systolic blood pressure but not for diastolic blood pressure.	Allele G is associated with increased response to Aldosterone antagonists or amiloride in people with Hypertension as compared to allele A.	G	G
914	rs4149601	NEDD4L (PA31534)	"Beta blocking agents, selective (PA164712547),""diuretics (PA151249535)"""	This was found both for SBP reduction (19.5 ± 16.8 vs. 15.0 ± 19.3 mmHg, P < 0.001) and DBP reduction (15.4 ± 8.3 vs. 14.1 ± 8.4 mm Hg, P = 0.02).	Genotypes AG + GG are associated with increased response to Beta blocking agents, selective or diuretics in people with Hypertension as compared to genotype AA.	AG + GG	G
915	rs4149601	NEDD4L (PA31534)	hydrochlorothiazide (PA449899)	Response was determined by reduction in blood pressure. The systolic blood pressure and diastolic blood pressure reductions in A carriers were greater than those in GG carriers by 6.1 mm Hg (p=0.009) and 2.7 mm Hg (p=0.027), respectively, suggesting that NEDD4L rs4149601 A allele carriers are particularly sensitive to hydrochlorothiazide treatment. No association is found in the patients without hydrochlorothiazide or with hydrochlorothiazide treatment plus another drug.	Allele A is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	A	G
916	rs292449	NEDD4L (PA31534)	hydrochlorothiazide (PA449899)	CC and CG patients had significantly greater reduction in Systolic and in Diastolic Blood pressure than those with GG genotype. A significant association was also seen between the haplotype rs4149601G/rs292449C and greater response to hydrachlorothiazide in Whites. The GC SNP creates ambiguity in knowing which strand is being reported on. The SNP is in a positive chromosomal strand gene, so hopefully the genotypes are being reported in relation to the positive strand.	Genotypes CC + CG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	CC + CG	G
917	rs2269879	DOT1L (PA134993717)	hydrochlorothiazide (PA449899)	In the PEAR cohort, in Whites: 5.5 mmHg greater mean systolic bp response(p = 0.0002 uncorrected) and a 3.5 mmHg greater mean diastolic bp response (p = 0.0016 uncorrected). [stat_test:linear regression]. More than 90% of participants were receiving 25 mg/day HCTZ (the rest received 12.5 mg/day). This did not replicate significantly in a second cohort(GERA) and authors concluded that there could possibly be an association between this SNP and blood pressure response to HCTZ in Caucasians, but that it requires further investigation. Significance for this segment of the study was set at p < 0.01 for a partially corrected p, and in Whites, this level was met when a partial correction for multiple testing was done. But for a compound, corrected p predetermined by the authors to be the significance point for both segments of the study, the significance test failed.	Genotypes CT + TT are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.	CT + TT	T
918	rs688	LDLR (PA227)	lovastatin (PA450272)	as measured by decreases in total cholesterol. Patients with genotype CC had decreases in between that of patients with the TT (highest decrease) or CT (lowest decrease).	Genotype TT is associated with increased response to lovastatin as compared to genotype CT.	TT	C
919	rs5925	LDLR (PA227)	lovastatin (PA450272)	as measured by decreases in total cholesterol. Patients with the TT genotype had levels in between patients with the CC and CT genotype.	Genotype CC is associated with increased response to lovastatin as compared to genotype CT.	CC	T
920	rs14158	LDLR (PA227)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). Patients with the GG genotype had a rate of SVR of 41% and those with the AA or AG genotype a rate of SVR of 20%. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV as compared to genotypes AA + AG.	GG	G
921	rs2108622	CYP4F2 (PA27121)	warfarin (PA451906)	Patients in this study were treated with low dose (1-2mg/day) warfarin. No association was found between this SNP and response to warfarin (metabolism or prothrombin time (INR)).	Genotype CC is not associated with response to warfarin as compared to genotypes CT + TT.	CC	C
922	rs2108622	CYP4F2 (PA27121)	"aspirin (PA448497),""clopidogrel (PA449053)"""	Patients had undergone percutaneous coronary intervention. Cases had definite stent thrombosis during the first 5 days after stent implantation. Controls had no stent thrombosis during the first 30 days following stent implantation. Those with the CT or CC genotype had an increased risk for stent thrombosis as compared to those with the TT genotype. However, this was only significant in multivariate analysis; it was not significant in univariate analysis (p=0.055). Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	CC + CT	C
923	rs12980275	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This variant is associated with null virological response (NVR) and sustained virologic response (SVR) in a genome-wide association study of Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin in this discovery sample. Two SNPs near the gene IL28B on chromosome 19 to be strongly associated with NVR (rs12980275, P = 1.93 × 10-13, and rs8099917, 3.11 × 10-15). These associations in an independent cohort (combined P values, 2.84 × 10-27 (OR = 17.7; 95% CI = 10.0-31.3) and 2.68 × 10--32 (OR = 27.1; 95% CI = 14.6-50.3), respectively). Compared to NVR, these SNPs were also associated with SVR (rs12980275, P = 3.99 × 10-24, and rs8099917, P = 1.11 × 10-27).	Allele A is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	A	A
924	rs12980275	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	especially in HCV genotype 1/4 patients.	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	AA	A
925	rs12980275	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	AG + GG	A
926	rs12980275	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype AA is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	AA	A
927	rs12980275	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	The AA genotype of rs12980275 was found significantly associated with hematologic response in polycythemia vera (PV) (p=0.036) and in the combined PV and ET cohort (p=0.014). In the ET cohort alone, no significant difference was found.	Genotype AA is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Myeloproliferative Disorders as compared to genotypes AG + GG.	AA	A
928	rs8105790	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	The associated allele is not explicitly stated, so I assumed that the association was with the minor allele, and dbSNP lists C as the minor allele in Asians.	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	C	T
929	rs8105790	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes CC + CT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	CC + CT	T
930	rs4803217	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes AA + AC.	CC	C
931	rs4803217	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	in African-American patients. The associations were stronger for IFNL4-rs368234815 than rs4803217 for undetectable HCV RNA at week 24 in Virahep C (p=0.03) trial and week 20 in HALT-C (p=0.03) trial.	Genotypes AC + CC are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	AC + CC	C
932	rs11881222	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	The associated allele is not explicitly stated, so I assumed that the association was with minor allele, and dbSNP lists G as the minor allele in Asians.	Allele G is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	G	A
933	rs11881222	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes AG + GG.	AA	A
934	rs11881222	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	in HCV genotype 2 patients using univariate analysis.	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AG.	AA	A
935	rs11881222	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	AG + GG	A
936	rs28416813	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	The rs28416813 SNP was found to be highly associated (r-squared > 0.85) with rs12979860.	Allele G is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.	G	C
937	rs28416813	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	Actually, the associated allele is not stated, so I assumed that the association was with the minor allele, but it is not clear from dbSNP which is the minor allele in Asians.	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	C	C
938	rs28416813	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes CG + GG.	CC	C
939	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	A GWAS showed that, in patients of European ancestry, the CC genotype of this SNP is associated with a twofold (95% CI 1.8-2.3) greater rate of SVR (sustained virological response) than is the TT genotype to treatment of chronic Hepatitis C genotype I infection with peginterferon-alpha-2a or -2b combined with ribavirin. In African -Americans, the response rate ratio is in the same direction, but three-fold (95% CI 1.9-4.7) . In Hispanics, the response ratio is two-fold (95% CI 1.4-3.2). The overall genome-wide association has significance p = 1.37 x 10 -28. Based upon the allele frequency in different population groups, this polymorphism appears to explain about half of the response rate difference between different populations. An association between baseline viral load and genotype was also found.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	CC	C
940	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	The association was with SVR(sustained virological response) . Subjects were coinfected with HIV. Patients were treated with ribavirin plus peginterferon alfa-2a OR peginterferon alfa-2b. The association was significant for HCV genotype 1 and for genotype 4, and was present but was not significant for genotype 3.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
941	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Patients received peginterferon alpha-2A or 2B, along with ribavirin. This effect was found in HCV genotypes 1 and 4 but not 3. These patients were coinfected with HIV. The association was with SVR. 75% of CC vs 38% of CT and TT achieved SVR. Note: the frequency of CC in patients with spontaneous HCV clearance was significantly higher than in chronically HIV/HCV coinfected patients.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
942	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	These patients had Hepatitis C, genotypes 2 and 3. CC patients had higher baseline HCV RNA levels . 67% of CC patients achieved RVR (rapid virological response) vs. 47% of TT patients.	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	CC	C
943	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	These patients had Hepatitis C, genotypes 2 and 3. SVR for patients who received 24 weeks of treatment was significantly lower in TT patients than in the rest. There was no association for patients who received 12 weeks of treatment (175 patients).	Genotypes CC + CT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	CC + CT	C
944	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	Patients were co-infected with HIV. p listed is for RVR.	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
945	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	The subtype of peginterferon alpha was not specified. The association was with SVR(sustained viral response). Patients were monoinfected with HCV genotype 1. Nonresponders and relapsers were grouped together. Allele frequency listed is for entire cohort of 61.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
946	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	The association was with SVR (sustained virological response).	Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
947	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	The peginterferon type was listed only as pegylated interferon- alpha. Patients were followed for 24 weeks post-treatment. There was only one TT individual.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
948	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	These patients were also HIV infected. Treatment was with ribavirin plus peginterferon alfa- 2a or -2b. The increased response was significant for Hepatitis C types 1 and 4 (pooled after no significant differences were found between the two) and was marginal for types 2 and 3. The effect was mainly due to increased viral clearance during the first 12 weeks of treatment. 86 CC; 110 CT or TT.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
949	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Response was measured by sustained virological response (SVR), defined as undetectable hepatitis C genotype 1 viral RNA in patient serum 24 weeks after treatment cessation. Patients with the CC genotype had a greater chance of achieving SVR compared to patients with the CT and TT genotypes. Peginterferon and ribavirin treatment were given in combination (PEG-IFN/RBV).	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
950	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Significantly lower baseline plasma levels of IP-10 were associated with this SNP. Lower levels of IP-10 were found to be statistically significantly associated with better treatment outcome. This SNP was found to be in strong linkage disequilibrium with rs8099917.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
951	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
952	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes CT + TT.	CC	C
953	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"interferon alfa-n1 (PA164746538),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with early virological response (EVR) in recipient patients before liver transplant. EVR was defined as a decrease of greater than or equal to 2 log10 during the first 12 weeks of therapy.	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
954	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"interferon alfa-n1 (PA164746538),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) after liver transplantation. Presence of CC genotype in both donors and recipients was associated with increased SVR when compared to other genotype combinations.	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
955	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Genotype CC is associated with higher mean baseline HCV RNA level and also steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV (RVR).	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
956	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	Patients were infected with HCV genotype 1 or 4. Sustained viral response (SVR) was defined as undetectable plasma HCV RNA 24 weeks after the completion of treatment. The two SNPs rs12979860 (IL28B) and rs368234815 (IFNL4) are in strong LD (r squared of 0.82). The SNPs were also tested by HCV genotype (1 or 4) and were both equally predictive. The AUROC model that included rs12979860 was 0.742 (95% CI: 0.672-0.813)	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
957	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Response here refers to sustained virological response (SVR). This cohort includes patients with both HCV and mixed cryoglobulinemia (CV).	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
958	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
959	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). The authors compared CC vs CT Vs TT for their potential association with a clinical outcome.	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	CC + CT	C
960	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). The authors compared CC vs CT Vs TT for their potential association with a clinical outcome.	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	CC + CT	C
961	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	in HCV genotype 1 infected patients. The association was not significant in HCV genotype 2/3 infected patients.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
962	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	in HCV-1 infected patients. The association was not significant in HCV-3 infected patients. In this predominantly Caucasian cohort, IFNL4 genotype (rs368234815) performed very similarly to IFNL3 (rs12979860) and they are in very high LD (r2=0.98).	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	TT	C
963	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with increased sustained virological response (SVR; 73.1%[19 of 26] vs. 43.7%[35 of 80], P=0.0126) as well as increased occurrence of complete early virological response (cEVR; 80.8%[21 of 26] vs. 51.2%[41 of 80], P=0.011) when compared to patients with non-CC genotypes.	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
964	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""ribavirin (PA451241)"""	in patients with HCV genotypes 2 or 3 infection.	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
965	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"ledipasvir (PA166128166),""sofosbuvir (PA166122593)"""	in HCV genotype 1 patients. Patients with the CC genotype have higher SVR rates than patients with the TT genotype. The SVR rate was 98.9% in women and 98.2% in individuals with the rs12979860-CC genotype, 95.1% in patients with the CT genotype and 90.9% in TT genotype patients. Black patients had a lower SVR rate than individuals of other racial groups; however, that association did not reach statistical significance (P= 0.08)	Genotype CC is associated with increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
966	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV as compared to genotypes CT + TT.	CC	C
967	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
968	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	T	C
969	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	"Patients were analyzed by HCV genotype (1,2,3,4). Patients with HCV genotype 1 were divided into groups receiving dual therapy (GT1 (d); peg-intron alpha 2a/b, ribavirn) or triple therapy (GT1 (t); peg-intron alpha 2a/b, ribavirn, telaprevir). Sustained virological response (SVR) is a measure of therapeutic efficacy. Variables that were significant in univariate analysis were included in the multivariate analysis. The authors designated three ""beneficial"" genotypes that were found at higher frequencies in patients who achieved SVR: rs12979860 CC, rs8099917 TT, rs368234815 TT/TT. These genotypes were often found together. 98% of patients with GT1 (d), 100% of patients with GT1(t), 96% of patients with HCV genotype 2, 92% of patients with HCV genotype 3 and 98% of patients with HCV genotype 4 had those genotype combinations. rs12979860 CC was the only single SNP associated with SVR across all groups. rs12979860 CC was significantly associated with SVR in GT1(d) (p<0.01). 71% of GT1(d) patients had rs12979860 CC and s368234815 TT/TT achieved SVR. In univariate analysis, the CC genotype was a significant predictor of SVR in GT1(d) as well as in patients infected with HCV genotype 2/3 (p=0.03). The CC genotype was found to be significant in a multivariate analysis of predictive factors of SVR within all HCV genotype 1 infected patients. The CC genotype was also associated with higher HCV RNA concentration at baseline in patients with HCV genotype 3 (p<0.001), 2/3 (p<0.001) and GT1(d) (p<0.001) as well as increased ALT levels in HCV genotype 2 (p=0.026) and 2/3 patients (p=0.011)."	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
970	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""ribavirin (PA451241)"""	in patients with genotype 4 (HCV-4). The response was measured by sustained virological responses (SVR).	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
971	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"deleobuvir (PA166128130),""faldaprevir (PA166128132)"""	in patients with HCV genotype 1 infection. Response rates (sustained virologic response, SVR) were higher among patients with the IL28B CC genotype than among patients with non-CC genotypes in the BID28W and TID28W-NR groups (P=0.05 and P=0.02, respectively) after adjustment for viral subtype.	Genotype CC is associated with increased response to deleobuvir and faldaprevir in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
972	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with decreased incidence of sustained virological response (SVR; OR: 0.37, 95%CI:[0.23–0.59], P=2.47E-5, multivariate analysis) when compared to CT/CC genotypes. However, when rs368234815 and rs12979860 were introduced in the same logistic model, the TT genotype was associated with increased incidence of SVR (OR: 3.41, 95%CI:[1.01–11.4], P=0.0477). Hence, the polarity of the association between rs12979860-TT genotype and SVR is questionable.	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	TT	C
973	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes CT + TT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	CT + TT	C
974	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
975	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	This genotype is associated with first phase viral elimination (HCV clearance after 24 hours of treatment), rapid virological response (RVR; HCV RNA below limit of detection at treatment week 4) and sustained virological response (SVR; undetectable HCV RNA 24 weeks after treatment termination).	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
976	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	IL28B CC genotype was associated with SVR (67% vs 30% in non-CC, P=0.028) in children.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
977	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). Patients with the CC genotype had a rate of SVR or 64% and those with the CT or TT genotype a rate of SVR of 37%.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV as compared to genotypes CT + TT.	CC	C
978	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype was associated with sustained virological response (SVR). However, this genotype was associated with increased incidence of spontaneous HCV clearance when compared to patients (OR:0.32, 95%CI:[0.18-0.57], P = 6.2E10-5) with chronic hepatitis or those without an infection (OR:0.31, 95%CI:[0.17-0.56], P = 2.2E10-5).	Genotype CC is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
979	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). This genotype is also associated with increased incidence of SVR in patients without rapid virological response (RVR; OR:5.2, 95%CI:[3.9–6.9], P<0.001) when compared to those of CT/TT genotypes.	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
980	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) and early virological response (EVR).	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CT.	CC	C
981	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	PEG-interferon alfa (2a and b) was co-adminstered with ribavirin. Response was assessed by sustained virological response (SVR) percent by genotype. HCV RNA <400,000 IU/ml, age, and low stage liver fibrosis were also independently associated with SVR.	Genotype CC is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
982	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	in Moroccan patients with hepatitis C virus genotype 1 infection. The CC genotype was not associated with SVR in HCV genotype 2 infected individuals, but with non-CC genotypes.	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
983	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"boceprevir (PA165948902),""peginterferon alfa-2a (PA164749390)"",""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	The favorable allele C of rs12979860 was significantly associated with SVR to triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1. The effect of rs12979860 on triple therapy-induced clearance in treatment-experienced patients is restricted to those who experienced prior PegIFN/RBV relapse.	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	C	C
984	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"interferons (PA451999),""ribavirin (PA451241)"""	Measured according to impact on sustained virological response. Significant only in non-cryoglobulinemic patients. Not significant in cryoglobulinemic patients. CC to CT p = 0.023; CC to TT p = 0.017.	Genotype CC is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
985	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"boceprevir (PA165948902),""peginterferon alfa-2a (PA164749390)"",""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	in both naïve patients and treatment-experienced patients. rs12979860-CC was a stronger predictor of SVR12 than rs8099917-TT.	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	CC	C
986	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	among Egyptian patients infected with HCV genotype 4.	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	CC	C
987	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non-CC), (p=0,036).	Genotype CC is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Myeloproliferative Disorders as compared to genotypes CT + TT.	CC	C
988	rs12979860	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	only in the allelic model.	Allele C is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele T.	C	C
989	rs8113007	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes AT + TT.	AA	A
990	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This variant is associated with null virological response (NVR) and sustained virologic response (SVR) in a genome-wide association study of Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin in this discovery sample. Two SNPs near the gene IL28B on chromosome 19 to be strongly associated with NVR (rs12980275, P = 1.93 × 10-13, and rs8099917, 3.11 × 10-15). These associations in an independent cohort (combined P values, 2.84 × 10-27 (OR = 17.7; 95% CI = 10.0-31.3) and 2.68 × 10--32 (OR = 27.1; 95% CI = 14.6-50.3), respectively). Compared to NVR, these SNPs were also associated with SVR (rs12980275, P = 3.99 × 10-24, and rs8099917, P = 1.11 × 10-27).	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	T	T
991	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The rates of SVR in the patients with TT, TG and GG were 57.9% (127/219), 14.5% (11/76) and 0% (0/4) respectively. The G allele of the IL28B genotype was significantly associated with poor response to IFN therapy (P=0.0001).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
992	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Treatment was with ribavirin plus peginterferon alfa-2a or alfa-2b. TT was associated with SVR (sustained viral response). This SNP is reported to be in LD with rs12979860. Patients completed 48 weeks of therapy.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
993	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Treatment was with ribavirin plus peginterferon alfa-2a or alfa-2b. GG + GT were associated with increased non-viral response. This SNP is reported to be in LD with rs12979860. Patients completed 48 weeks of therapy.	Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	GG + GT	T
994	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	no GG patients were seen. SVR (at 24 weeks) was seen in 87% TT vs. 50% GT.	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	TT	T
995	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	These patients had HCV genotype 2. TT patients had a significantly higher rate of achieving RVR(seronegativity for HCV at 4 wks of treatment) (85.2% vs 72%) but not of SVR. Treatment was with ribavirin and one of the two peginterferon alfas.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
996	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Patients had HCV genotypes 2a and 2b. Genotype-related differences in response were more profound in genotype 2b-infected patients. Treatment was with (peginterferon alfa-2a OR peginterferon alfa-2b) and ribavirin.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
997	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The association was with SVR in HCV genotype 2b patients, but not in type 2a.	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
998	rs8099917	IFNL3 (PA134952671)	peginterferon alfa-2b (PA164784024)	The association was with SVR in HCV genotype 2a patients, but not in type 2b. This is for interferon monotherapy.	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
999	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	no GG patients were seen. RVR seen in 83.1% TT vs. 57.1% GT.	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	TT	T
1000	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	The association was with SVR (sustained virological response).	Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1001	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	The type of peginterferon alfa was not specified. The patients were co-infected with HIV-1. An association with SVR (sustained viral response) at 24 weeks was found in HCV genotype 1-infected patients, but not in genotype 3-infected patients.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1002	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The association was for SVR(sustained virological response); 53% in 202 TT patients; 19.4% in 72 TG + GG patients.	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1003	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Response was measured by sustained virological response (SVR), defined as undetectable hepatitis C genotype 1 viral RNA in patient serum 24 weeks after treatment cessation. Patients with the TT genotype had a greater chance of achieving SVR compared to patients with the GT and GG genotypes. Peginterferon and ribavirin treatment were given in combination (PEG-IFN/RBV).	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1004	rs8099917	IFNL3 (PA134952671)	"interferon alfa-n1 (PA164746538),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) after liver transplantation. Presence of CC genotype in both donors and recipients was associated with increased SVR when compared to other genotype combinations.	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1005	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1006	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	Carriers of the rs8099917G-risk genotypes were associated with increased risk of treatment failure in patients with HCV viral genotype 1 or 4 when compared to those with HCV viral genotype 2 or 3.	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C.	GG + GT	T
1007	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV as compared to genotypes GG + GT.	TT	T
1008	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	Carriers of the rs8099917G-risk genotypes were associated with increased risk of treatment failure when compared to those with TT genotype.	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	GG + GT	T
1009	rs8099917	IFNL3 (PA134952671)	"interferon alfa-n1 (PA164746538),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	This genotype is associated with early virological response (EVR) in recipient patients before liver transplant. EVR was defined as a decrease of greater than or equal to 2 log10 during the first 12 weeks of therapy.	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1010	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	This genotype is associated with sustained virological response (SVR).	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1011	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) or transient response (TR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1012	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype reached genome-wide significance and is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Table 2 in the paper.	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	G	T
1013	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Supplementary Table 2 in the paper.	Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	GT	T
1014	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR). SVR is defined as negative OCR test for Hepatitis C 6 months after the cessation of therapy. The authors do not indicate polarity of the association. However, decreased polarity can be inferred from Supplementary Table 2 in the paper.	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	GG	T
1015	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Carriage of the G allele was the best predictor of null-R (not achieving a hepatitis C virus (HCV) RNA drop of >= 1 log at week 4) within logistic regression analysis.	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	GG + GT	T
1016	rs8099917	IFNL3 (PA134952671)	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""ribavirin (PA451241)"""	in patients with HCV genotypes 2 or 3 infection.	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1017	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	The IL28B TT genotype was associated with an increased likelihood of sustained virological response as compared to those with the GT or GG genotype. Forward stepwise likelihood ratio logistic regression.	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1018	rs8099917	IFNL3 (PA134952671)	peginterferon alfa-2b (PA164784024)	This genotype is associated with rapid virological response (RVR; P<0.001) and sustained virological response (SVR; OR:12.34, 95%CI:[6.46-23.60], P<0.001) in patients receiving 48 weeks of therapy.	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1019	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""telaprevir (PA165958354)"""	"Patients were analyzed by HCV genotype (1,2,3,4). Patients with HCV genotype 1 were divided into groups receiving dual therapy (GT1 (d); peg-intron alpha 2a/b, ribavirn) or triple therapy (GT1 (t); peg-intron alpha 2a/b, ribavirn, telaprevir). Sustained virological response (SVR) is a measure of therapeutic efficacy. Variables that were significant in univariate analysis were included in the multivariate analysis. The authors designated three ""beneficial"" genotypes that were found at higher frequencies in patients who achieved SVR: rs12979860 CC, rs8099917 TT, rs368234815 TT/TT. These genotypes were often found together. 98% of patients with GT1 (d), 100% of patients with GT1(t), 96% of patients with HCV genotype 2, 92% of patients with HCV genotype 3 and 98% of patients with HCV genotype 4 had those genotype combinations. rs8099917 TT was the strongest predictor of SVR in GT1(t) patients (p=0.026) and was strongly correlated with SVR in patients infected with HCV genotype 4 (P<0.001). In univariate analysis, the TT genotype was a significant predictor of SVR in GT1(d) (p<0.01) and GT1(t) (p=0.02). The TT genotype was found to be significant in a multivariate analysis of predictive factors of SVR within all HCV genotype 1 infected patients. The CC genotype was also associated with higher HCV RNA concentration at baseline in patients with HCV genotype 3 (p=0.005), 2/3 (p=0.017) and GT1(d) (p<0.001) as well as increased ALT levels in HCV genotype 2/3 (p=0.077)."	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1020	rs8099917	IFNL3 (PA134952671)	"interferon alfa-2a, recombinant (PA164779048),""interferon alfa-2b, recombinant (PA164783990)"",""ribavirin (PA451241)"""	in patients with genotype 4 (HCV-4). The response was measured by sustained virological responses (SVR).	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1021	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	A multivariate logistic model showed that the IL28B major genotype (TT) was an independent factor contributing to SVR (OR, 7.14; 95% CI, 2.19-23.22; P=0.001).	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1022	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	in HCV genotype 2 patients. Subgroup analysis showed that IL-28B SNP were significantly associated with SVR in genotype 2a patients but not in genotype 2b patients.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	TT	T
1023	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	Egyptian patients with TT genotype showed significantly higher SVR rate than minor allele (TG/GG) carriers (74% vs. 26%, P=0.004). Logistic regression analysis revealed that TT carriers had 2.8 higher chance for SVR achievement than G allele carriers TG/GG (OR=2.8, 95% CI=1.4-5.6, P=0.004).	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	TT	T
1024	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	GG + GT	T
1025	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT.	TT	T
1026	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	SVR was achieved in more patients in the IL28B major allele group than in the minor allele group (15/17 vs. 7/15) after PEG-IFN/RBV combination therapy in children with HCV genotype-1 infection.	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G.	T	T
1027	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) and early virological response (EVR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1028	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR) and end of treatment response (ETR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1029	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype is associated with sustained virological response (SVR).	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT.	TT	T
1030	rs8099917	IFNL3 (PA134952671)	"interferons (PA451999),""ribavirin (PA451241)"""	Measured according to impact on sustained virological response. Significant only in non-cryoglobulinemic patients. Not significant in cryoglobulinemic patients. GG to TT p = 0.049.	Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.	GG	T
1031	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"",""simeprevir (PA166122590)"""	in treatment-naïve patients and relapsers.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1032	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)"""	for chronically HCV G2-infected patients who did not achieve rapid virologic response (non-RVR). This variant is not associated SVR for patients infected with genotype-2 chronic hepatitis C and have achieved RVR.	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	TT	T
1033	rs8099917	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	Response to treatment assessed by whether patients had successfully cleared the virus after six months of therapy.	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T.	G	T
1034	rs8099917	"IFNL3 (PA134952671),""IFNL4 (PA166049147)"""	"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"""	only in the allelic model.	Allele T is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele G.	T	T
1035	rs7248668	IFNL3 (PA134952671)	"peginterferon alfa-2a (PA164749390),""ribavirin (PA451241)"""	The associated allele is not explicitly stated, so I assumed that the association was with minor allele, and dbSNP lists A as the minor allele in Asians.	Allele A is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	A	G
1036	rs7248668	IFNL3 (PA134952671)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes AA + AG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	AA + AG	G
1037	rs10853728	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotypes CG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	CG + GG	C
1038	rs10853728	(no entry)	"peginterferon alfa-2b (PA164784024),""ribavirin (PA451241)"""	This genotype has decreased association with sustained virological response (SVR).	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.	GG	C
1039	rs28493229	"COQ8B (PA134988974),""ITPKC (PA29977)"""	Immunoglobulins (PA164712817)	(no entry)	Genotypes CC + CG are associated with decreased response to Immunoglobulins in children with Mucocutaneous Lymph Node Syndrome as compared to genotype GG.	CC + CG	G
1040	rs2279343	CYP2B6 (PA123)	bupropion (PA448687)	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide). 48.0 % of patients with CYP2B6 rs2279343 AA genotype in the bupropion only group succeeded in ceasing smoking compared with 35.5 % of patients carrying the AG or GG genotypes (CYP2B6*4) (35.5 %).	Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.	AA	A
1041	rs2279343	CYP2B6 (PA123)	cyclophosphamide (PA449165)	(no entry)	Genotypes AG + GG are associated with decreased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to genotype AA.	AG + GG	A
1042	rs1800471	TGFB1 (PA350)	rituximab (PA451261)	"Patients with the CG genotype were more likely to be classified as ""responders"" to treatment, as compared to those with the GG genotype. ""Responders"" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Combination with rs1800470 AG genotype led to an even higher probability of responding to treatment, as compared to the GG genotype and rs1800470 AA genotype combined."	Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG.	CG	C
1043	rs1800471	TGFB1 (PA350)	etanercept (PA449515)	When combined with the IL1RN VNTR in intron 2, A2 allele (no rsID available). Those with the CG-A2 positive combined genotype were more likely to be non-responders to treatment, as compared to those with any other combination of genotypes. However, no significant difference in genotype frequencies was seen between responders and non-responders when considering the rs1800471 SNP or IL1RN VNTR alone. Responders defined using the American College of Rheumatology (ACR) response criteria and response criteria based on the modified disease activity score (DAS)28 index. Non-responders failed to fulfill both these criteria.	Genotype CG is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype GG.	CG	C
1044	rs1800470	TGFB1 (PA350)	rituximab (PA451261)	"Patients with the AG genotype were more likely to be classified as ""responders"" to treatment, as compared to those with the AA genotype. ""Responders"" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Combination with rs1800471 CG genotype led to an even higher probability of responding to treatment, as compared to the AA genotype and rs1800471 GG genotype combined. Please note alleles have been complemented to the plus chromosomal strand."	Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	AG	G
1045	rs1800469	TGFB1 (PA350)	glatiramer acetate (PA449760)	Significant only when also combined with the HLA-DRB1*15 allele. Risk of not responding to the drug was significantly increased in individuals carrying this allele combination. This risk was further increased in individuals with the HLA-DRB1*15-rs1800469 A-rs333 del allele combination and HLA-DRB1*15-rs1800469 A-rs333 del-rs1012335 G allele combination.	Allele A is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	A	A
1046	rs25487	XRCC1 (PA369)	fluorouracil (PA128406956)	as measured by tumor reduction with preoperative chemoradiotherapy.	Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT.	CC	T
1047	rs25487	XRCC1 (PA369)	"carboplatin (PA448803),""cisplatin (PA449014)"",""fluorouracil (PA128406956)"""	(no entry)	Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.	T	T
1048	rs25487	XRCC1 (PA369)	"fluorouracil (PA128406956),""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	Response was determined by survival rates.	Genotype CC is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	CC	T
1049	rs25487	XRCC1 (PA369)	Platinum compounds (PA164713176)	Patients with the T allele had reduced response rate to platinum-based chemotherapy as compared to those with the CC genotype. Response defined as complete or partial response. Meta-analysis with 10 studies. Note that in further analyses, this result was only significant in those of Asian ethnicity (not Caucasians) and those with colorectal cancer (not gastric cancer). No significant results were seen for overall survival or progression-free survival. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT is associated with decreased response to Platinum compounds in people with Colorectal Neoplasms and Stomach Neoplasms as compared to genotype CC.	CT + TT	T
1050	rs25487	XRCC1 (PA369)	"cisplatin (PA449014),""radiotherapy (PA166122986)"""	All patients had stage II-IV nasopharyngeal cancer and progression free survival (PFS) was the primary endpoint.	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	TT	T
1051	rs25487	XRCC1 (PA369)	Platinum compounds (PA164713176)	Those with the CT or TT genotypes had a greater likelihood of being a responder to therapy, ascompared to those with the GG genotype. Responders defined as having complete or partial response, and non-responders defined as having stable or progressive disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	CT + TT	T
1052	rs25487	XRCC1 (PA369)	Platinum compounds (PA164713176)	Patients with GA or GG genotypes of XRCC1 G1196 had better response than AA genotype carriers (Genotyping study: OR = 0.72, 95%CI: 0.53-0.96, P = 0.028; Meta-analysis: OR = 0.74, 95%CI: 0.62-0.89, P = 0.001).	Genotypes CC + CT are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	CC + CT	T
1053	rs25487	XRCC1 (PA369)	platinum (PA150595617)	Pooled odds ratios (ORs) were performed for an allele model, a homozygous model, a heterozygous model, a recessive model and a dominant model. The association was significant for response rate and overall survival with the recessive model, but was not associated with progression free survival.	Genotypes CT + TT is associated with decreased response to platinum in people with Lung Neoplasms as compared to genotype CC.	CT + TT	T
1054	rs25487	XRCC1 (PA369)	Platinum compounds (PA164713176)	Patients were treated with cisplatin or carboplatin in combination with a third-generation drug (gemcitabine, paclitaxel, pemetrexed or vinorelbine). Patients with the CC genotype had better overall response rates as compared to those with CT or TT genotypes. The authors also found this association in a subgroup of EGFR native patients. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	CC	T
1055	rs1799782	XRCC1 (PA369)	Platinum compounds (PA164713176)	Subjects with the AA or AG genotype had a higher response rate to chemotherapy, as compared to those with the GG genotype. Additionally, individuals who carried both the AA or AG genotype, and the XPC PAT +/+ genotype (xeroderma pigmentosum complementation group C poly (AT) deletion/insertion polymorphism) also had a higher response rate to chemotherapy. Response was defined as experiencing complete or partial remission; non-response was stable or progressive disease.	Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
1056	rs1799782	XRCC1 (PA369)	Platinum compounds (PA164713176)	(no entry)	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
1057	rs1799782	XRCC1 (PA369)	Platinum compounds (PA164713176)	Pooled odds ratios (ORs) were performed for an allele model, a homozygous model, a heterozygous model, a recessive model and a dominant model. The association was only significant for response rate with the recessive model, but was not associated with overall survival or progression free survival.	Allele G is associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to allele A.	G	G
1058	rs2075650	TOMM40 (PA38274)	hmg coa reductase inhibitors (PA133950441)	as part of a three SNP genetic risk score with rs2231142 in ABCG2 and rs10455872 in LPA. Associated allele not explicitly stated but methods reference Chasman et al., so used the associated allele from there [PMID:22331829].	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.	G	A
1059	rs7412	APOE (PA55)	"atorvastatin (PA448500),""pravastatin (PA451089)"",""simvastatin (PA451363)"""	As measured by reduction in LDLc. Association was significant only at high doses.	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.	C	C
1060	rs7412	APOE (PA55)	atorvastatin (PA448500)	as measured by decreases in LDL-cholestrol.	Genotype CT is associated with increased response to atorvastatin as compared to genotype CC.	CT	C
1061	rs7412	APOE (PA55)	rosuvastatin (PA134308647)	The minor allele of this SNP is associated with increased fractional LDL-C reduction on rosuvastatin.	Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC.	CT + TT	C
1062	rs445925	(no entry)	hmg coa reductase inhibitors (PA133950441)	Carriers of the rs445925 A SNP respond to statins with an additional 4.3% increase per allele in LDL-C lowering effect compared with non-carriers.	Allele A is associated with increased response to hmg coa reductase inhibitors as compared to allele G.	A	G
1063	rs4420638	APOC1 (PA51)	hmg coa reductase inhibitors (PA133950441)	as measured by lesser reductions in LDL-C. These individuals were also more likely to start out with higher LDL-C before treatment.	Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases or Hypercholesterolemia as compared to allele A.	G	A
1064	rs13181	ERCC2 (PA27848)	"bevacizumab (PA130232992),""capecitabine (PA448771)"",""cisplatin (PA449014)"",""docetaxel (PA449383)"",""epirubicin (PA449476)"",""oxaliplatin (PA131285527)"",""trastuzumab (PA451743)"""	"Patients with the GG genotype had increased response in multivariable analysis. However, note that this was only a ""nominally"" significant association: formally significant was defined as p<0.0026, and nominally significant as p<0.05. No association with progression-free survival or overall survival was found. Please note that alleles have been complemented to the plus chromosomal strand."	Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT.	GG	T
1065	rs1052555	ERCC2 (PA27848)	Platinum compounds (PA164713176)	Those with the AA or AG genotypes had a decreased likelihood of being a responder to therapy, ascompared to those with the GG genotype. Responders defined as having complete or partial response, and non-responders defined as having stable or progressive disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	G
1066	rs11615	ERCC1 (PA155)	Platinum compounds (PA164713176)	Please note; specific p-value for this significant association not given, but a 5% probability level was considered significant. [stat_test: logistic regression]	Genotype AA is associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to genotype GG.	AA	A
1067	rs11615	ERCC1 (PA155)	"fluorouracil (PA128406956),""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	Response was determined by survival rates.	Genotype GG is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	GG	A
1068	rs11615	ERCC1 (PA155)	"cisplatin (PA449014),""gemcitabine (PA449748)"""	This SNP was presented as ERCC1 C/T at codon 118. Patients the T allele were significantly less likely to have disease progression as compared to patients homozygous for the C allele. No other association between outcome (time to progression or overall survival) and genotype was found for this SNP.	Genotype AA is associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	AA	A
1069	rs11615	ERCC1 (PA155)	"capecitabine (PA448771),""radiotherapy (PA166122986)"""	p-value and OR below for multivariate analysis. In univariate analysis, 30.6% of those with the AA genotype achieved pathological complete response, compared with 16.2% of those with the AG genotype and 0% of those with the GG genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype AA.	AG + GG	A
1070	rs11615	ERCC1 (PA155)	Platinum compounds (PA164713176)	Platinum-based doublets consisting of cisplatin or carboplatin plus gemcitabine, vinorelbine, taxane or pemetrexed. Response defined as complete or partial response; non-response defined as stable disease or progression disease. Significant results were also seen within a group of patients with squamous cell carcinoma subtype. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	AA + AG	A
1071	rs11615	ERCC1 (PA155)	"bevacizumab (PA130232992),""capecitabine (PA448771)"",""cisplatin (PA449014)"",""docetaxel (PA449383)"",""epirubicin (PA449476)"",""oxaliplatin (PA131285527)"",""trastuzumab (PA451743)"""	"Patients with the GG genotype had decreased overall survival in multivariable analysis. However, note that this was only a ""nominally"" significant association: formally significant was defined as p<0.0026, and nominally significant as p<0.05. No association with progression-free survival or response was found. Please note that alleles have been complemented to the plus chromosomal strand."	Genotype GG is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.	GG	A
1072	rs3212948	ERCC1 (PA155)	"fluorouracil (PA128406956),""leucovorin (PA450198)"",""oxaliplatin (PA131285527)"""	NB: Improved overall response rate is reported as for the G allele, gene is on the negative strand so given here as the C allele.	Allele C is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	C	G
1073	rs10995	VASP (PA37276)	hydrochlorothiazide (PA449899)	"The rs10995 G-allele was associated with better blood pressure response to hydrochlorothiazide versus noncarriers (delta systolic BP/delta diastolic BP: -12.3/-8.2 versus -6.8/-3.5 mm Hg, respectively, delta systolic BP P=3×10-4, delta diastolic BP P=5×10-5)"". rs10995 G-allele was associated with increased mRNA expression of VASP (vasodilator-stimulated phosphoprotein)."	Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.	AG + GG	G
1074	rs3752120	ZNF432 (PA134935907)	"adrenergics, inhalants (PA10405),""beclomethasone (PA448547)"",""budesonide (PA448681)"",""corticosteroids (PA10832)"",""fluticasone propionate (PA449686)"",""fluticasone/salmeterol (PA165290926)"",""salbutamol (PA448068)"""	"This is stated as ""Having 2 copies of the mutant allele and not being treated with inhaled corticosteroids produces a higher bronchodilator response than having 2 mutant alleles and being treated with inhaled corticosteroids(ICS)."" By ""mutant"" allele, presumably the minor allele (T) is meant. CAMP has 3 arms: budesonide,nedocromil and placebo. Subjects in the budesonide arm were considered exposed to ICS. For LOCCS(which was used as a replication cohort), subjects who said that they had used ICS either daily or 2-6x/wk over the past 6 months were considered to have used ICS. Subjects who responded: ""1-2x/month"", ""<1x/month"" or ""never"" were considered to not have used ICS. A comparison between genotypes was not done. The authors state that the clinical implication is not clear,and that ""Inhaled corticosteroids appear to modulate the association of bronchodilator response with variant(s) in the ZNF432 gene among adults and children with asthma."""	Genotype TT is associated with decreased response to adrenergics, inhalants, beclomethasone, budesonide, corticosteroids, fluticasone propionate, fluticasone/salmeterol or salbutamol in people with Asthma.	TT	C
1075	rs11666735	FCAR (PA28055)	pravastatin (PA451089)	In patients treated with placebo, carriers of the A allele had an increased risk of myocardial infarction compared to patients with the GG genotype. This association was abolished with pravastatin treatment. Risk reduction with pravastatin was significantly higher in carriers of the A allele compared to non-carriers. This variant was described as Asp92Asn which is the position in the mature protein, corresponding to codon 113 in the full transcript.	Genotypes AA + AG are associated with increased response to pravastatin in men with Myocardial Infarction as compared to genotype GG.	AA + AG	G
1076	rs1126757	IL11 (PA29781)	escitalopram (PA10074)	Carriers of the T allele responded significantly better to escitalopram treatment, as compared to CC homozygotes. Response was defined as a percentage Montgomery-Asberg Depression Rating Scale (MADRS) change of greater than 50% between baseline and 12 weeks. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CT + TT is associated with increased response to escitalopram in people with Depression as compared to genotype CC.	CT + TT	C
1077	rs4815273	(no entry)	"diuretics (PA151249535),""hydrochlorothiazide (PA449899)"",""Thiazides, plain (PA164713347)"""	The association was with systolic blood pressure response. Observations: 2.91 mm Hg increased reduction of systolic blood pressure per T allele in PEAR + GERA, 0.39 mm Hg increased reduction of systolic blood pressure per T allele in NORDIL, and 2.34 mm Hg increased reduction of systolic blood pressure per T allele in PEAR + GERA + NORDIL. This association was significant in PEAR + GERA but not in the replication cohort NORDIL nor in the 3 cohort meta-analysis.	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	T	C
1078	rs2740204	OXT (PA32857)	clozapine (PA449061)	"Full-text was not accessible. Associated allele is unclear. It was described as the ""variant"". I interpreted this to be T, since authors are Canadian so patients are probably White, and dbSNP shows T to be the minor allele in Whites."	Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele G.	T	G
1079	rs3746544	SNAP25 (PA35980)	methylphenidate (PA450464)	For the genetic component, in the CGI-S model, a dominant effect in SNAP25 rs3746544 was found with a significant improvement in the symptoms. Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Genotypes GG + GT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	GG + GT	G
1080	rs8636	SNAP25 (PA35980)	amisulpride (PA162565877)	"This is the ""overdominant model"", the recessive model was not significant after correction (CT+TT vs CC). They did not show CT vs CC. (TT is low frequency) but additive model CC vs CT vs TT was also significant after correction. Response was measured by PANNS."	Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.	CT	T
1081	rs244076	ADA (PA24503)	methotrexate (PA450428)	although not significant after Bonferroni correction.	Allele C is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid.	C	T
1082	rs3918242	MMP9 (PA30889)	Methyldopa (PA164712898)	Statistics given for likelihood of non-response.	Genotypes CT + TT are associated with decreased response to Methyldopa in people with Gestational hypertension as compared to genotype CC.	CT + TT	C
1083	rs3918242	MMP9 (PA30889)	"Antihypertensives (PA164712445),""hydralazine (PA449894)"",""Methyldopa (PA164712898)"",""nifedipine (PA450631)"""	Statistics given for likelihood of non-response.	Genotype CT is associated with decreased response to Antihypertensives, hydralazine, Methyldopa or nifedipine in people with gestational hypertension as compared to genotype CC.	CT	C
1084	rs115501901	NCOA3 (PA31472)	salbutamol (PA448068)	The allele associated with increased response and low frequency is not explicitly stated. Response is increased for carriers of the rare, minor allele. GALAII genotyping was done using the Affymetrix LAT1 Array, which was designed to capture Latino population variation.	Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype CC.	CT	C
1085	rs62205366	GNAS (PA175)	dobutamine (PA449381)	Carriers of the C allele had a significantly greater increase in left ventricular fractional shortening (LVFS), left ventricular ejection fraction (LVEF) and systolic blood pressure (SBP) after administration of 10, 20 and 30 ug/kg/min of dobutamine, as compared to TT homozygotes. Doses of dobutamine were given on the same day sequentially, and atropine was administered prior to dobutamine. Subjects all were required to be CC homozygotes for rs1801253 in the ADRB1 gene.	Genotypes CC + CT are associated with increased response to dobutamine in healthy individuals as compared to genotype TT.	CC + CT	T
1086	rs7121	GNAS (PA175)	"cisplatin (PA449014),""fluorouracil (PA128406956)"""	Characterized by a major histopathological response with less than 10% residual vital tumor cells in resection specimens.	Genotype CC is associated with increased response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT.	CC	C
1087	rs4925300	CDH4 (PA26300)	ziprasidone (PA451974)	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. It was unclear whether the allele was associated with an increased or decreased response to drug.	Allele A is associated with response to ziprasidone in people with Schizophrenia.	A	G
1088	rs1044396	CHRNA4 (PA26490)	varenicline (PA164781343)	CC genotype had lower success rate when in treatment with varenicline (29.5%) compared with patients with CT or TT genotypes.	Genotype GG is associated with decreased response to varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	GG	G
1089	rs2832407	GRIK1 (PA28973)	topiramate (PA451728)	75.5% of participants met the criteria for an alcohol use disorder. At target dose (week 5 of treatment), carriers of the A allele reported a higher percentage of heavy drinking days (%HDD), as compared to those with the CC genotype (controlling for baseline %HDD).	Genotypes AA + AC is associated with decreased response to topiramate in people with Alcohol-Related Disorders as compared to genotype CC.	AA + AC	C
1090	rs1012335	IFNAR1 (PA29670)	glatiramer acetate (PA449760)	Significant only when also combined with the HLA-DRB1*15 allele, rs1800469 allele A and rs333 del allele. Risk of not responding to the drug was significantly increased in individuals carrying this allele combination.	Allele G is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele C.	G	G
1091	rs12659	SLC19A1 (PA327)	"carboplatin (PA448803),""cisplatin (PA449014)"",""fluorouracil (PA128406956)"""	(no entry)	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.	A	A
1092	rs1051266	SLC19A1 (PA327)	methotrexate (PA450428)	(no entry)	Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	TT	T
1093	rs1051266	SLC19A1 (PA327)	methotrexate (PA450428)	(no entry)	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	T	T
1094	rs1051266	SLC19A1 (PA327)	"folic acid (PA449692),""hydroxychloroquine (PA164777036)"",""methotrexate (PA450428)"",""sulfasalazine (PA451547)"""	(no entry)	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.	T	T
1095	rs1051266	SLC19A1 (PA327)	"capecitabine (PA448771),""fluorouracil (PA128406956)"",""irinotecan (PA450085)"",""leucovorin (PA450198)"""	This SNP was presented as an A>G nucleotide change. Patients were split into two groups based on treatment. One group received irinotecan, fluorouracil, and leucovorin, and the other group received irinotecan and capecitabine. Patients with the GG genotype showed significantly greater rapid response rate as compared to patients carrying the A allele. In addition, when combined with rs2306283, patients homozygous for the G allele for this SNP and carrying the A allele at rs2306283 had significantly higher rapid response rates than patients with any other combination of genotypes.	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	CC	T
1096	rs1051266	SLC19A1 (PA327)	methotrexate (PA450428)	(no entry)	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	CT + TT	T
1097	rs1051266	SLC19A1 (PA327)	methotrexate (PA450428)	Alleles were given as G and A. No patients were homozygous for the variant G allele. Response measured as relapse-free survival.	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	CT	T
1098	rs1051266	SLC19A1 (PA327)	methotrexate (PA450428)	(no entry)	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	TT	T
1099	rs9606186	COMT (PA117)	risperidone (PA451257)	"When combined with the C allele in rs2020917 and the C allele in rs933271. Patients with the haplotype C-C-C across these three SNPs have poorer response to risperidone. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	C	C
1100	rs9606186	COMT (PA117)	risperidone (PA451257)	"The GG genotype group had a higher percentage of ""responders"" compared to the CG and CC genotype groups. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders"". Significant results were seen for the entire study population and the male subgroup (n = 45). No significant results were seen for the female subgroup (n = 85)."	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	GG	C
1101	rs737865	COMT (PA117)	bupropion (PA448687)	Authors caution inadequate power for this to be a strong conclusion.	Genotype AA is associated with decreased response to bupropion in smokers as compared to genotypes AG + GG.	AA	A
1102	rs933271	COMT (PA117)	risperidone (PA451257)	"When combined with the C allele in rs9606186 and the C allele in rs2020917. Patients with the haplotype C-C-C across these three SNPs have poorer response to risperidone. ""Responders"" were classified as patients who showed a reduction of 40% or more in Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone monotherapy. All other patients were considered ""nonresponders""."	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	C	T
1103	rs5993883	COMT (PA117)	quetiapine (PA451201)	This association was significant after Bonferroni correction. The T allele was frequently observed in poor responders to quetiapine. Patients were classified as good responders if they had a reduction of Positive and Negative Syndrome Scale (PANSS) score of >=50% and poor responders if they had a reduction of PANSS score of <50%.	Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	T	T
1104	rs6269	COMT (PA117)	quetiapine (PA451201)	This association was significant after Bonferroni correction. The A allele was frequently observed in poor responders quetiapine. Patients were classified as good responders if they had a reduction of Positive and Negative Syndrome Scale (PANSS) score of >=50% and poor responders if they had a reduction of PANSS score of <50%.	Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	A	A
1105	rs4680	COMT (PA117)	morphine (PA450550)	(no entry)	Genotypes GG + AG are associated with increased dose of morphine as compared to genotype AA.	GG + AG	G
1106	rs4680	COMT (PA117)	fluvoxamine (PA449690)	The outcome was inversely proportional to the enzyme activity: better effects in Met-carriers (A-allele), worse effects in Val/Val homozygotes (G-allele). The effect became significant at the fourth week of treatment, and influence final response rates. Fluvoxamine plasma levels had marginal effects on outcome. Only abstract of the article available and no p-value was reported in the abstract.	Genotype GG is associated with decreased response to fluvoxamine in people with Depressive Disorder, Major as compared to allele A.	GG	G
1107	rs4680	COMT (PA117)	venlafaxine (PA451866)	Response was reported as week 8 change from baseline HAM-D-17 as compared to placebo per genotype. For GG carriers venlafaxine treatment response appeared larger ( - 5.9 points, p-value 0.0013 versus placebo, unadjusted for multiplicity), when compared to AG and carriers. But the confidence intervals are overlapping.	Genotype GG is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	GG	G
1108	rs4680	COMT (PA117)	venlafaxine (PA451866)	The rs4680 A allele was associated with increased response to venlafaxine as measured on the Clinical Global Impression of Improvement (CGI-I) scale, as compared to GG homozygotes. No significant association was seen for remission on this same scale. Patients were treated with venlafaxine for 6 months.	Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG.	AA + AG	G
1109	rs4680	COMT (PA117)	paroxetine (PA450801)	AA > AG > GG for response. A = Met allele; G = Val. The effect became significant at week 3 of treatment.	Allele A is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to allele G.	A	G
1110	rs4680	COMT (PA117)	entacapone (PA164748726)	(no entry)	Genotype GG is associated with increased response to entacapone in people with Parkinson Disease as compared to genotype AA.	GG	G
1111	rs4680	COMT (PA117)	nicotine (PA450626)	Patients with the GG genotype who were treated with sublingual nicotine as treatment for nicotine dependence had a greater likelihood of smoking abstinence after 12 weeks of treatment, as compared to A allele carriers. After 8 weeks of treatment with sublingual nicotine, patients stopped taking the drug. Abstinence was defined as neither a cigarette nor any other form of nicotine for at least 7 continuous days between when sublingual nicotine treatment ceased (week 8) and final follow-up (week 12).	Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.	GG	G
1112	rs4680	COMT (PA117)	methylphenidate (PA450464)	Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002).	Genotypes AA + AG is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype GG.	AA + AG	G
1113	rs4680	COMT (PA117)	clozapine (PA449061)	Patients with the GG genotype (described as Val/Val in the paper) had a greater improvement on the Positive and Negative Symptoms Scale (PANSS), Negative Symptoms Subscale, as compared to those with the AA or AG genotypes (described as Met carriers). PANSS score was measured at baseline and then after 12 weeks of treatment.	Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AA + AG.	GG	G
1114	rs4680	COMT (PA117)	morphine (PA450550)	(no entry)	Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G.	A	G
1115	rs4680	COMT (PA117)	modafinil (PA450530)	Hispanic subjects with the GG genotype had significantly higher Treatment Effectiveness Scores when treated with modafinil compared to placebo. This significant association was not seen when comparing modafinil treatment against placebo in subject with the AA or AG genotypes.	Genotype GG is associated with increased response to modafinil in people with methamphetamine dependence as compared to genotypes AA + AG.	GG	G
1116	rs4680	COMT (PA117)	"morphine (PA450550),""remifentanil (PA451232)"""	Infants with the AA or AG genotypes were quicker to achieve a pain-free ALPS-Neo score than infants with the GG genotype. The paper refers to these alleles as Val and Met, where the G allele = Val and the A allele = Met.	Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG.	AA + AG	G
1117	rs4680	COMT (PA117)	morphine (PA450550)	Infants with the GG genotype took longer to achieve a pain-free ALPS-Neo score than infants with the AA or AG genotypes. The paper refers to these alleles as Val and Met, where the G allele = Val and the A allele = Met.	Genotype GG is associated with decreased response to morphine in infants with Pain as compared to genotypes AA + AG.	GG	G
1118	rs4680	COMT (PA117)	remifentanil (PA451232)	Infants with the AA genotype were quicker to achieve a pain-free ALPS-Neo score than infants with the AG or GG genotypes. The paper refers to these alleles as Val and Met, where the G allele = Val and the A allele = Met.	Genotype AA is associated with increased response to remifentanil in infants with Pain as compared to genotypes AG + GG.	AA	G
1119	rs4680	COMT (PA117)	methylphenidate (PA450464)	G allele (Val) showed a significant association with good methylphenidate response P = 0.009. The G/G genotype was twice as frequent in the responder group compared to the non-responders P = 0.034. No genotyping information included in the article.	Allele G is associated with increased clearance of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	G	G
1120	rs4680	COMT (PA117)	methylphenidate (PA450464)	Symptom severity scores of all three genotype groups decreased following methylphenidate administration (P< 0.001), however G/G homozygote children had significantly less severe symptoms than those with A/A genotype after treatment (P = 0.015). Note: article also states: Methylphenidate also significantly decreased the CGI-S scores but this reduction was not modified by COMT genotypes.	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	GG	G
1121	rs4680	COMT (PA117)	methylphenidate (PA450464)	The A allele and G allele are reported in the paper as the Val allele and Met allele respectively.	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	GG	G
1122	rs165599	COMT (PA117)	risperidone (PA451257)	(no entry)	Allele G is associated with increased response to risperidone in people with Schizophrenia.	G	G
1123	rs165599	COMT (PA117)	bupropion (PA448687)	GG smokers quit more readily on placebo. On bupropion, A carriers had 19% abstinence on placebo and 33% abstinence on bupropion, while GG smokers had 38% abstinence on placebo and 22% abstinence on bupropion. Also, the haplotype with rs737865 may be important. G-G haplotype (for rs737865 and rs165599) smokers of European-American ethnicity may not benefit from bupropion, while the smokers of European-American origin with an A allele at rs165599 have a substantial probability of benefit.	Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.	AA + AG	G
1124	rs165854	PI4KA (PA162399305)	antipsychotics (PA452233)	When combined with rs1468412 AA and AT genotypes. rs165854 AG+GG/rs1468412 AA+AT was associated with a significantly increased likelihood of patients having an incomplete antipsychotic response within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale.	Genotypes AG + GG is associated with decreased response to antipsychotics in people with Schizophrenia.	AG + GG	G
1125	rs8136867	MAPK1 (PA30616)	antidepressants (PA452229)	Patients with major depressive disorder OR bipolar disorder. Subjects with the AG genotype are more likely to show remission. Non-remitters were defined as having a Hamilton Depression Rating Scale (HDRS) score of > 7 after at least one adequate antidepressant trial during the current or most recent depressive episode. No significant differences were seen when considering patients' resistance or responsiveness (please see paper for definitions of these).	Genotype AG is associated with increased response to antidepressants in people with Mental Disorders.	AG	G
1126	rs5751876	ADORA2A (PA24584)	methotrexate (PA450428)	although not significant after Bonferroni correction.	Allele T is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid.	T	T
1127	rs2269577	XBP1 (PA37400)	Platinum compounds (PA164713176)	"Patients with the CC genotype were more likely to respond to platinum-based regimens, as compared to those with the GG genotype. ""Response"" was defined as patients exhibiting complete or partial response, according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines."	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	CC	G
1128	rs2284018	CACNG2 (PA26016)	lithium (PA450243)	This is significant in the second cohort listed but not in the first.	Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder as compared to genotypes CC + CT.	TT	C
1129	rs1883112	NCF4 (PA31465)	idarubicin (PA449961)	Idarubicin + cytarabine treatment. Patients with the AA genotype were more likely to have complete remission.	Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.	AA	G
1130	rs13058338	RAC2 (PA34163)	idarubicin (PA449961)	Idarubicin + cytarabine treatment. Patients with the AT genotype were more likely to have complete remission.	Genotype AT is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.	AT	T
1131	rs5030655	CYP2D6 (PA128)	metoprolol (PA450480)	This variant is part of the CYP2D6*6 PM haplotype.	Genotype DELDEL is associated with increased response to metoprolol.	DELDEL	A
1132	rs4253778	PPARA (PA280)	fenofibrate (PA449594)	"Patients with the GG genotype were more likely to be a ""high responder"" to fenofibrate treatment. High responders were classified as having a relative reduction of triglyceride levels > 30% after at least 3 years of fenofibrate treatment. Patients with less than or equal to 30% reduction in triglyceride levels were classified as ""low responders""."	Genotype GG is associated with increased response to fenofibrate in people with Diabetes Mellitus as compared to genotypes CC + CG.	GG	G
1133	rs715171	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study described this variant within the FAM9B gene. [stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	C
1134	rs5934731	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	[stat_test: chi squared allele test]	Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	C	C
1135	rs2106809	ACE2 (PA425)	captopril (PA448780)	GG homozygotes had a significantly greater decrease in diastolic blood pressure after 4 weeks of treatment, as compared to A allele carriers. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to captopril in women with Hypertension as compared to genotypes AA + AG.	GG	A
1136	rs5906072	(no entry)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study reported alleles A and G. [stat_test: chi squared allele test]	Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	T	T
1137	rs3813928	HTR2C (PA194)	risperidone (PA451257)	HTR2C is on the X chromosome and this variant described as rs3813928 (c.-995G>A). Males with A genotype plus females with AA/AG genotype had 4.1% higher ATEC (ie. less response) than males with G genotype or females with GG genotype.	Allele A is associated with decreased response to risperidone in children with Autistic Disorder as compared to genotype GG.	A	G
1138	rs518147	HTR2C (PA194)	risperidone (PA451257)	This was not significant in male patients. The HTR2C is x-linked and males have only one copy, the authors analyzed male and female samples separately.	Genotype CC is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CG + GG.	CC	G
1139	rs3761555	GRIA3 (PA28968)	"Selective serotonin reuptake inhibitors (PA164713257),""venlafaxine (PA451866)"""	Regression model looking at interaction between genetic and environemental factors. The TT genotype with nLES high adversity was associated with non-response, compared to the CC/CT genotype and nLES low adversity. Please note; in the paper this SNP was reported with A and G alleles - here we use T and C to represent these. nLES = life event scale.	Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	TT	T
1140	rs502434	GRIA3 (PA28968)	"Selective serotonin reuptake inhibitors (PA164713257),""venlafaxine (PA451866)"""	Regression model looking at interaction between genetic and environemental factors. The CC genotype with CTQ-SF high adversity was associated with non-response, compared to the TT/TC genotype and CTQ-SF low adversity. Please note; in the paper this SNP was reported with A and G alleles - here we use T and C to represent these. CTQ-SF = childhood trauma questionaire 28-item short form.	Genotype CC is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	CC	T
1141	rs3810651	GABRQ (PA28504)	venlafaxine (PA451866)	Those with the AA/AT genotype are more likely to be responders. Please note; this is an A/T SNP and due to inconsistencies reported for other SNP alleles in the paper this should be kept in mind.	Genotypes AA + AT are associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotype TT.	AA + AT	T
1142	rs17435	MECP2 (PA30729)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study described this variant within the MECP2 gene which is on the minus chromosomal strand, the allele associated with increased response is therefore not clear. [stat_test: chi squared allele test]	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	A	T
1143	rs1734787	MECP2 (PA30729)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study described this variant within the MECP2 gene which is on the minus chromosomal strand, and reported the association between complementary alleles T and G. [stat_test: chi squared allele test]	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.	A	A
1144	rs1734791	MECP2 (PA30729)	"cisplatin (PA449014),""fluorouracil (PA128406956)"",""mitoxantrone (PA450526)"""	The study described this variant within the MECP2 gene which is on the minus chromosomal strand, the allele associated with increased response is therefore not clear. [stat_test: chi squared allele test]	Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	A	A
